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Glossary 
An anticoagulant is an agent that prevents the clotting of blood.1 
Antiplatelet agents (e.g., aspirin or clopidogrel) reduce platelet aggregation and, 
therefore, the formation of clots.1 
Atrial fibrillation is a heart condition that causes an irregular and often abnormally fast 
heart rate.2 
Clinically relevant bleeding often refers to acute or subacute, clinically observable 
bleeding that does not meet the criteria for major bleeding, and that requires hospital 
admission, doctor-led medical or surgical treatment, or changes in antithrombotic 
treatment.3 
Deep vein thrombosis is a blood clot that develops within a deep vein in the body, usually 
in the leg.4 
Direct evidence refers to the results obtained from direct comparisons in a study, i.e. the 
two interventions are assessed one versus the other (e.g., apixaban v warfarin). 
An embolism is the condition in which an embolus becomes lodged in an artery and 
obstructs its blood flow. The most common form of embolism is pulmonary embolism, in 
which a blood clot is carried in the circulation to lodge in the pulmonary artery. An 
embolus in any other artery constitutes a systemic embolism.1 
Genotype is the genetic constitution of an individual or group, as determined by the 
particular set of genes it possesses.1  
Genotyping is the process of determining differences in the genetic make-up (genotype) 
of an individual by examining the individual's DNA sequence, using biological assays, and 
comparing it to another individual's sequence or a reference sequence. 
Indirect evidence refers to the results obtained from an estimation of the comparison of 
two interventions, using a comparator that both have in common in other studies (e.g., 
apixaban v edoxaban in the definition for network meta-analysis). 
International normalised ratio is a measure of how long it takes for blood to begin to form 
clots. Prothrombin is a plasma protein produced by the liver. Clotting is caused by a series 
of clotting factors which activate each other, including the conversion of prothrombin to 
thrombin. The test used to measure the activity of this clotting factor is called the 
prothrombin time (PT). The international normalised ratio (INR) is a highly-controlled 
version of the PT, using standardised ingredients, and the results are exactly reproducible 
no matter which laboratory or in which country the test is performed. The INR is 
specifically used to measure the exact effect of warfarin in the blood. The higher the INR 
the less likely that there will be a clot, but the more likely a bleed. Many patients have a 
target INR of 2.0 – 3.0 as an ideal compromise for reducing the chances of a clot while 
                                             
1 Oxford Concise Medical Dictionary (2015) 
2 https://www.nhs.uk/conditions/atrial-fibrillation/ 
3 http://heart.bmj.com/content/103/8/623 
4 https://www.nhs.uk/conditions/deep-vein-thrombosis-dvt/ 
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being safe with respect to bleeding. The target range may be lower or higher than this 
depending on individual circumstances.5 
Low-molecular-weight heparin is a type of heparin that is more readily absorbed and 
requires less frequent administration than standard heparin preparations used as 
anticoagulant therapy.1 
Major bleeding can be defined as clinically observable bleeding at a critical site (e.g., 
intracranial) or that leads to death, with a reduction in haemoglobin level by at least 
2g/dL or requiring a transfusion of at least two units of packed red blood cells.3 
Meta-analysis is a method used to synthesise direct pair-wise comparisons for a given 
outcome (e.g., apixaban v warfarin, or edoxaban v warfarin). 
Network meta-analysis can estimate indirect comparisons between interventions that have 
a common comparator (e.g., apixaban v edoxaban in the meta-analysis example, using 
warfarin as the common comparator), allowing the coverage of a wider range of 
interventions. 
Novel oral anticoagulants, also called non-vitamin K antagonist oral anticoagulants, include 
apixaban, dabigatran, edoxaban, and rivaroxaban. 
Oral anticoagulation therapy is an anticoagulant that is taken by mouth. Warfarin is the 
main oral anticoagulant used in the UK.6 It is a vitamin K antagonist, other vitamin K 
antagonists include phenprocoumon and acenocoumarol, and non-vitamin K antagonists 
include apixaban, dabigatran, edoxaban, and rivaroxaban. 
Pharmacist-managed anticoagulation services include drug dose adjustment based on INR 
measurements interpreted by the pharmacist, medication/drug interaction review and 
providing patient and/or healthcare provider education through clinic visits or telephone 
follow-up. 
Primary prevention is avoidance of the onset of disease by behaviour modification or 
treatment.1 
A pulmonary embolism is a blocked blood vessel in the lungs. It can be life-threatening if 
not treated quickly.7 
Quality-adjusted life-year is a year of life adjusted by the quality of life that a patient 
experiences with their medical condition. 
Randomised controlled trials are studies in which a number of similar people are randomly 
assigned to two (or more) groups to test a specific drug, treatment or other intervention. 
Rankograms are two-dimensional treatment-specific plots, presenting on the horizontal 
axis the possible ranks of the treatment, and on the vertical axis, the probability for the 
treatment to assume each of the possible ranks according to a specific outcome.8 
                                             
5 https://labtestsonline.org.uk/tests/pt 
6 https://www.nhs.uk/conditions/warfarin/ 
7 https://www.nhs.uk/conditions/pulmonary-embolism/ 
8 http://methods.cochrane.org/cmi/glossary 
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Routine medical care in the USA is provided in anti-thrombosis clinics by physicians and 
nurses. In the UK, it can be provided by GPs or in specialist clinics or hospitals, according to 
UK guidelines.9 
Secondary prevention is the avoidance or alleviation of disease by early detection and 
appropriate management.1 
Self-management involves testing by the patient at home, with the patient making any dose 
adjustments according to rules based on their INR measurement.10 
Self-monitoring is the equivalent of self-testing. 
Self-testing is testing by the patient at home and communicating the results to a physician 
who returns any dose adjustments. 
A systemic embolism is a blockage in any artery other than the pulmonary artery, see 
embolism. 
Time in therapeutic range can be determined by the Rosendaal et al. (1993) method, which 
is also known as linear interpolation, this is a way of calculating the percentage of time that 
a patient’s INR is within the set therapeutic range (usually 2.0 to 3.0), based on the 
measurements taken and the time between these measurements.11 
Venous thromboembolism is a condition in which a blood clot forms in a vein. This is most 
common in a leg vein, where it's known as deep vein thrombosis. A blood clot in the lungs 
is called pulmonary embolism.12 
Vitamin K antagonists are anticoagulants that include warfarin, phenprocoumon and 
acenocoumarol.  
                                             
9 https://www.westsuffolkccg.nhs.uk/wp-content/uploads/2013/01/Anticoagulants-guideline-on-
the-mgmt-of-pts-tx-with-warfarin-phenindione-acenocoumarol.pdf 
10 Heneghan et al. 2016 
11 https://www.inrpro.com/rosendaal.asp 
12 https://www.nhs.uk/Tools/Pages/VTE-self-assessment.aspx 
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Abbreviations 
AF Atrial fibrillation 
AMS Anticoagulant medical service 
ApoE Apolipoprotein E 
bd Bis die or bis in diem or twice daily 
CBT Cognitive behavioural therapy 
CRB Clinically relevant bleeding 
DAOCs Direct-acting oral anticoagulants 
DVT  Deep vein thrombosis  
HTA Health Technology Assessment 
INR International normalised ratio  
LMWH Low-molecular-weight heparin 
MD Mean difference 
MI Myocardial infarction 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NIHR National Institute for Health Research 
NMA Network meta-analysis 
NOACs Novel oral anticoagulants 
NR Not reported 
OAC Oral anticoagulant 
OAT Oral anticoagulation therapy  
od Omne in diem or once daily 
PMAS  Pharmacist-managed anticoagulation services  
PMWT Pharmacist-managed warfarin therapy 
PE Pulmonary embolism  
QALY Quality-adjusted life-year 
RCTs Randomised controlled trials  
n-RCTs Non-randomised controlled trails  
RMC Routine medical care  
SE Standard error 
TTR Time in therapeutic range  
UCM Usual care medicine 
VKA Vitamin K antagonist 
VTE Venous thromboembolism  
WMD Weighted mean difference  
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Abstract 
Background 
Current NICE guidelines recommend the use of both warfarin and novel oral anticoagulants 
(NOACs) for the prevention and treatment of stroke related to atrial fibrillation (AF), and 
for venous thromboembolism (VTE). This review was commissioned to assess uncertainties 
about the evidence on the efficacy, safety and patient/clinician experience in adults with 
AF or VTE. 
 
Methods 
We undertook a rapid overview of systematic reviews, searching four databases for 
systematic reviews published from 2014 and using a comprehensive review on oral 
anticoagulants (OACs) efficacy and safety by Sterne et al. (2017). Data extraction 
frameworks were developed for each dimension examined. The quality of reviews was 
assessed using criteria for quantitative, mixed-methods or qualitative evidence syntheses, 
as appropriate. Results were synthesised narratively and thematically. 
 
Results  
Twenty-three reviews were included in this overview. In relation to efficacy and safety, the 
findings of Sterne’s review indicate that NOACs show advantages over warfarin for the 
prevention of AF-related stroke for most efficacy and safety outcomes, especially apixaban 
(5mg bd). There is no strong evidence to support the use of NOACs for VTE for primary 
prevention, acute treatment and secondary prevention. Ten genotyping reviews were 
assessed, however, none provided evidence specific to AF and VTE populations. There was 
limited, low-quality evidence, from six reviews of self-management, indicating that 
education, or education plus patient decision aids, were beneficial for AF populations. 
Results were mixed among mixed-diagnoses groups. Pharmacist-managed anticoagulation 
may be beneficial, compared with usual care, among mixed-diagnoses groups. No review 
evaluated pharmacist-managed anticoagulation services exclusively among populations with 
AF and no interventions exclusively targeted a VTE population. Evidence from nine reviews 
of stakeholder experiences suggests that patients and most clinicians value drug efficacy 
first, followed by safety. There were no clear patterns regarding which factors are most 
important for patients’ decisions around OACs or OAC adherence. 
 
Conclusion 
This overview of reviews informs policy decisions in the choice of OACs for the prevention 
and treatment of AF-related stroke and VTE. It also identifies dimensions for clinicians to 
consider when prescribing and monitoring OACs in terms of their and patients’ needs and 
preferences. 
 
PROSPERO Registration: CRD42017084263 
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Executive Summary 
Background 
NICE guidelines recommend the use of oral anticoagulants for the treatment of an irregular 
heartbeat (atrial fibrillation, hereafter AF), and for clots arising in large veins (venous 
thromboembolism, hereafter VTE). Warfarin, a vitamin K antagonist, was until recently the 
only available oral drug for anticoagulation. Novel oral anticoagulants (NOACs) have been 
introduced, in recent years, as alternatives to warfarin. Four NOACs are currently licensed 
for use in England: dabigatran, rivaroxaban, apixaban and edoxaban. 
 
In the UK, AF is the most common cardiac arrhythmia and is associated with approximately 
12,500 strokes every year. The underutilisation of anticoagulants, in patients with AF at 
high risk of stroke, has been identified as a major gap in clinical care. VTE was responsible 
for 44,000 hospital admissions, in 2013, and its recurrence is an important cause of long-
term morbidity. 
 
Current NICE guidelines recommend the use of both warfarin and NOACs for the prevention 
and treatment of AF and VTE. However, since the last update in 2014, several uncertainties 
relating to their efficacy, safety and patient experience have been raised. Firstly, warfarin 
requires frequent blood monitoring to maintain levels of anticoagulation within a narrow 
range of therapeutic effect, in order to reduce the risk of stroke and risk of bleeding. NOACs 
do not require close monitoring, although concerns have been raised that the lack of 
monitoring may reduce adherence. Secondly, warfarin’s action can be altered by a number 
of medications, food and alcoholic drinks, which requires adjustments by the patient and 
clinician. NOACs do not require such adaptations but their potential adverse interactions 
are also less known than those of warfarin, due to their recent availability. 
 
NOACS are currently more expensive than warfarin, as they are newer. However, due to 
changing patient preferences, the regular monitoring required for warfarin, the interactions 
of warfarin with medications, food and drinks, and a potentially greater risk of severe 
haemorrhage with warfarin, there is a growing shift towards prescribing NOACs. 
 
Data from several potentially influential trials on patients who took anticoagulants for AF 
and VTE have been reviewed since the last update of NICE guidelines in 2014. This current 
literature review was commissioned to assess the clinical evidence, published since then, 
on the efficacy, safety, and patient/clinician experience of warfarin and NOACs in order to 
guide optimal decision making among NHS commissioners, clinicians and patients. 
 
Methods 
We undertook a rapid overview of reviews. We searched four electronic databases for 
citations published from 2014 onwards. Combinations of free-text and database-specific 
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terms were developed around the concepts of: (oral anticoagulants and synonyms) AND 
(condition where appropriate) AND (systematic review). Potentially relevant documents 
were also received from Department of Health and Social Care collaborators. 
 
Titles and abstracts were screened and were coded according to their main focus (e.g., drug 
efficacy, drug safety, patient adherence, genotyping, patient/clinician experience). Since 
the efficacy and safety of oral anticoagulants were recently assessed in a comprehensive 
systematic review commissioned via the NIHR Health Technology Assessment Programme 
(Sterne et al. 2017), we summarised and critiqued this review for evidence on efficacy and 
safety. Full reports were retrieved for the remaining included citations and these were 
screened. Citations were excluded if they: 
 
• were published prior to 2014 
• were not available in English 
• focused specifically on non-OECD settings 
• did not focus on adults eligible for oral anticoagulation 
• did not focus on oral anticoagulants for the prevention of stroke related to AF or 
the acute treatment and primary and secondary prevention of VTE 
• did not focus on one of the following five anticoagulants: warfarin, dabigatran, 
rivaroxaban, edoxaban, or apixaban 
• were not a systematic review 
• did not assess therapeutic doses of warfarin compared with NOACs 
• did not include health or cost outcomes 
 
Data extraction frameworks were developed to code included reviews according to specified 
characteristics. Included reviews were assessed for methodological quality using AMSTAR or 
AMSTAR2 criteria, or quality assessment criteria for mixed-methods reviews and qualitative 
evidence syntheses, as appropriate. 
 
The synthesis focused on efficacy, safety, self-monitoring, genotyping, and patient and 
clinician experience reviews. Reviews were brought together in two stages. First, we 
descriptively mapped the characteristics of all reviews, in order to understand the different 
aims, populations, settings, interventions and comparisons, and patient outcomes or 
experiences. This process identified over 400 recent systematic reviews of efficacy and 
safety. In consultation with NHS commissioners, the decision was made to focus on the most 
recent, rigorous and comprehensive overview of systematic reviews located, which 
addressed our research questions (Sterne et al. 2017). Next, we mapped the characteristics 
from all review types to the policy priorities highlighted in our research questions, to 
understand where evidence exists that addresses these priorities and where there are gaps. 
 
To assure review quality, searches were developed by an information scientist using free 
text and thesaurus terms; manual screening on title and abstract and then full reports, and 
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quality assessment, were undertaken by two reviewers until agreement was reached, then 
single screening was undertaken; syntheses were conducted by at least two researchers; 
and EPPI-Reviewer© specialist software (Thomas et al. 2010) was used to manage data. 
External academics, clinician advisors, and NHS and Department of Health and Social Care 
stakeholders were consulted throughout the review process. The overview protocol was 
registered on PROSPERO. No changes were made to the protocol during the conduct of the 
overview, although findings for efficacy and safety were based on a single recent 
comprehensive high quality systematic review (Sterne et al. 2017) rather than an overview 
of multiple reviews. 
 
Results 
Efficacy and Safety 
The findings of Sterne’s review indicate that NOACs show advantages over warfarin for the 
prevention of AF-related stroke and systemic embolism for most efficacy and safety 
outcomes. Of these, apixaban (5mg bd) offers the best balance between efficacy and safety 
and had the highest probability of being most cost-effective. There was no strong evidence 
to support the use of NOACs for VTE for primary prevention (compared with low-molecular-
weight heparin; assessed for hip- and knee-surgery patients only), acute treatment 
(compared with warfarin) and secondary prevention (compared with warfarin and aspirin). 
However, in terms of safety, apixaban (5mg bd) and rivaroxaban (15mg bd, then 20mg od) 
may reduce the risk of major and clinically relevant bleeding, compared with warfarin, for 
the acute treatment and secondary prevention of VTE. For secondary prevention of VTE, 
aspirin was likely to be the most cost-effective alternative to warfarin. 
 
Despite the high quality of Sterne’s review, the breadth of important issues studied, and 
the inclusion of many high-quality trials, several effect estimates were imprecise. This was 
mainly due to the unavailability of direct comparisons between the NOACS, the reliance on 
short-term trial data, and the limited generalisability of trial data to clinical contexts. 
Sterne et al. (2017) concluded that prescribers and patients may, therefore, choose to 
exercise caution when considering the results of these reviews. 
Genotyping 
Genotyping has the potential to provide information about risks and treatment, in specific 
populations, carrying specific genes. However, the review evidence that currently exists on 
genotyping-guided dosing is not specific to patient populations with AF and VTE. Available 
reviews address important questions related to genotyping, including whether clinical 
outcomes vary between patients who are treated with standard dosing vs. genotype-guided 
dosing, and whether warfarin dose requirement varies between patients with different gene 
variants. The issue of inter-ethnic variation in dose requirement was also addressed. In order 
to appropriately investigate these important questions and make meaningful 
recommendations for AF and VTE patients, rigorous evaluations of pharmacogenetics, 
focused in these patient populations, are needed. 
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Self- or pharmacist-managed interventions 
In analyses focused specifically on AF populations, there appears to be limited evidence, of 
low quality, to support the beneficial effects of education and education plus patient 
decision aids on time in therapeutic range (TTR). Results from one study, of uncertain 
quality, indicated that there was little evidence to support the effectiveness of self-testing 
on improving time in INR, compared with usual care, but it did not perform worse. In terms 
of self-management, the results from three low-quality primary studies suggested it was 
uncertain whether or not self-management may improve TTR, compared with usual care. 
 
Among mixed-diagnoses groups, the low-to-moderate quality evidence suggested that self-
testing interventions may improve the INR values in therapeutic range, compared with usual 
care. However, findings from moderate-quality evidence were more mixed, with both 
positive (longer) and negative (shorter) time in therapeutic range for the self-testing 
intervention, compared with usual care. The evidence for self-management interventions 
was mixed for types of outcomes, with both higher and lower INR numbers in therapeutic 
range, and shorter and longer time in therapeutic range, compared with usual care. Low-
quality meta-analytic evidence indicated that self-management may be as effective as usual 
care but does not offer enhancements over and above usual care, in terms of TTR. The 
variation in findings suggests the presence of potential moderators operating. 
 
The review-level evidence for pharmacist-managed anticoagulation, as an alternative to 
usual physician care,13 was more consistent. Findings from mixed-quality studies, rated as 
high and uncertain, suggest that pharmacist-managed anticoagulation may improve TTR, 
compared with usual care, among mixed-diagnoses groups. There were no reviews 
evaluating pharmacist-managed anticoagulation services exclusively for populations with AF 
and none of the interventions were exclusively examined in populations with VTE. 
Stakeholder perspectives 
Reviews of patient and physician perceptions, preferences and values, and reviews of 
interventions assessing these outcomes, found that when initiating or switching OAC 
medication, patients and most clinicians value drug efficacy above other factors. This was 
followed by safety (i.e. risk of bleeding). Many other factors were important to 
patients/clinicians when initiating, continuing or switching OAC therapy. These included 
their knowledge, experience, changes in patient cognition and memory due to the condition 
itself, patient characteristics such as age, gender, lifestyle, employment status, support 
needs, or patient-clinician factors such as communication and perceptions about who bears 
the responsibility for decision-making. No clear patterns emerged about which were most 
important in patients’ decisions about initiating, switching or continuing OAC therapy, and 
to facilitate patient adherence with treatment. 
                                             
13 Although pharmacist management may not strictly be self-management, it can be easier to 
access for patients and could reduce pressure on GP or specialist services, and is, therefore, 
included here in self-monitoring. 
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Due to the variability in factors that might influence a decision to either initiate warfarin 
therapy, switch to NOAC therapy, or continue with any OAC therapy, some review authors 
suggested that where efficacy and safety are equal, there is a need for individualised 
discussions with patients, which should include a tailored framing of all potential risks 
associated with treatment. Most review authors recommended that these factors be 
integrated into decision-making tools, to help structure discussions with patients about 
therapy and allow both patients and physicians to clarify their preferences and values. 
However, evaluations of interventions addressing preferences and values have shown limited 
success. This may be influenced by communication styles, a clarification of which factors 
matter most to each patient, and the extent to which patients and clinicians feel that the 
decision to adopt or switch OAC therapy is their responsibility. 
 
Discussion 
The findings of this overview of reviews support the use of NOACs for the prevention of 
stroke in AF patients, especially apixaban (5mg bd). There is no evidence supporting the use 
of NOACs for primary prevention, acute treatment and secondary prevention of VTE. The 
impact of warfarin versus NOACs use on INR clinics’ capacity, and in patients with impaired 
renal function, was not addressed by Sterne and colleagues. Regarding self-monitoring 
pathways, small improvements were seen but no clear recommendations can be drawn for 
education, self-monitoring, self-testing and pharmacist-led management due to the limited, 
mixed evidence found. As for stakeholder perspectives, results suggest that efficacy, 
followed by safety, are the factors that patients and clinicians mainly base their decisions 
on. Decisions may also depend on the extent to which patients and clinicians feel it is their 
individual or shared responsibility. No review-level data were identified about experiences 
of the impact of NOACs and warfarin on patient lifestyle, and few data on patient quality 
of life or clinician perceptions of NOACs and warfarin. The currently available evidence 
syntheses on genotypes are not generalisable to AF and VTE populations. 
 
Where efficacy and safety of specific oral anticoagulation therapies have been established, 
the next priority should be to consider which factors matter to patients and clinicians in 
their decision to initiate or maintain a therapy. This could help clinicians to determine the 
level of support and information to provide to patients, including communication of risks, 
benefits and preferences. The lack of recognition of these factors, and the need to assess 
these for each patient, drug and medical condition may explain the limited effects of self-
monitoring, self-management, educational and decision-making interventions. 
Furthermore, age, gender, socio-economic status and ethnicity may be influential in 
efficacy, safety, and self- and pharmacist-managed interventions, but could not be assessed 
due to a lack of review-level data. 
 
This overview represents the most up-to-date evidence base on OACs. It has been drawn 
together using rigorous and transparent methods and takes into account the strength of 
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evidence. However, since it is an overview of reviews, it does not provide fine detail on 
populations, interventions and outcomes that may have been reported at primary study 
level. While the reviews on efficacy and safety (conducted by Sterne et al. 2017) were rated 
as high quality, authors concluded that prescribers and patients may choose to exercise 
caution when considering the results of these reviews. This was due to a lack of direct 
comparisons between NOACs, a reliance on short-term data, and limited generalisability to 
clinical contexts. Reviews on anticoagulant management approaches, genotyping and 
perspectives ranged from low to moderate quality. This needs to be considered when 
interpreting the findings. The substantial overlap in primary studies across the reviews on 
genotyping merits consideration since this may give undue weight to some findings. 
 
Conclusion 
This overview of reviews can be used to inform decisions about the choice of OACs for the 
prevention and treatment of AF and VTE (efficacy and safety). It also identifies dimensions 
for clinicians to consider when prescribing and monitoring OAC therapy in terms of patients’ 
needs for support and information (and how to provide the latter), their ability to 
understand, and preferences for decision-making about therapy. 
 
Some questions could not be addressed, or only limited or mixed evidence was identified. 
New evidence syntheses could usefully address: 
 
• the impact of OACs on renal functions;  
• the efficacy of self-monitoring or self-management for a range of conditions in which 
VTE is a risk factor;  
• differences between genotypes in examining clinical outcomes, treatment 
maintenance and adverse effects specific to AF and VTE populations; and  
• the influence of gender and age on the OACs’ efficacy, safety and patient 
experience.  
Research gaps were also apparent and new primary research could address: 
 
• the relationships between age, cognition and memory in AF and VTE populations; 
• AF and VTE patients’ support needs and preferences with respect to the specific 
drug therapies recommended by Sterne et al. (2017); 
• the most effective strategies to help clinicians assess AF and VTE patients’ 
willingness and ability to decide on OACs therapy; 
• self-monitoring and self-management in AF and VTE; 
• the limited effectiveness seen in interventions using decision aids; and 
• the need for a practical tool to guide clinicians in appraising patients’ and their 
own perceptions of their role and responsibility when decisions must be made 
regarding the initiation and maintenance of OACs therapy.  
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Focusing future research efforts in these areas may support clinicians in understanding their 
choices in prescribing, as well as supporting patients in their need for appropriate 
information and how it might be provided, in order to aid their understanding and inform 
decisions about OACs therapy. 
 
PROSPERO Registration: CRD42017084263  
The effective, safe and appropriate use of anticoagulation medicines: A systematic 
overview of reviews 
 
 
19 
 
1  Background 
Current NICE guidelines recommend the use of oral anticoagulants for the treatment of an 
irregular heartbeat, and for clots arising in large veins (NICE 2012, 2014, 2015, 2016a). Two 
types of oral anticoagulants are most commonly prescribed: warfarin was until recently the 
only available oral drug for anticoagulation. This drug is a vitamin K antagonist (VKA): it acts 
to prevent the carboxylation of clotting factors II, VII, IX, and X by inhibiting vitamin K 
epoxide reductase (Ha and Bhagavsan 2015). More recently non-vitamin K antagonist oral 
anticoagulants (NOACs) have been introduced, which are newer alternatives to warfarin.  
Also known as direct oral anticoagulants, NOACs work as active site-directed inhibitors of 
thrombin or Factor Xa (Ha and Bhagavsan 2015). Four NOACs are currently licensed for use 
in England: dabigatran, rivaroxaban, apixaban and edoxaban (NICE 2016b). 
Anticoagulation medications are used to prevent strokes related to non-valvular atrial 
fibrillation (AF) and for the acute treatment and secondary prevention of venous 
thromboembolism (VTE). AF is the most common cardiac arrhythmia and increases the risk 
of clot formation within the heart, which can lead to stroke. Risk of thromboembolic stroke 
is increased five-fold among those with AF, with approximately 12,500 AF-related strokes 
each year (The Association of the British Pharmaceutical Industry 2014). Strokes 
experienced by people with AF are typically more severe, with less chance of recovery, 
higher mortality and morbidity and longer hospital stays, compared to those without AF 
(Atrial Fibrillation Society 2014). The under-utilisation of anticoagulation therapy in patients 
with AF at high risk of stroke has been identified as a major gap in clinical care (Lee et al. 
2011). 
Venous thromboembolism (VTE) occurs when blood clots form in deep veins, usually in the 
legs or pelvis (known as deep vein thrombosis). These may also be displaced to the 
pulmonary arteries, resulting in pulmonary embolism. It has been noted that over 44,000 
hospital admissions, in 2013, were due to pulmonary embolism or deep vein thrombosis 
(NICE 2016c). Risk factors for VTE include age (with older people being at a higher risk); 
patients undergoing major surgery (especially hip fracture surgery, and other illness such as 
cancer), and hospitalised general medical patients having long periods of inactivity in bed 
(NHS Confederation 2009). Recurrence of VTE within eight years is estimated at 
approximately 30% and is an important cause of long-term morbidity, being identified as a 
risk factor for chronic leg ulceration and pulmonary hypertension (Barnes et al. 2015; NHS 
Confederation 2009). 
Current NICE guidelines (last updated in 2014) recommend the use of both warfarin and 
NOACs for the prevention and treatment of AF and for the treatment of VTE (NICE 2012, 
2014). However, since the publication of the NICE guidance, several uncertainties have been 
raised relating to the efficacy, safety and patient experience of anticoagulation medicines. 
These are discussed further below. 
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Warfarin requires frequent monitoring through blood tests to ensure that treated patients’ 
levels of anticoagulation remain within a narrow range of therapeutic effect. Patients are 
thought to be less compliant with monitoring due to the frequency with which they must 
visit outpatient clinics (Abdou et al. 2016). Anticoagulation levels are measured as an 
international normalised ratio (INR), with a normal range limit of 2 to 3. If the INR falls to 
less than 2 (under dose), the risk of stroke increases; whereas an INR of more than 3 
(overdose) increases the risk of intracranial bleeding. The action of newer, alternative 
NOACs (dabigatran, rivaroxaban, edoxaban, and apixaban) is much more accurate, reducing 
the need for such close surveillance (Mekaj et al. 2015). Some authors, however, have 
expressed concern about adherence to anticoagulation medication in the absence of regular 
monitoring (Suryanarayan and Schulman 2014). Nonetheless, a recent literature review 
suggested no reported differences between warfarin and NOACs in terms of patient 
adherence (Abdou et al. 2016). As an alternative to frequent clinic visits, self-monitoring of 
warfarin may reduce the demand on anticoagulation clinics (and associated costs). However, 
despite being recommended by NICE (NICE 2017), it has been suggested that uptake has 
been low, possibly due to the upfront cost pressures and limited evidence of cost savings. 
Due to the complexity of warfarin’s mode of action and metabolism, its effect can be altered 
by a number of medications and food and alcoholic drinks. This can present challenges to 
patients. For example, a consistent intake of vitamin K and modified alcohol intake is 
important. Patients need to recheck INR levels when starting new medications, particularly 
antibiotics. While NOACs do not require these adjustments they have not been available for 
as long as warfarin, thus less is known about their potential adverse interactions, 
particularly for patients with other co-morbidities (Willett and Morrill 2017). However, some 
suggest that this concern may be offset by the lower risk of severe haemorrhage reported 
within clinical trials of NOACs when compared with warfarin (Graham et al. 2014, Larsen et 
al. 2014). For example, some studies have shown that for older patients, over the age of 65 
years, the risks of ischaemic stroke and intracranial bleeding and mortality were 
significantly reduced with dabigatran, compared with warfarin (Graham et al. 2014). 
Furthermore, there is some evidence to suggest that gastrointestinal bleeding is associated 
with NOACs among AF populations, although this effect has not been observed consistently 
(Ruff et al. 2014). 
NOACS are currently more expensive than warfarin (as they are newer). However, due to 
changing patient preferences, the regular monitoring required for warfarin, the interactions 
of warfarin with medications and drinks, and a potential greater risk of severe haemorrhage 
with warfarin, there is a growing shift towards prescribing NOACs. 
Data from several potentially influential trials have been reviewed since the last update of 
relevant NICE guidelines, in 2014. These may provide important new information to help 
guide optimal decision making for anticoagulants among NHS commissioners, clinicians and 
patients. Preliminary scoping searches led to the identification of over 800 systematic 
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reviews, published from 2014 onwards, that addressed the use of anticoagulants in either 
AF or VTE (Arnold et al. 2017, Hicks et al. 2016, Verdecchia et al. 2015, Zhang et al. 2015). 
Most comprehensively, a recent HTA systematic review concluded that there was no strong 
evidence that NOACs should replace warfarin for the prevention and treatment of VTE 
(Sterne et al. 2017). However, among AF populations there is some evidence to suggest that 
NOACs show advantages over warfarin. Furthermore, recent reviews on patient adherence 
and the patient/clinician experience of anticoagulants for AF and VTE have been brought 
together in qualitative evidence syntheses (Borg et al. 2012; Brown et al. 2012; Mas Dalmau 
et al. 2017), which may add important information about experiences of anticoagulation. 
 
2  Aims of review 
Preliminary searches suggest that the research evidence on oral anticoagulants has been 
synthesised considerably, but it is not clear how these address current policy priorities. To 
address this need, an overview of reviews was conducted with the aim to assess the clinical 
evidence, published since the 2014 NICE guidance. Its objective was to highlight where the 
evidence is cumulative, robust and addresses policy priorities, and note where gaps for 
future research synthesis or primary research necessitate commissioning. 
 
To address the uncertainties related to the clinical evidence on efficacy, safety and 
patient/clinician experience of oral anticoagulants, the following research questions were 
addressed: 
 
1. What evidence syntheses have been conducted to address the efficacy of UK-
approved oral anticoagulant therapy with respect to: 
a. Warfarin versus NOACs in different patient cohorts? 
b. The impact of warfarin versus NOACs on INR clinic capacity? 
c. The evidence for an optimised pathway on genotyping?  
d. The evidence for an optimised pathway on self-monitoring? 
2. What evidence syntheses have been conducted to address the safety of UK-approved 
oral anticoagulant therapy with respect to: 
a. Renal function and the long-term use of NOACs? 
b. Complications associated with warfarin and NOACs including bleeding and 
stroke risk? 
3. What are patient and clinician experiences of UK-approved oral anticoagulant 
therapy concerning: 
a. The impact of NOACs and warfarin on patient lifestyle? 
b. Medicines adherence and compliance of NOACs and warfarin? 
c. Clinician perceptions of NOACs and warfarin? 
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d. Monitoring INRs in patients receiving VKAs and the effect on patient 
adherence?  
 
3  Methods 
We undertook an overview of existing systematic reviews. This approach provides a 
systematic and transparent method for bringing together existing evidence rapidly, so is 
particularly suited for addressing policy questions (Gough and Thomas 2016).   
 
Search 
To locate the most recent systematic reviews, relevant electronic sources were searched in 
October 2017. Searches were limited to four electronic health databases: MEDLINE, 
Embase, ASSIA and CINAHL. To maximise efficiency, one broad search was conducted in 
each of the databases to identify systematic reviews addressing efficacy, safety or patient 
experience. We limited the searches to 2014 onwards (the year in which the most recent 
relevant NICE guidelines were published). Citations (titles and abstracts) were uploaded into 
EPPI-Reviewer (specialist systematic review software), for the management of publication 
retrieval, coding and synthesis (Thomas et al. 2010). Collaborators at the Department of 
Health and Social Care also provided potentially relevant, published and unpublished 
research and policy documents for screening. See Appendix 1 for the MEDLINE search 
strategy, which was translated for use in the other databases. 
 
Screening for study inclusion/exclusion 
Following a pilot screening stage, all citations were screened on the basis of title and 
abstract. Relevant studies were retrieved, and full-text reports rescreened using the same 
process. Systematic review citations were assessed for inclusion/exclusion using the criteria 
in Table 1 below:  
 
Table 1: Exclusion criteria. 
Exclusion criteria Details 
Exclude date of publication Published prior to 2014  
Exclude on language Is not available in English 
Exclude on setting Review focuses specifically on non-OECD settings. 
Exclude on population Does not focus on adults (18 years or older) eligible for 
oral anticoagulation 
Exclude on topic a) Does not focus on oral anticoagulants for stroke 
prevention in atrial fibrillation (AF) or acute treatment 
and primary and secondary prevention of venous 
thromboembolism, VTE); where the focus of >50% of 
included studies is on AF and/or VTE populations or data 
for these groups are extractable  
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Exclude on topic b) Does not focus on one of the following five 
anticoagulants: warfarin, dabigatran, rivaroxaban, 
edoxaban, or apixaban 
Exclude on method Is not a systematic review (i.e. authors do not describe 
search strategy and search at least two databases, 
inclusion/exclusion criteria and quality assessment 
methods not reported); OR the citation is a conference 
abstract) 
Exclude on comparator 
(efficacy and safety synthesis 
only) 
Does not assess therapeutic doses of warfarin  
compared with NOACs (dabigatran, rivaroxaban, 
edoxaban, and apixaban) 
Exclude on outcomes  Does not include health, patient experience or cost 
outcomes 
Exclude duplicate Duplicate record 
 
Title and abstract screening resulted in over 400 recent systematic reviews of efficacy and 
safety. In consultation with NHS commissioners, the decision was made to focus on the most 
recent, rigorous and comprehensive overview of systematic reviews located, which 
addressed our research questions (Sterne et al. 2017). 
 
Data extraction 
Bespoke data extraction frameworks were developed to code the included reviews according 
to key characteristics. These descriptive codes allowed us to describe the type and quantity 
of evidence available, including: 
• Year of publication; 
• Date range of included primary studies; 
• Setting (community, hospital); 
• Main topic focus (e.g., efficacy, safety, experiences, or cost); 
• Target population (health condition, or at risk group); 
• Participant characteristics (e.g., age, and gender); and 
• Intervention characteristics (e.g., type of oral anticoagulant, or self-monitoring). 
 
Reviews were additionally coded according to their relevant characteristics of interest, for 
example: 
• Countries of included studies; 
• Number of primary studies included in the review; 
• Primary study design(s); 
• Type of outcomes measured (e.g., mortality, stroke or thromboembolic 
complications, bleeding, hospitalisation, health-related quality of life, or patient 
experiences); and 
• Extent of overlap of primary studies across reviews. 
 
Relevant characteristics were added as they emerged from the data. 
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Risk of bias assessment 
All relevant reviews were assessed for methodological quality using AMSTAR or AMSTAR2 
criteria (Shea et al. 2007; Shea et al. 2017), or quality assessment criteria for reviews of 
mixed methods and qualitative evidence syntheses (Aromataris et al. 2015). Criteria were 
summed and categorised as low, medium or high quality, as appropriate. Two reviewers 
quality-assessed a common set of reviews and met to agree them in order to establish 
consistency. Once consistency was achieved, one reviewer quality-assessed each review and 
these assessments were checked by a second reviewer, with discussion to resolve any 
differences in ratings. Remaining disagreements in ratings were resolved by a third 
reviewer, where needed. The risk of bias tools are provided in Appendices 2 and 3. 
 
Synthesis of evidence 
The overview synthesis comprised a descriptive map of reviews organised by the efficacy, 
safety and cost-effectiveness of oral anticoagulation medication (Chapter 5) genotyping 
(Chapter 6), efficacy of self-monitoring interventions for the management of 
anticoagulation medication (Chapter 7), and adherence and patient and clinician 
experiences (Chapter 8). Reviews were brought together in two stages. First, we mapped 
the characteristics of the reviews, in order to understand the different aims, populations, 
settings, interventions and comparisons, patient/clinician outcomes or experiences, and risk 
of bias ratings. Next, we mapped these characteristics, and the review findings, to the 
policy priorities highlighted in our research questions to highlight gaps in the existing 
evidence base. 
 
For reviews of efficacy, safety and cost-effectiveness of oral anticoagulation medication, 
data were extracted by one reviewer and checked by another (shared between MR, LB and 
CK). All discrepancies were resolved through discussion. A description of the findings from 
four systematic reviews with network meta-analyses (NMAs) of randomised controlled trials 
(RCTs) were extracted. Effect size estimates were not extracted due to the large number 
of comparisons within each review. Statements about effectiveness were, therefore, 
reported (as summarised by Sterne and colleagues) by each outcome (stroke, symptomatic 
VTE, symptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), 
major, clinically relevant and intracranial bleeding, myocardial infarction, and death from 
all causes). For details about network plots, and summary statistics, such as odd ratios (ORs) 
and 95% credible intervals, please refer to Sterne et al. (2017)’s report. Following on from 
this, Sterne and colleagues’ rankogram analyses are presented.14 The main conclusions of 
the cost-effectiveness analyses, where carried out, are also reported (please refer to Sterne 
et al. 2017 for detailed methods). Summaries emphasise the comparisons involving warfarin 
and NOACs, with reference to other interventions (LMWH and antiplatelets), where 
informative. 
                                             
14 Rankogram analyses calculate the probability that each treatment is best, second best, and so 
on. 
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For the reviews of self-monitoring, data were extracted by one reviewer and checked by 
another (shared between MR and CK). Time in therapeutic range (TTR) was selected as the 
primary outcome measure, due to consistency in reporting across the reviews and clinical 
relevance. Data were extracted by condition (AF/VTE), where possible, otherwise data for 
mixed conditions were extracted. Meta-analytic data were extracted, where available, 
otherwise the direction of effects and statistical significance were extracted. Findings were 
synthesised by the type of self-monitoring intervention including education, education and 
decisions aids, self-testing, self-management, and pharmacist-managed anticoagulation. 
The findings were synthesised in tables and narratively. 
 
For the reviews of stakeholder perspectives and experiences, two researchers (GB and MK) 
discussed and devised the coding tool appropriate to the included reviews. After agreeing 
on the tool, the two researchers independently carried out data extraction and then met to 
discuss and agree these findings. Reviews were grouped according to their aims and the two 
researchers developed themes from the review authors’ findings. 
 
A narrative synthesis approach was taken for the reviews of genotyping. The narrative was 
structured by review aim, with findings from each included review with similar aims 
discussed, in turn, and compiled by at least two members of the review team (GS, RW, HB). 
 
Quality assurance 
Two reviewers screened a subset of the same reviews using the inclusion/exclusion criteria 
until an inter-rater agreement >90% was attained. This was followed by single reviewer 
screening. Disagreements or queries on inclusion were referred to a third reviewer, as 
needed. The same process was applied during data extraction and risk of bias/quality 
assessment stages of the overview, with a second reviewer checking each review’s data 
extraction and risk of bias/quality assessment. Quality assurance checks of data extraction 
and risk of bias assessment were conducted using a random sample of included reviews. The 
overview protocol was registered on PROSPERO. No changes were made to the protocol 
during the conduct of the overview, although findings for efficacy and safety were based on 
a single recent comprehensive high quality systematic review (Sterne et al. 2017) rather 
than an overview of multiple reviews. 
 
Stakeholder involvement 
The Department of Health and Social Care’s Science, Research and Evidence Directorate 
and NHS England were consulted, as was a group of external academic and clinician advisors, 
with expertise in anticoagulation therapy who had worked previously with NHS England. In 
addition, to reduce the risk of duplicating the research effort of updating clinical guidelines 
in this research area, relevant teams at NICE were provided with the overview protocol.
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4  Results: Flow of included reviews 
A total of 3,119 references were located through searching. A total of 425 systematic 
reviews examining efficacy and/or safety were identified, precluding their analysis within 
the timelines set for this overview. One was a recently published NIHR HTA report of OACs 
efficacy and safety, and was determined to be the most comprehensive and highest quality 
for the purposes of this overview (Sterne et al. 2017); the other 424 were excluded. Of the 
remaining citations that were not focused on efficacy or safety, 49 were potentially relevant 
based on title and abstract and their full-text reports were retrieved (along with Sterne et 
al. 2017). After assessment of full-text reports a total of 23 reviews (including Sterne et al. 
2017) were included in this overview. The flow of reviews through the overview process is 
listed in Appendix 4.  
 
The review of efficacy and safety comprised multiple evidence syntheses concerning the 
range of UK-approved oral anticoagulant therapies. These are discussed in detail in Chapter 
5. Another ten reviews examined genotyping and are described in Chapter 6. A further six 
reviews focused on self-monitoring and are discussed in Chapter 7. A total of nine reviews 
were identified that examined patients’ and clinicians’ perspectives about the issues related 
to utilisation and uptake of OACs and are reported in Chapter 8. Three of the included 
reviews were common to both self-monitoring and patient/clinician perspectives. As 
requested by the policy team, additional reference lists of reviews of economic evaluations 
and reviews of overdose or reversal treatments are provided in Appendices 5 and 6. 
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5  Results: Reviews of efficacy and safety of oral anticoagulant 
therapies 
Summary of evidence reported in Sterne et al. (2017) 
• Four systematic reviews with network meta-analyses (NMAs) of randomised 
controlled trials (RCTs) were conducted to identify the most effective, safe and cost-
effective oral anticoagulants. 
 
• The reviews covered four conditions or stages: Prevention of stroke in non-valvular 
atrial fibrillation (AF; Review 1); Primary prevention of venous thromboembolism 
(VTE) among those admitted to hospital and deemed to be at high risk (Review 2); 
Acute treatment of VTE (Review 3); and Secondary prevention of VTE (Review 4). 
 
• Each review included RCTs of adults aged 18 years or older, who were eligible for 
oral anticoagulation. 
 
• Interventions included warfarin, five novel oral anticoagulants (NOACs), including 
one that is not licensed in the UK,15 low-molecular-weight heparin (LMWH) and 
antiplatelets (aspirin and/or clopidogrel). 
 
• Outcomes measured included stroke, symptomatic VTE, symptomatic deep-vein 
thrombosis (DVT), symptomatic pulmonary embolism (PE), major, clinically relevant 
and intracranial bleeding, myocardial infarction, and death from all causes. 
 
• RCTs were most often conducted in more than one centre, including some in multiple 
countries. Study locations were America, Europe, Asia, Australia, New Zealand, 
South Africa, Russia and Israel. 
 
• Analyses were based on Bayesian fixed-effect models due to insufficient replication 
of intervention comparisons to allow estimation of the heterogeneity.16 Investigation 
of potential moderators of effects (such as age and comorbidities) was, therefore, 
not possible in most cases. 
 
• Reviews most often provided either direct-only evidence syntheses or indirect-only 
evidence syntheses for the NMAs. Where syntheses contained both direct and indirect 
comparisons and findings conflicted, the authors emphasised direct comparisons. All 
                                             
15 Apixaban (Eliquis®, Bristol-Myers Squibb, USA; Pfizer, USA), edoxaban (Lixiana®, Daiichi Sankyo, 
Japan), rivaroxaban (Xarelto®, Bayer HealthCare, Germany), dabigatran (Praxada®, Prazaxa®, 
Pradax®, Boehringer Ingelheim GmbH, Germany), as well as betrixaban (Portola Pharmaceuticals, 
San Francisco, CA, USA), which is not licensed in the UK. For licensed doses, see Appendix 7. 
16 For detailed information on analytic methods, see Sterne et al. (2017)’s report p50. 
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comparisons between different NOACs were based on indirect evidence derived from 
the networks (as there were no direct comparisons for these located in the 
literature). 
 
• Rankogram analyses (the probability that each treatment is best, second best, and 
so on) and cost-effectiveness analyses were also reported (discussed below). 
 
• The quality of each of the reviews presented by Sterne et al. (2017) was assessed 
using six domains17 of the Cochrane Risk of Bias Tool, which categorises risk as ‘low’, 
‘high’ or ‘unclear’ for each study. For each review, the AMSTAR risk of bias showed 
low risk in 11 domains,18 high risk in two domains19 and unclear in three domains.20 
 
• Overall, the review authors rated the primary included studies as being at low risk 
of bias, although for the review on the prevention of stroke related to AF, the risk 
of bias was mixed (low, high and unclear) at the outcome level. 
 
• No overlap between primary studies occurred, as each review examined specific 
topics. 
 
Summary of findings 
• Among AF populations, NOACs showed advantages over warfarin for most efficacy 
and safety outcomes. Of these, apixaban (5mg bd) offered the best balance between 
efficacy and safety and had the highest probability of being most cost-effective. 
 
• There is no strong evidence to support the use NOACs for VTE for primary prevention 
(compared with low-molecular-weight heparin (LMWH)), acute treatment (compared 
with warfarin) and secondary prevention (compared with warfarin and aspirin).  
 
• However, in terms of safety, apixaban (5mg bd) and rivaroxaban (15mg bd, then 
20mg od) may reduce the risk of major and clinically relevant bleeding, compared 
with warfarin, for acute and secondary treatment and for secondary prevention of 
VTE. 
 
                                             
17 1. Sequence generation; 2. Allocation concealment; 3. Blinding of participants and personnel; 4. 
Blinding of outcome assessment; 5. Incomplete outcome data; and 6. Selective reporting. 
18 Including use of PICO, inclusion criteria, duplicate screening, duplicate data extraction, 
description of included studies, risk of bias in RCTs, detail of funding arrangements, appropriate 
meta-analytic methods for RCTs, explored meta-analytic findings in light of risk of bias, discussed 
findings in light of heterogeneity, and reported conflicts of interests. 
19 Failed to report excluded studies and the justifications for their exclusion, and failed to test and 
discuss publication bias. 
20 Failed to provide a statement about following or deviating from the protocol, failed to conduct a 
comprehensive search strategy (not up to date), and the integration of risk of bias in the 
interpretation of the results was unclear. 
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• For secondary prevention of VTE, aspirin was likely to be the most cost-effective 
alternative to warfarin. 
 
• authors concluded that prescribers and patients may choose to exercise caution 
when considering the results of these reviews. This was due to a lack of direct 
comparisons between NOACs, a reliance on short-term data, and limited 
generalisability to clinical contexts. 
 
 
More detailed findings of the NMAs are provided below. Tabular details are provided in the 
appendices, including each review’s key characteristics (Appendices 8 and 9) and their 
quality appraisal using AMSTAR criteria (Appendix 10). 
 
Review 1. Prevention of stroke in AF  
This review aimed to identify the most effective, safest and cost-effective oral 
anticoagulants to prevent stroke in AF. Forty-one papers detailing 23 RCTs carried out in 
primary care and anticoagulation clinics were included21 (see Appendix 8). The size of 
studies varied widely, from 75 to 21,105 participants, with a total of 94,656 participants. 
All studies focussed on adults with non-valvular AF (including permanent or chronic, 
persistent, intermittent and paroxysmal). Mean age ranged from 63.3 to 81.5 years, and the 
percentage of men ranged from 44.9% to 82.9%.22 
 
Warfarin was examined in all but two of the 23 studies, and was compared against a NOAC 
in 12 studies, and against aspirin in nine. Thirteen studies compared one NOAC each with 
warfarin (n=12) or aspirin (n=1). Edoxaban was the NOAC most commonly studied (n=4), 
followed by apixaban or dabigatran (n=3 each), rivaroxaban (n=2) and betrixaban23 (n=1). 
The doses and frequencies of administration varied. The duration of treatment varied widely 
across trials, from three to 42 months. Mean time in therapeutic range (TTR) for warfarin 
ranged between 45.1% and 83%. NMAs were performed for seven outcomes: stroke or 
systemic embolism, ischaemic stroke, myocardial infarction (MI), major bleeding, clinically-
relevant bleeding (CRB), intracranial bleeding and all-cause mortality. All trials provided 
data on stroke24 and 15 measured myocardial infarction. Major bleeding and all-cause 
mortality (k=18 each) were the safety outcomes most frequently reported (see Appendix 
9). 
 
                                             
21 Arms that were considered not to provide any evidence of interest to inform health decisions in 
the UK were excluded from the analyses by the primary review authors. 
22 Mean age was reported in only 61% of the trials, and percentage of males in 78%. 
23 Betrixaban is not licensed in the UK. 
24 More precisely, 15 trials assessed stroke or systemic embolism, and 13 measured ischaemic 
stroke. 
The effective, safe and appropriate use of anticoagulation medicines: A systematic 
overview of reviews 
 
 
30 
 
The review authors Sterne et al. (2017) concluded that the primary studies were at low risk 
of bias. Two trials were at a low risk of bias for all six domains; 11 were at a high risk for 
one domain (all for blinding of participants and personnel); three were at a high risk for two 
or more domains (including blinding of participants/personnel, outcome assessments and 
allocation concealment). The remaining trials (k=7) were unclear for at least one domain 
(but had no high-risk domains). Grouping studies by each outcome, risk of bias was identified 
as ‘mixed’ (low, high and unclear ratings). 
 
Findings and the risk of bias are summarised by outcome in Appendix 12. Rankogram 
analyses for warfarin (INR 2–3); dabigatran (150mg bd); edoxaban (60mg od); rivaroxaban 
(20mg od); apixaban (5mg bd); and antiplatelet therapy (≥ 150mg od), suggested that: 
 
• Warfarin was ranked among the worst-performing drugs for risk of stroke or systemic 
embolism and ischaemic stroke, and was not among the best three anticoagulants 
for any of the outcomes 
• Warfarin (INR 2–3) was ranked as the worst-performing for risk for intracranial 
bleeding 
• With the exception of the CRB outcome, apixaban (5mg bd) was likely to be one of 
the best-performing for all outcomes (major bleeding, intracranial bleeding, all-
cause mortality, stroke or systemic embolism, ischaemic stroke and MI) and had 
highest probability of being most cost-effective25 
• Edoxaban (60mg od) was ranked second-best for reducing the risk of major bleeding 
and all-cause mortality (though there was evidence that edoxaban 30 and 60mg bd 
may increase that risk) 
• With the exception of the all-cause mortality and MI outcomes, rivaroxaban (20mg 
od) was ranked lower in performance, compared with apixaban (5mg bd), dabigatran 
(150mg bd) and edoxaban (60mg od), across all outcomes 
• Antiplatelet therapy (aspirin/clopidogrel ≥150mg od) was ranked among the lowest-
performing for risk of stroke or systemic embolism and was not among the best three 
anticoagulants for any of the outcomes 
 
Overall, in patients with AF, it was concluded: 
 
• NOACs showed advantages over warfarin for most outcomes 
• Among treatments in the rankogram analyses (warfarin (INR 2–3); dabigatran (150mg 
bd); edoxaban (60mg od); rivaroxaban (20mg od); apixaban (5mg bd); and 
antiplatelet therapy (≥ 150mg od)):  
• Warfarin and antiplatelet therapies were not ranked in the top three for any of 
the outcomes 
                                             
25 Antiplatelet (≥ 150mg od) therapy was not included in the cost-effectiveness analysis. 
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• Apixaban (5mg bd) was likely to be one of the best anticoagulants for reducing 
the risk of stroke or systemic embolism, major bleeding, intracranial bleeding, 
all-cause mortality, stroke or systemic embolism, ischaemic stroke, and MI 
• Apixaban also had the highest probability of being most cost-effective25 
 
Review 2. Primary prevention of VTE  
This review aimed to identify the most effective, safe and cost-effective oral anticoagulants 
for the primary prevention of VTE, in hospital settings. Forty-six articles detailing 43 RCTs 
were included.26 However, only 38 RCTs were included in the analysis.27 Adults considered 
to be at a high risk of VTE due to a medical condition (e.g., cancer, major trauma, or stroke) 
or surgery (hip or knee) were included. Of the 43 trials, 36 focused on patients who 
underwent a surgery; 18 for the hip, 17 for the knee, and one assessed both. The seven 
remaining studies assessed patients with a variety of medical conditions associated with a 
high risk of VTE.28 Study size ranged from 67 to 8,323 participants, with a total of 77,563 
participants overall. Where reported, mean age ranged from 41 to 76 years, and the 
percentage of men ranged from 13.1 to 62.7.29 
 
Thirty-nine of the 43 studies assessed a LMWH.30 Thirty-one compared one NOAC each with 
either LMWH (k=27), a placebo (k=3) or both LMWH and warfarin (k=1). Rivaroxaban was the 
NOAC that was most commonly studied (k=11), followed by dabigatran (k=7), apixaban and 
edoxaban (k=6 each) and betrixaban31 (k=1). The doses and frequencies of administration 
varied. For the analyses, ‘standard doses’ of LMWH included tinzaparin (0.45mL od), 
enoxaparin (40mg od or 30mg bd) and dalteparin (5,000 IU). In the surgery trials, LMWH was 
started before the operation in 16 studies, after in 19, and one compared pre-op with post-
op treatments. Overall, the duration of treatment varied from 432 to 182.633 days. None of 
the RCTs with warfarin reported the mean TTR. 
 
NMAs were conducted for seven outcomes. Among the 43 papers, the most common efficacy 
outcome was symptomatic PE (k=35),34 followed by symptomatic VTE (k=29) and 
                                             
26 Arms that were considered not to provide any evidence of interest to inform health decisions in 
the UK were excluded from the analyses by the primary review authors. 
27 Three trials were excluded from all NMAs because they used non-standard variants of heparin. No 
reference nor reasons for exclusion were provided for the two other trials. One of the latter was 
included in the assessment of major bleeding (39 studies were included for this outcome). 
28 Such as metastatic cancer, congestive heart failure, acute respiratory failure, infection (without 
septic shock), acute rheumatic disorder, or inflammatory bowel disease. 
29 Mean age and percentage of males were reported in 88% of trials. 
30 Standard dose for LMWH included tinzaparin (0.45mL od), enoxaparin (40mg od or 30mg bd) and 
dalteparin (5,000 IU). 
31 Betrixaban is not licensed in the UK. 
32 One trial provided LMWH for 3.3 to 11.3 days, and apixaban for 14.9 to 34.9 days. 
33 In three studies, the NOAC was given for a longer period than the comparator (LMWH). 
34 30 trials were included in the analyses for PE, 28 for VTE, 20 for DVT, nine for MI, 34 for major 
bleeding, 25 for CRB, and 24 for mortality. No explanation was given for these differences in the 
numbers of trials included in the analyses. 
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symptomatic DVT (k=25), and these were analysed separately for medical conditions or type 
of surgery (hip or knee). The safety outcomes included major bleeding (k=39), all-cause 
mortality (k=28), CRB (k=27), and myocardial infarction (k=9), and these were assessed 
collectively across conditions. 
 
Review authors (Sterne et al. (2017) judged the studies to be at a low risk of bias. Five trials 
were at a low risk of bias for all six domains, across all outcomes; eight were at a high risk 
for one or more domain (six for blinding of participants and personnel; one for blinding of 
outcome assessment, and allocation concealment; and one for blinding of participants and 
personnel, and incomplete outcome data). The remaining 30 were unclear for at least one 
domain, with none at high risk (some were at low risk across all domains for some outcomes, 
but not others). Blinding of participants and providers was a common issue for trials that 
had an open-label design (i.e. neither the participants nor the providers and assessors were 
blind to the treatment received). Similarly, by synthesis of outcome, risk of bias was also 
rated generally as low, but with some concerns. 
Findings are summarised by outcome in Appendix 13.35 Rankogram analyses for warfarin 
(INR 2–3); apixaban (2.5mg bd); dabigatran (220mg bd); rivaroxaban (10mg od); and LMWH 
post/pre-op (standard dose)36 suggested that: 
 
• Warfarin was likely to be the best intervention to reduce the risk of major bleeding 
events 
• Rivaroxaban (10mg od) was likely to be one of the worst anticoagulants for major 
bleeding and CRB 
• LMWH (post-op, standard dose) was likely to be the best or second-best intervention 
to reduce the risk of CRB 
• Among AF populations, NOACs showed advantages over warfarin for most efficacy 
and safety outcomes. Of these, Apixaban (5mg bd) offered the best balance between 
efficacy and safety and had the highest probability of being most cost-effective 
• There is no strong evidence to support the use NOACs for VTE for primary prevention 
(compared with low-molecular-weight heparin (LMWH), acute treatment (compared 
with warfarin) and secondary prevention (compared with warfarin and aspirin) 
• However, in terms of safety, apixaban (5mg bd) and rivaroxaban (15mg bd, then 
20mg od) may reduce the risk of major and clinically relevant bleeding compared 
with warfarin for acute and secondary treatment and secondary prevention of VTE 
• For secondary prevention of VTE, aspirin was likely to be the most cost-effective 
alternative to warfarin 
 
                                             
35 Following Sterne et al. (2017), results for which the ratio between the limits of the 95% 
confidence intervals exceeded nine are not reported. 
36 Standard dose for LMWH included tinzaparin (0.45mL od), enoxaparin (40mg od or 30mg bd) and 
dalteparin (5,000 IU). Apixaban (2.5mg bd) and betrixaban (40mg od) were not included in the 
comparisons due to the lack of precision in their estimates. 
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Overall, for the primary prevention of VTE, Sterne et al. (2017) concluded: 
 
• Neither the clinical effectiveness analysis nor the cost-effectiveness analysis 
(comparing dabigatran (220mg bd), rivaroxaban (10mg od), and apixaban (2.5mg bd), 
with LMWH (post-op, standard dose) as usual care) provided strong evidence that 
NOACs should replace LMWH for the primary prevention of VTE after hip or knee 
surgery 
• Among treatments in the rankogram analyses (warfarin (INR 2–3); apixaban (2.5mg 
bd); dabigatran (220mg bd); rivaroxaban (10mg od); and LMWH post/pre-op 
(standard dose)), warfarin was likely to be the best to prevent major bleeding, and 
LMWH the best or second-best for CRB 
 
Review 3. Acute treatment of VTE  
The aim of Review 3 was to assess the most effective, safest and cost-effective oral 
anticoagulants for the acute treatment of VTE in hospital settings. Nine RCTs (referenced 
in ten papers) were included. The population consisted of adults with a new or recurrent 
objectively confirmed diagnosis of acute symptomatic VTE. Trial size ranged from 520 to 
8,292, with a total of 28,803 patients. The mean age of patients ranged from 54.7 to 59.1 
years, and the percentage of male patients ranged from 51 to 62. Four NOACs were assessed: 
rivaroxaban (n=4); dabigatran (n=2); apixaban (n=2); and edoxaban (n=1). 
 
All nine trials compared the NOAC with warfarin. Trials lasted from 12 to 48 weeks, with 
assessments made at the end of the treatment period. Mean TTR ranged from 56.9% to 63.5% 
among the eight studies that measured it.37 The outcomes that were assessed in the NMAs 
were symptomatic VTE (n=8),38 symptomatic DVT (n=9), symptomatic PE (n=9), myocardial 
infarction (n=5), major bleeding (n=9), CRB (n=8), and all-cause mortality (n=8). 
 
The trials were generally rated as at low risk of bias by Sterne et al. (2017). Three trials 
were at a low risk of bias for all six domains; four were at a high risk for one domain (blinding 
of participants and personnel) and one was at a high risk for two domains (blinding of 
participants and personnel and incomplete outcome data). One trial was at low risk across 
all domains for some outcomes, but not others. Similarly, by synthesis of outcome, risk of 
bias was rated as generally low. 
 
Findings are summarised by outcome in Appendix 14. Rankogram analyses for warfarin 
(INR2-3), apixaban (5mg bd), dabigatran (150mg od), edoxaban (60mg or 30mg (17.6%) od) 
and rivaroxaban (15mg bd then 20mg od) suggested that: 
 
• Warfarin had a high probability of being ranked worst for major bleeding and CRB 
                                             
37 Page 171 of Sterne’s report mentions a range of 50.3% to 62.7%, but Table 107 shows values from 
56.9% to 63.5%. 
38 Table 107 in Sterne’s report shows eight studies, while the summary (p171) only mentions seven. 
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• Apixaban (5mg bd) had a high probability of being ranked best for major bleeding 
and CRB and of being ranked best, or second best, for symptomatic DVT, 
symptomatic VTE and all-cause mortality 
• In the comparison of apixaban (5mg bd), dabigatran (150mg od), edoxaban (60mg or 
30mg (17.6%) od), rivaroxaban (15mg bd then 20mg od) and warfarin (as usual care), 
apixaban (5mg bd) was the most cost-effective alternative to warfarin at willingness-
to-pay thresholds of £20,000 to £30,000 
• However, the reviewers concluded that further research on the relative efficacy and 
safety of apixaban, compared with other NOACs would increase the strength of 
evidence 
 
Overall, in patients receiving acute treatment of VTE, the review authors (Sterne et al. 
(2017) concluded that: 
 
• There was no clear evidence that NOACs or warfarin were more beneficial in terms 
of reducing symptomatic VTE, DVT or PE 
• Apixaban (5mg bd) and rivaroxaban (15mg bd then 20mg od) may reduce the risk of 
major bleeding and CRB, compared with warfarin 
• Apixaban (5mg bd) may reduce the risk of major bleeding, compared with some other 
NOACs (dabigatran 150mg od, edoxaban 60mg or 30mg (17.6%) od, and rivaroxaban 
15mg bd then 20mg od) 
• Apixaban (5mg bd) was likely to be the most cost-effective alternative to warfarin, 
although more research into the relative efficacy and safety of apixaban compared 
with other NOACs is needed 
 
Review 4. Secondary prevention of VTE  
The aim of Review 4 was to assess the most effective, safest and most cost-effective oral 
anticoagulants for the secondary prevention of venous thromboembolic disease. Ten RCTs 
(reported in 11 articles), examining interventions in primary care and anticoagulation 
clinics, were included.39 Adults who had completed a minimum of three months of 
anticoagulant therapy for objectively confirmed, first VTE (DVT and/or PE), without 
recurrence, were included. Trial size ranged from 162 to 2,866, with a total of 10,390 
patients. The mean age ranged from 53 to 67.3 years, and the percentage of males from 
52.8 to 63.9.40 
 
Three NOACs were assessed; dabigatran (150mg bd) (n=2), apixaban (2.5 and 5mg bd) (n=1), 
and rivaroxaban (20mg od) (n=1). Three trials compared the NOAC with placebo and one 
compared dabigatran with warfarin. Four trials compared warfarin with placebo (n=2) or no 
                                             
39 Arms that were considered not to provide any evidence of interest to inform health decisions in 
the UK were excluded from the analyses by the primary review authors. 
40 Mean age was reported in 90% of trials, and percentage of males in all of them.  
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treatment (n=2), and two compared aspirin (100mg od) and placebo. Studies lasted from 3 
to 51.6 months. Mean TTR was reported in three of the five warfarin trials ranging from 64% 
to 81%. Seven outcomes were assessed in the NMAs including symptomatic VTE (n=10); 
symptomatic DVT (n=9); symptomatic PE (n=9); myocardial infarction (n=5); major bleeding 
(n=10); CRB (n=6); and all-cause mortality (n=9). 
 
The trials were generally rated as at low risk of bias by Sterne et al. (2017). Three trials 
were at a low risk of bias for all six domains; two were at a high risk for one domain (blinding 
of participants and personnel); and one was at a high risk for two domains (blinding and 
allocation concealment). The remaining four were a combination of low risk and unclear 
risk of bias. Similarly, by synthesis of outcome, risk of bias was also rated generally as low, 
but with some concerns. 
 
Findings are summarised by outcome in Appendix 15.41 Rankogram analyses could not be 
performed due to the substantial proportion of imprecise estimates. Overall, for the 
secondary prevention of VTE using warfarin and NOACs, Sterne and colleagues concluded: 
 
• There was no clear evidence of differences between NOACs and warfarin, and 
between the different NOACs for symptomatic VTE and DVT 
• For symptomatic PE, the risk was higher with apixaban (2.5mg bd) than warfarin, 
and lower with dabigatran (150mg bd) and rivaroxaban (20mg od) than apixaban 
(2.5mg bd) 
• For major or clinically relevant bleeding, the risks were higher with warfarin, 
dabigatran (150mg od) and rivaroxaban (20mg od), than with placebo. However, 
compared with warfarin, the risk of these outcomes was lower for dabigatran (150mg 
bd) and apixaban (2.5mg and 5mg bd) 
• For major bleeding and CRB, the risk was higher with dabigatran (150mg bd) and 
rivaroxaban (20mg od) than apixaban (2.5mg bd and 5mg bd) 
• Warfarin and NOACs (apixaban 2.5mg and 5mg bd; dabigatran 150mg bd; and 
rivaroxaban 20mg od) reduced the risks of VTE and DVT, compared with aspirin 
 
In the comparison of aspirin, warfarin, apixaban (2.5 and 5), dabigatran, and rivaroxaban, 
with no treatment, aspirin was likely to be the most cost-effective alternative to warfarin 
at willingness-to-pay thresholds of £20,000 and £30,000 per QALY, although there was 
uncertainty about whether or not it was more cost-effective than no treatment. It was not 
cost-effective to prescribe NOACs or warfarin. The reviewers concluded that more research, 
comparing the cost-effectiveness of aspirin and no pharmacotherapy, would be beneficial. 
Quality appraisal of the four reviews with AMSTAR 
                                             
41 Results for which the limits of the 95% confidence intervals exceeded nine were excluded from 
synthesis of indirect effects (due to imprecision). 
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As shown in Appendix 10, the quality of reviews was rated using AMSTAR criteria (Shea et 
al. 2007). The risk of bias was judged to be low across 11 domains. Two domains showed 
high risk of bias; one because the reviews did not present information on the excluded 
studies, and one for not testing nor discussing potential publication bias. 
 
The risk of bias was unclear for three domains (transparency between report and protocol, 
search strategy, and discussion of findings in light of risk of bias). A protocol was registered 
for each review, but there was no indication as to whether these protocols were followed 
integrally or modified. In terms of the searches, whilst comprehensive, they were last 
updated 2.5 years before the publication of the report (a maximum of a two-year gap 
between search and publication date is required for a low risk on AMSTAR). Lastly, whilst 
the review authors (Sterne et al. 2017)’s analysis of risk of bias was very comprehensive, 
there was little integration of these assessments into the review conclusions about the 
efficacy and safety of anticoagulants.
The effective, safe and appropriate use of anticoagulation medicines: A systematic 
overview of reviews 
 
 
37 
 
6  Results: Reviews of genotyping 
Summary of evidence 
• Ten reviews were assessed in this synthesis. Within these reviews, 50% or more of the 
58 included primary studies assessed populations which included those with AF and/or 
VTE. 
 
• However, the outcomes that were reported in these studies were estimated from mixed 
patient populations, i.e. populations which comprised AF and/or VTE alongside patients 
with other indications for warfarin use. 
 
• Because the data of the AF/VTE population could not be extracted from the mixed-
population data presented in the reviews, none of the studies met our overview’s 
original inclusion criteria. Of the 22 identified reviews that focused on genotyping, four 
were not systematic reviews, six did not include AF or VTE patient populations, one did 
not focus specifically on anticoagulation and one did not have any information on health 
or cost outcomes. 
 
• Despite this, it was felt that the remaining reviews have value and highlight some of the 
clinical implications of genotyping within this patient population. We have, therefore, 
produced a descriptive synthesis of the identified research. 
 
• Genotyping was examined in different ways: 
• Six reviews looked at how clinical outcomes differed between patients who 
received genotype-guided dosing, compared with those who received non-
genotype-guided dosing, such as those using clinical dosing algorithms; 
• Three reviews investigated how warfarin maintenance doses differed between 
patients with different gene polymorphisms; 
• One review investigated how adverse outcomes differed between patients with 
different gene polymorphisms; and 
• Three of the reviews investigated how ethnicity may play a role in the variation 
observed in anticoagulant dosing and clinical outcomes between patients. 
 
• The reviews investigated polymorphisms of four main genes CYP4F2, the VKORC1, the 
CYP2C9 and the Apolipoprotein E (ApoE). 
 
• The assessed reviews included total populations ranging from 1,766 to 5,688 patients 
who had at least one indication for the use of anticoagulation therapy. 
 
• Reviews included, Asian, Caucasian, African American and Hispanic patients; however, 
ethnicity was not always clearly reported (e.g., ‘White’ or ‘Black’ populations); and 
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included studies varied in their proportions of male and female patients, ranging from 
12.6% to 70% female participants. 
 
• The most common clinical outcome assessed was the time within therapeutic range 
(TTR), assessed in six of the ten reviews. Other clinical outcomes included an 
international normalised ratio (INR) > 4, time to maintenance dose and adverse events, 
namely minor and major bleeding and thrombolytic events. 
 
• Seven of the reviews included only randomised controlled trials. One review included 
case-control and cohort studies and another included prospective clinical trials. Finally, 
one review provided insufficient information to determine which study designs were 
included. 
 
• Quality appraisal of the reviews (AMSTAR) showed a low risk of bias across five 
domains,42 moderate risk of bias across six domains43 and high risk of bias in the 
remaining seven domains.44 
 
• Of the included reviews, 50% focused primarily on the same eight primary studies, 
indicating a high degree of overlap. 
 
Introduction 
This systematic overview assessed the use of genotyping in oral anticoagulant therapy for 
stroke prevention in atrial fibrillation (AF) or acute treatment and primary and secondary 
prevention of venous thromboembolism (VTE). 
 
Patients who are prescribed anticoagulants, commonly warfarin, for these conditions take 
the medication on a daily basis as the drug has a narrow ‘therapeutic window’ or period of 
time in which the drug is effective (Xu et al. 2014). Warfarin and other anticoagulants are 
broken down in the body and particular genes can affect the rate at which this occurs. The 
rate at which warfarin is broken down in the body varies between patients, therefore the 
dose of warfarin prescribed must be tailored to individuals. Knowing a patient’s ‘genotype’, 
or which particular genes are present, can help to determine the optimal daily dose of 
anticoagulant required for the specific patient (Dean 2012). 
 
                                             
42 Including use of: PICO, duplicate data extraction, description of included studies, appropriate 
meta-analytic methods for RCTs, discussion of heterogeneity, publication bias and conflict of 
interest statements. 
43 Failed to report/provide: specified inclusion criteria, risk of bias assessment for RCTs/NRCTs, 
appropriate meta-analysis methods, and the impact of risk of bias on meta-analysis or in the 
interpretations on results. 
44 Publication of a protocol, comprehensive search strategy, reported duplicate screening, list of 
excluded studies, and funding arrangements. 
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Findings 
Ten reviews assessed the use of genotyping in oral anticoagulant therapy (Chen et al. 2016; 
Dahal et al. 2015; Franchini et al. 2014; Goulding et al. 2015; Jin et al. 2014; Shi et al. 2015; 
Sun et al. 2016; Tang et al. 2015; Xu et al. 2014; Yu et al. 2016). The characteristics of 
these reviews are reported in Appendices 16 and 17. A list of 22 reviews of genotyping 
excluded at full text screening is provided in Appendix 20. 
Our inclusion criteria required that for any review to be included, 50% or more of the 
included studies had to be related to AF and/or VTE populations. As the reviews identified 
in this synthesis did not report results separately for AF and VTE patients, but instead 
reported, in the reviews, results from mixed patient populations, e.g., those with AF, VTE 
and other indications for warfarin use, such as heart valve disease, none of the studies met 
our original inclusion criteria. The baseline risk of developing a particular outcome, for 
example, a thrombolytic event will differ between populations of patients with different 
conditions. Furthermore, some outcomes differ in definition between conditions; for 
example, the INR used to determine the therapeutic range of an anticoagulant varies 
between conditions being treated (Chen et al. 2016). The data for AF/VTE populations could 
not be extracted from the mixed-population data presented in the reviews. Consequently, 
there is uncertainty that the outcomes are generalisable to AF/VTE patients in the UK who 
are prescribed anticoagulants for stroke prevention. 
The evidence, however, from these reviews does hold value and highlights some of the 
clinical implications of genotyping within the AF and or VTE patient populations, as well as 
providing evidence related to the role of patient ethnicity in genotype-guided dosing. 
Therefore, what follows is a descriptive synthesis, of the reviews published from 2014 
onwards, that assesses the use of genotyping in oral anticoagulant therapy. 
Characteristics of included reviews 
Of the included reviews, four considered the role of ethnicity in genotype-guided dosing 
(Chen et al. 2016; Jin et al. 2014; Sun et al. 2016; Yu et al. 2016). The reviews investigated 
inter-ethnic variation in dose requirement i.e. the impact of gene polymorphisms on 
anticoagulant dose requirements in Caucasian, Asian and African populations. This type of 
information could be relevant in a UK setting, as a country with a growing multi-ethnic 
population. 
The main gene polymorphisms considered in the included reviews were those of the genes:  
• CYP4F2 assessed in six of the ten reviews (Chen et al. 2016; Dahal et al. 2015; 
Goulding et al. 2015; Shi et al. 2015; Sun et al. 2016; Xu et al. 2014); 
• VKORC1 assessed in six of the ten reviews (Dahal et al. 2015; Franchini et al. 2014; 
Goulding et al. 2015; Jin et al. 2014; Shi et al. 2015; Xu et al. 2014); 
• CYP2C9 assessed in six of the ten reviews (Dahal et al. 2015; Franchini et al. 2014; 
Goulding et al. 2015; Shi et al. 2015; Tang et al. 2015; Xu et al. 2014); and 
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• Apolipoprotein E (ApoE) assessed in one review (Yu et al. 2016). 
Goulding et al. (2015) also included studies that looked at the genotypes of HLA-B*5701, HIV 
anti-retroviral resistance mutations, TMPT, CYP2C19 and CYP3A5. 
The reviews included patient populations with a wide variety of indications for anticoagulant 
medication including patients with AF, VTE, PE, cardiomyopathy, trans-ischemic attack, 
heart value replacement (HVR), deep-vein thrombosis (DVT), prosthetic value replacement, 
stroke, rheumatic heart disease and valvular heart disease. 
Review aims 
Broadly, the reviews had two main aims. The first was to identify how clinical outcomes 
differed between patients who received anticoagulant dosing which was genotype-guided, 
compared with those who received standard clinical dosing (Dahal et al. 2015; Franchini et 
al. 2014; Goulding et al. 2015; Shi et al. 2015; Tang et al. 2015; Xu et al. 2014). The clinical 
outcomes were mainly time within therapeutic range (TTR) and adverse events, such as 
minor or major bleeding. The second main aim was to determine how warfarin maintenance 
dose differed between patients with different gene polymorphisms (Jin et al. 2014; Sun et 
al. 2016; Yu et al. 2016). These reviews typically looked at the mean difference in warfarin 
dose as the primary outcome. Finally, one review also investigated how adverse outcomes 
differed between patients with different gene polymorphisms (Chen et al. 2016). 
Reviews of genotype-guided dosing 
Dahal et al. (2015) aimed to compare genotype-guided dosing with standard dosing in adult 
patients with various indications for warfarin use. Ten RCTs (2,505 patients in total) were 
included, of which nine included AF/VTE populations. Warfarin doses ranged from 2.5-
10mg/day (where specified), and included studies testing CYP2C9, CYP4F2 and VKORC1. The 
studies’ populations included 0 to 100% White, 0 to 35%, Black and 0 to 100% Asian 
participants, with average ages ranging from 41.6 to 70.5 years. The majority of participants 
were male; 44.6 to 70% of studies’ participants were female. The countries in which the 
studies were based were not reported. The review’s primary outcome was percentage time 
in therapeutic range (TTR). Secondary outcomes were major bleeding, time to maintenance 
dose, supra-therapeutic INR of >4, thromboembolism, non-major bleeding and all-cause 
mortality. Studies’ follow-ups ranged from 0.5 to six months. 
Franchini et al. (2014) aimed to assess whether or not genotype-guided and standard dosing 
resulted in different rates of clinically relevant events. Nine RCTs (2,812 patients in total) 
were included in the review, all of which included AF/VTE populations. All but one study 
focused on warfarin; one other focused on acenocoumarol and phenprocoumon and the 
review looked at the CYP2C9 and VKORC1 gene polymorphisms. Mean/median age ranged 
from 41 to 70 years, with 65 to 100% of White ethnicity and 36 to 58% female. The countries 
in which the studies were based were not reported. The review’s primary outcomes were 
incidence of major bleeding, thrombosis and death. Secondary outcomes were time to reach 
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a therapeutic INR, percentage of TTR, time to reach a stable dose, percentage time spent 
at sub-therapeutic INR and number of days in hospital. Studies’ follow-ups ranged from 22 
to 90 days. 
Goulding et al. (2015) explored whether genotype-guided prescribing reduced adverse drug 
events (ADEs) and improved drug treatment responses. Fifteen RCTs (5,688 patients in total) 
were included in the review, of which eight included AF/VTE populations. Studies included 
patients from a clinical setting taking warfarin, acenocoumarol/phenprocoumon, tacrolimus 
(immunosuppressant for post organ transplant, interleukin-2 inhibitor), 
clopidogrel/prasugrel/azathioprine (antiplatelet drugs), antiretroviral agents or abacavir 
and looked at CYP2C29, VKORC1, CYP4F2, HLA-B*5701, CYP2C19, CYP3A5, TMPT and HIV 
anti-retroviral resistance mutations. Populations were ethnically diverse, ranging from 0 to 
100% Caucasian, 0 to 100% Chinese, 0 to 27% Black and unspecified proportions of Hispanic 
participants. Mean/median ages ranged between 41 and 70 years. Seventeen to 69% of the 
participants were female. Studies were conducted in 19 countries, including Canada, China, 
France, Greece, Israel, The Netherlands, Sweden, UK, and the USA. Outcomes included 
percentage time in therapeutic international normalised ratio range and adverse drug 
events such as haemorrhage and thrombosis. Follow-ups ranged from seven days to four 
months. 
Shi et al. (2015) assessed whether genotype-guided warfarin dosing can improve clinical 
outcomes in comparison to conventional dosing. Eleven RCTs (2,678 patients in total) were 
included in the review, of which eight included AF/VTE adult populations. Studies were 
conducted in the USA, China, Israel, UK and Sweden. The review focused on warfarin and 
looked at CYP2C9, VKORC1 and CYP4F2. The ethnicity and gender of studies’ participants 
was not reported. The median age was 59.7 years. The review’s primary outcome was TTR; 
secondary outcomes were INR greater than 4, time to maintenance dose and the first target 
INR, adverse events during anticoagulation treatment, frequency of major bleeding, 
thromboembolic events and death from any cause. Follow-ups ranged from 28 days to three 
months. 
Tang et al. (2015) aimed to determine whether genotype-guided dosing of coumarin 
anticoagulants did not improve the percentage time in the therapeutic INR range. Eight 
RCTs (1,805 patients in total) were included in the review, of which seven included AF/VTE 
adult populations. Studies were conducted in Europe, Asia and the USA. The review focused 
on coumarin anticoagulants and looked at VKORC1 and CYP2C9. Mean age ranged from 41.6 
to 70.5 years and 12 to 70% were female. Ethnicity was not reported. The primary outcome 
was the mean difference in percentage time within the therapeutic INR range. Secondary 
outcomes were major bleeding events, thromboembolic events, and INR at or greater than 
four events. Follow-ups ranged from 28 to 90 days. 
Xu et al. (2014) assessed whether genotype-guided pharmacogenetic dosing of warfarin is 
superior to clinical dosing. Eight RCTs (2,098 patients in total) were included in the review, 
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of which seven included AF/VTE adult populations. Study locations were not reported. The 
review focused on warfarin, with doses ranging between 5 and 10mg, and looked at CYP2C9, 
VKORC1 and CYP4F2 polymorphisms. The age, gender and ethnicity of populations were not 
reported. The primary outcome was time within the therapeutic range; secondary outcomes 
were major and minor bleeding, thromboembolic events and INR ≥4. Follow-ups ranged from 
28 to 90 days. 
Reviews of genotype influence on maintenance dosage  
Jin et al. (2014) estimated the impact of VKORC1-1639G>A genetic polymorphism upon 
warfarin dose requirement. Thirty-two prospective clinical trials (5,005 patients in total) 
were included, of which 25 included AF/VTE adult populations. The review focused on 
warfarin and looked at the VKORC1-1639G>A polymorphism. Study populations included 
Caucasian, Asian or African ethnicities, with mean ages from 36.0 to 86.7 years; 12.6 to 
64.9% of studies’ participants were female. Studies were conducted in 16 countries: Brazil, 
Canada, China, Egypt, France, India, Iran, Japan, Korea, Lithuania, Malaysia, Morocco, 
Sudan, Turkey, UK, and the USA. The primary outcome was weighted mean maintenance 
dose of warfarin. Follow-up durations were not specified. 
Sun et al. (2016) aimed to investigate the impact of the CYP4F2 polymorphism on warfarin 
dose requirements. Twenty-two studies (4,549 patients in total) were included, of which 11 
included AF/VTE adult populations. The review focused on warfarin, with doses ranging from 
2.51 to 22.52mg/day and looked at CYP4F2 polymorphism. The majority of the studies’ 
populations were Chinese (n=16), with two studies of Japanese populations and one each of 
Indian, Turkish, Korean and Asian. The majority of participants, 53.5%, were female; their 
age was not reported. The review assessed mean difference in daily warfarin dose. Follow-
up durations were not reported. 
Yu et al. (2016) assessed the impact of APOE alleles on mean daily warfarin dose. Nine RCTs 
(1,766 patients in total) were included, all of which included AF/VTE adult populations. 
Studies were conducted in Brazil, China, Egypt, India, Malaysia, Sweden, UK and the USA. 
The review focused on warfarin and looked at Apolipoprotein E (ApoE). The studies’ 
populations were Caucasian, Asian and/or African-American, with ages ranging from 42.3 to 
71 years; 34.6 to 65.5% were female. The review assessed the warfarin dose associated with 
each genotype. The duration of follow-ups was not reported. 
 
Reviews of genotypes and adverse outcomes  
One review also investigated how adverse outcomes differed between patients with 
different gene polymorphisms. Chen et al. (2016) evaluated the impact of the CYP4F2 
polymorphism on bleeding complications and over-anticoagulation due to coumarin. Eight 
case-control and cohort studies (3,101 patients) were included, of which seven included 
AF/VTE adult patient populations. Studies were published between 2008 and 2014. The 
review focused on warfarin and acenocoumarol, with doses ranging from 3 to 7mg per day. 
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The studies’ populations included Caucasian, Asian and African-American participants.  
Their average ages ranged from 4.8 [sic] to 66 years; 41.0 to 54.7% of studies’ participants 
were female. The countries in which the studies were based were not reported. The review 
assessed total haemorrhage, major haemorrhage, INR<4 and over-anticoagulation. Studies’ 
follow-ups ranged from three to 45 months. 
Quality of included reviews 
Quality appraisal of the reviews (AMSTAR) showed a low risk of bias across five domains 
(PICO, duplicate data extraction, description of included studies, appropriate meta analytic 
methods for RCTs, discussion of heterogeneity, publication bias and conflict of interest 
statements).  The included studies demonstrated a moderate risk of bias across six domains 
in that they failed to report or provide clear information on the following: specified inclusion 
criteria, risk of bias assessment for RCTs/NRCTs, appropriate meta-analysis methods, the 
impact of risk of bias on meta-analysis or in the interpretations of results.  There was a high 
risk of bias in the remaining seven domains. These focused on the publication of protocols, 
comprehensive search strategy, reported duplicate screening, list of excluded studies and 
funding arrangements. Quality assessment ratings are shown in Appendix 18. 
 
Overlap of primary studies included in the reviews 
A total of 58 primary studies that focused on AF and VTE were included in the ten reviews.  
Overlap in primary studies on AF and VTE was noticeable but was not consistent across 
included reviews. Five of the ten reviews focused primarily on the same eight primary 
studies (Dahal et al. 2015; Franchini et al. 2014; Shi et al. 2015; Tang et al. 2015; Xu et al. 
2014). These primary studies were: Anderson et al. 2007; Borgman et al. 2012; Burmester 
et al. 2011; Hillman et al. 2005; Jonas et al. 2013; Kimmel et al. 2013; Pirmohamed et al. 
2013; and Sconce et al. 2005. However, the remaining five reviews drew on a variety of 
other primary studies. Details are provided in Appendix 19.
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7  Results: Reviews of self-monitoring 
Summary of evidence  
 
• Six reviews were included in this synthesis, which covered five types of self-
monitoring interventions; education only (n=1), education plus patient decision aid 
(to inform preferences for anticoagulation therapy) (n=1), self-testing with guidance 
on dosing from a clinician) (n=3), self-management (n=2) (self-testing and treatment 
according to an algorithm), and pharmacist-managed anticoagulation (warfarin) 
therapy (PMWT)45 (n=3).46 
 
• Time in therapeutic range (TTR) and proportion of international normalised ratio 
(INR) in range were used to assess effectiveness. 
 
• One review focused exclusively on participants with AF, one on participants 
predominately with AF and/or VTE and the remaining four reported data from 
participants with a range of conditions that included AF/VTE populations. Of the 
mixed populations, data for participants with AF could be isolated in two reviews. 
No reviews reported data exclusively on populations with VTE. 
 
• Four reviews exclusively examined RCTs; the remaining two included both RCTs and 
non-RCTs. 
 
• Two reviews focused exclusively on warfarin; the rest included more than one type 
of oral anticoagulant. 
 
• Only one review rated the trials within the review as being of high quality; another 
graded the evidence as being of moderate quality; and in two reviews the trials were 
mostly rated as low quality. In another two reviews, whilst risk of bias was 
conducted, the results were not interpreted nor applied to the findings, leading to 
uncertainty about the quality of these reviews’ conclusions. 
                                             
45 Although pharmacist management may not strictly be self-management, it can be easier to 
access for patients and could reduce pressure on GP or specialist services, and is, therefore, 
included here in self-monitoring. 
46 Some reviews assessed more than one intervention, so these numbers do not add up to six. 
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• AMSTAR quality appraisal of the reviews showed a low risk of bias across seven 
domains,47 moderate risk of bias across six domains48 and high risk of bias in the 
remaining three domains.49 
 
• Percentage of overlap in trials across reviews is calculated by intervention synthesis 
(0% for educational interventions, 0 to 100% for self-testing, 63 to 100% for self-
management and 31% for pharmacist managed therapy) (see Appendices 22 and 25 
for more details) 
 
Summary of findings 
 
Overall, among participants with AF, low-quality and limited evidence suggests: 
 
• Education only and education plus patient decision aids might improve 
anticoagulation management, compared with usual care. 
 
• Self-testing may be as effective as usual care but does not offer enhancements over 
and above usual care.  
 
• Self-management might improve the quality of anticoagulation management, 
compared with usual care. 
 
Overall, among mixed populations (including but not limited to AF and/or VTE), evidence 
from low- and moderate-quality studies suggests: 
 
• Self-testing interventions may improve the INR values in therapeutic range, 
compared with usual care. However, for the TTR outcome, using the Rosendaal 
interpolation method, findings were mixed, with both positive (longer) and negative 
(shorter) time in therapeutic range for the self-testing intervention, compared with 
usual care. 
 
• Self-management interventions had both positive (higher) and negative (lower) 
effects for INR numbers in therapeutic range, and positive (longer) and negative 
(shorter) effects for time in therapeutic range, compared with usual care. Low-
quality meta-analytic evidence indicated that self-management may be as effective 
                                             
47 Including use of PICO, duplicate screening, duplicate data extraction, description of included 
studies, risk of bias RCTs/nRCTs, appropriate meta-analytic methods for RCTs/nRCTs. 
48 Failed to: report conflict of interests; detail funding arrangements; explore meta-analytic 
findings in light of risk of bias; discuss findings in light of heterogeneity; provide study protocol or 
statement about deviations from it; provide a list of excluded studies. 
49 Failed to: specify inclusion criteria, search strategy, and examine publication bias. 
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as usual care, but does not offer enhancements over and above usual care, in terms 
of TTR. 
 
Overall, among mixed populations (including but not limited to AF and/or VTE) mixed-
quality evidence (high risk and uncertain) suggests: 
 
• Pharmacist-managed anticoagulation may improve TTR, assessed using the 
Rosendaal interpolation method, compared with usual care. 
 
A more in-depth synthesis of the findings is reported below and summarised in Appendix 
22. This details the size of effects, their direction and associated statistical information. 
Findings are organised by type of intervention. 
 
Intervention types 
Education, and Education and Decision aids 
Only one review examined the impact of education or education and decision aids on 
anticoagulant therapy effectiveness. Clarkesmith et al. (2017) built on their original 
review, first published in 2013 (Clarkesmith et al. 2013a), with updated searches in 2016. 
The review evaluated the effects of education, education and decision aids, or self-
management plus education (the latter reported in the section below on self-monitoring), 
compared with usual care, among adults with AF who were eligible for, or currently 
receiving, oral anticoagulant therapy (OAT). Twenty articles reporting on 11 randomised 
controlled trials (RCTs) were included with a total of 2,246 patients, aged between 59 and 
75 years. Time in therapeutic range or INR values in range were reported in six trials. The 
percentage of time in therapeutic range (TTR), using the Rosendaal et al. (1993) method 
was reported in four trials (Christensen et al. 2007; Clarkesmith et al. 2013b; Gadisseur et 
al. 2003; Vormfelde et al. 2014). In one trial the TTR was reported in days (Voller et al. 
2005) and one reported the percentage of INRs in range (McAlister et al. 2005). Follow-ups 
ranged from three to 12 months. 
 
Most of the studies included in the systematic reviews were conducted in Europe (five), and 
one was in Canada (McAlister et al. 2005). Ethnicity data were tabularised for individual 
studies, where reported (see Characteristics of included studies, in Clarkesmith et al. 
(2017), begins p38), but were not referred to or summarised by the primary review 
authors.50 Two of the interventions were conducted in a hospital or anticoagulation clinic 
setting (Christensen et al. 2007; Clarkesmith et al. 2013b; Gadisseur et al. 2003) and two of 
the trials were in general practices (McAlister et al. 2005; Vormfelde et al. 2014). The trials 
referred to the use of oral anticoagulation therapy (OAT) in general, rather than named 
drugs. Quality was assessed using the Cochrane ‘Risk of Bias’ tool (Higgins and Green 2011) 
                                             
50 The characteristics of the self-management studies are discussed here for simplicity, but the 
results of the self-management trials are discussed below in the section on self-management. 
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and the GRADE Working Group grades of evidence (Grade Working Group 2004).The evidence 
was categorised as being very low to low in quality, across different outcomes, based on the 
limitations of the individual studies, mainly due to the absence of information about the 
allocation concealment procedure or blinding and incomplete outcome data (attrition bias). 
 
Three of the included trials that compared education only with usual care reported 
percentage TTR (Clarkesmith et al. 2013b; Gadisseur et al. 2003; Vormfelde et al. 2014), 
though these data were not comparable and were, therefore, not combined in a quantitative 
synthesis.51 Clarkesmith et al. (2013b) found significantly higher percentage TTR in the 
education intervention group (median 76.2%, interquartile range (IQR) 64.1% to 97.3%), 
compared with the usual care group (median 71.3%, IQR 51.2% to 84.7%), at six months 
among an AF population, and although the direction of effects remained the same at 12 
months (median 76.0%, IQR 60.5% to 85.0% versus median 70.0%, IQR 62.0% to 79.0%, 
respectively), the difference did not obtain statistical significance. Vormfelde et al. (2014) 
found that the percentage TTR was significantly higher in the education intervention group 
(comprising a 20-minute video presentation, an eight-page brochure, and a corresponding 
questionnaire) (mean 69%, SD 25.1%), compared with the brochure only group (mean 64%, 
28.2%), at six months, among the AF population (unpublished data). 
 
McAlister et al. (2005) examined the effectiveness of a general education session plus 
patient decision aid to help clarify personal values regarding desired outcomes and 
preferences for therapy, preferred role in the decision process and any questions for their 
physician. Based on the percentage of INR values in range, McAlister et al. (2005) found 
that, compared with usual care, INR management improved in the intervention arm 
(p=0.020; INRs were between 2.0 and 3.0 on 72% of the days at three months versus 65% at 
baseline, in the intervention group, and 66% of the days at three months versus 70% of the 
days at baseline, in the control group). Nonetheless, at 12-month follow-up, INR control in 
both arms had returned to baseline levels. 
 
Overall, there appears to be some weak evidence to support the beneficial effects of 
education, and education plus patient decision aid, on TTR, at least in the short term. The 
lack of longer-term effects indicates that booster sessions may be helpful. Clarkesmith et 
al. (2017) concluded that the effect of self-monitoring plus education on INR values was 
uncertain, compared with usual care, due to the very low quality of the evidence and the 
likelihood that further high-quality trials may affect these results. 
 
                                             
51 Gadisseur et al. (2003) had provided unpublished data on the AF cohort for the three arms of the 
trial. However, due to a typo in the report, it is not possible to establish which data belonged to 
which intervention group, thus these data are not summarised here. The authors were contacted, 
but a reply was not received before the point of submission. 
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Self-monitoring: Self-testing and or self-management interventions 
Three reviews examined the impact of self-monitoring: Clarkesmith et al. (2017), Sharma 
et al. (2015) and Heneghan et al. (2016). The Clarkesmith et al. (2017) review (introduced 
in the section above on education) assessed three trials that examined the impact of self-
management plus education among AF populations (Christensen et al. 2007; Gadisseur et 
al. 2003; Voller et al. 2005). Two of these studies measured percentage TTR using the 
Rosendaal et al. (1993) method of calculation (Christensen et al. 2007; Gadisseur et al. 
2003) and were, therefore, pooled, using fixed-effect meta-analysis. The results showed 
that self-management plus education, whilst in a positive direction, did not statistically 
significantly improve TTR when compared with usual care (MD 6.3%, 95% CI -5.63% to 18.25%, 
I2=0%, 2 trials, 69 participants, very low-quality evidence). Voller et al. (2005) reported the 
cumulative percentage of time in INR, rather than TTR using the Rosendaal et al. (1993) 
method. Time in INR (mean 67.8%, SD 17.6%) was higher in the self-management group, 
compared with usual care (mean 58.5%, SD 19.8%) (no statistical tests were reported). 
 
Sharma et al. (2015) examined the effectiveness of self-monitoring of coagulation status in 
people receiving long-term vitamin K antagonist therapy, compared with standard clinic or 
GP care, in people with different clinical conditions. Twenty-six RCTs (8,763 participants), 
reported in 45 articles, were included. The majority of trials were conducted in Europe 
(n=22); three trials were conducted in Canada, and one in the USA. The self-monitoring 
intervention included both self-testing (self-testing, with guidance on dosing from a 
clinician) and self-management (self-testing and treatment according to an algorithm). The 
majority of the included trials (22/26) used the CoaguChek system for INR monitoring.52 Of 
the included trials, only two exclusively recruited participants with AF and both evaluated 
the CoaguChek system (Khan et al. 2004; Voller et al. 2005). The remaining trials targeted 
participants with heart valve disease (n=6) or participants with mixed diagnoses (including 
AF and heart valve disease, n=15; three were unspecified). Only one of the included trials 
targeted children (in mixed group), and across the included adult-based trials, participant 
age ranged from 16 to 91 years. Warfarin was received by participants in 14 trials (12 in 
mixed group) and was the most common anticoagulation drug reported. In seven trials, 
participants were taking phenprocoumon and/or acenocoumarol and/or fluindione (six in 
mixed group) and, in one trial, participants received either warfarin or phenprocoumon. In 
the remaining four trials (two in mixed group) the type of vitamin K antagonist therapy was 
unspecified. 
 
The time that INR was in the therapeutic range was reported in 18 trials, and the INR values 
reported in therapeutic range was measured in 12 trials. The length of follow-up ranged 
                                             
52 Two trials used either INRatio or the CoaguChek S, for INR measurement (but did not present 
results according to the type of the point-of-care device used), while the other two trials used the 
ProTime system. 
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from 14 weeks53 to more than 4 years. Nine trials reported follow-ups ≥ 12 months, and the 
type of standard care encompassed anticoagulation clinic (n=15),54 GP/physician (n=6), and 
anticoagulation clinic or GP/physician (n=5). Overall, the quality of the trials was generally 
low with only four trials judged to be at a low risk of bias. The majority of trials were judged 
to be at an ‘unclear’ or ‘high’ risk of bias. 
 
For the UK-based trial (Khan et al. 2004) that sampled participants with AF, whilst INR time 
in therapeutic range was higher in the self-testing intervention (mean % = 71.1; SD=14.5), 
compared with control (mean % = 70.4, SD=24.5), the difference was modest and did not 
reach statistical significance. The results for the Germany-based trial (Voller et al. 2005) 
were included within the Clarkesmith et al. (2017) review and are, therefore, already 
discussed above. However, Sharma et al. (2015) included statistical tests for the INR time 
outcome (Clarkesmith et al. (2017) did not report these) and, additionally, reported INR 
value data for this trial. Consistent with Clarkesmith et al. (2017), INR time in therapeutic 
range was higher for the self-management intervention (mean cumulative days = 178.8 
(SD=126)), compared with control (mean = 155.9 (SD=118.4)), albeit not statistically 
significantly. For the INR value in target range outcome there was a statistically significant 
effect (p=0.0061) favouring the self-management intervention: INR values in the 
intervention group were 67.8% (SD=17.6), versus 58.5% in the control group (SD=19.8). 
Nonetheless, Voller et al. (2005)’s study was identified as having a high risk of bias and in 
Khan et al. (2004) the risk of bias was categorised as unclear. 
 
Collectively, for the studies that measured INR time in the therapeutic range, in 15 of the 
18 trials, the values were higher among participants receiving the self-monitoring (either 
self-testing or self-management) intervention, compared with participants in standard care 
(three obtained statistical significance, p<0.001). A pooled synthesis of five trials was 
possible for self-testing interventions55 (including Khan et al. 2004, but not Voller et al. 
2005). Results showed a modest but significantly higher percentage of INR time in 
therapeutic range, (weighted mean difference (WMD) 4.44, 95% CI 1.71 to 7.18; p=0.001). 
A pooled synthesis of six trials was possible for self-management, compared with standard 
care. The results showed that a very modest difference was observed favouring intervention 
for the INR time outcome, although this effect was not statistically significant (WMD 0.47, 
95% CI –1.40 to 2.34; p=0.62). 
 
Variation in the measures used to assess INR values in therapeutic range prevented the 
pooling of data across trials for this outcome. Narrative synthesis showed that the INR values 
in therapeutic range were reported in eight trials that assessed AF or mixed indications. For 
                                             
53 There was a discrepancy between the text (p15), which reported a range from 14 weeks to 4 
years, and Table 31, which reported that follow-up in the Menendez-Jandula et al. (2005) study 
ranged from 0.3 to 16.9 months. 
54 Professional testing in clinic (13) or self-testing in clinic (2), which was compared with self-
management. 
55 Includes AF and HVD exclusive populations, and mixed indications. 
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the self-testing intervention, of the two trials that assessed this outcome, both reported 
better percentages of INR values in therapeutic range compared with control, and one was 
statistically significant (p<0.001). For self-management, five of the seven trials reported a 
higher percentage of INR values in the therapeutic range, than with usual care, and two of 
these were statistically significant (p<0.05). 
 
Overall, there is little evidence that self-monitoring (self-testing/self-management) of 
vitamin K antagonist therapy is more effective than standard clinic care, among populations 
with AF, in terms of TTR and INR values reported in therapeutic range. Among mixed-
diagnoses groups (i.e. those with a combination of AF, VTE and other conditions), there is 
some low-quality evidence to suggest that self-testing and self-management improve the 
percentage of TTR and INR values, compared with standard care, albeit modestly for the 
TTR outcome. The extent to which the groups with mixed diagnoses sampled patients with 
AF or heart valve disease was not reported and, therefore, requires clarification. 
 
Heneghan et al. (2016) updated their initial review (Garcia-Alamino et al. 2010), with 
searches conducted in November 2013 and July 2015.This led to the identification of an 
additional 10 trials for inclusion. A total of 27 included articles provided data on 28 RCTs 
(with a total of 8,950 participants)56 that were published between 1989 and 2013. Most of 
the trials were conducted in Europe (five in the UK, five in Germany, three in the 
Netherlands, three in Denmark, one in Ireland, one in France, one in Spain and one in 
Austria); seven were from the United States and Canada; and one was from Australia. 
 
Few trials focused exclusively on AF. Two trials exclusively sampled participants with atrial 
fibrillation (Khan et al. 2004; Voller et al. 2005);57 and 20 included people on long-term 
anticoagulation for any indication. Six included only those on oral anticoagulants after 
mechanical valve replacement (Azarnoush et al. 2011; Horstkotte et al. 1998; Kortke et al. 
2001; Sidhu and O'Kane 2001; Soliman Hamad et al. 2009; Thompson et al. 2013). 
 
A range of oral anticoagulants was evaluated. In most studies, the oral anticoagulant tested 
was usually warfarin (15 trials) followed by phenprocoumon or acenocoumarol (three trials); 
phenprocoumon (two trials) and warfarin or acenocoumarol (one trial). The type of oral 
anticoagulant was not reported in six trials. The range of settings for the intervention 
varied. Eleven trials were in a primary care setting, 13 trials were in specialist 
anticoagulation clinics; three were in either setting, and one trial used data from a medical 
                                             
56 One article (Gadisseur et al. 2003) contained data on two trials that compared self-monitoring or 
self-management of oral anticoagulation, with standard care. There were discrepancies in the 
numbers reported in the review, as there were 28 articles, describing 29 trials, if you include 
Gadisseur et al. (2003) as two trials. 
57 Summarised in Clarkesmith et al. (2017) and Sharma et al. (2015), therefore, not reported again 
here. Note that, like in Clarkesmith et al. (2017), Heneghan et al. (2016) only report the 
cumulative days outcome from Voller et al. 2005, and not the values in range outcome. 
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analysis laboratory. These settings correspond to the type of usual care which was used as 
a control. 
 
Trial follow-up ranged from two months (White et al. 1989) to 57 months (Matchar et al. 
2010). Overall, the available evidence was judged to be moderate according to GRADE 
(Grade Working Group 2004). The main flaw (related to the TTR outcome) was the absence 
of information on allocation concealment or blinding. 
 
The effects of the intervention varied across studies. In terms of TTR (15 trials with AF or 
mixed populations), according to the table of results58 (Heneghan et al. 2016, Additional 
tables, Table 1, pp80-81), three trials reported a statistically significant difference (p<0.01) 
between the intervention and control groups (Beyth et al. 2000, Christensen et al. 2011, 
Matchar et al. 2010).59 This difference ranged from -460 (Matchar et al. 2010; 66.2% control, 
62.4% intervention) to +24 (Beyth et al. 2000; 32% control, 56% intervention) percentage 
points, assuming that we correctly assigned the appropriate columns to intervention and 
control, as these were not labelled.61 Two differences were in a negative direction60 (control 
out-performed the intervention) and one was positive (i.e., the intervention group out-
performed the control). Of the remaining trials, five differences were negative (favoured 
control) and seven were positive (Rasmussen et al. 2012 had two arms, with two different 
decision tools; one found no difference). 
 
In 12 trials, the intervention was self-testing, in 15 trials it was self-management, and in 
one trial both interventions were assessed (Gadisseur et al. 2003). Fifteen trials62 (11 trials 
with AF or mixed populations) reported the percentage of INR values in the target range, 
overall (percentage of overall tests in range) or for each individual (percentage of tests for 
each individual in range), however, pooling of the results was not possible due to 
heterogeneity in the measures of INR.63 
 
Results64 showed that for the self-testing interventions, three trials were in a positive 
direction (longer TTR, one statistically significant) and four in a negative direction (shorter 
                                             
58 Note that the findings reported in the text (Heneghan et al. 2016, p16) differed from those in the 
table (Heneghan et al. 2016, Additional tables, Table 1). Here, we have reported the findings from 
the table, and noted any discrepancies in the footnotes. 
59 The authors also referenced Siebenhofer et al. (2007) as statistically significant (p<0.029), the 
significance level was not reported in the text; this had a positive effect (+9). 
60 Reported as positive in the text (p16). 
61 The authors were contacted for clarification, but we did not receive a response in time for this 
publication. 
62 Four of these (Horstkotte et al. 1998, Sidhu and O'Kane 2001, Kortke et al. 2001, Soliman Hamad 
et al. 2009) only assessed patients with heart valve replacements. 
63 The mean percentage of tests in range was reported as either the percentage of tests overall or 
the percentage of tests for each individual. 
64 According to the table of results (Heneghan et al. 2016, Additional tables, Table 1, pp80-81), 
assuming that we correctly assigned the appropriate columns to intervention and control, as these 
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TTR, two statistically significant) compared with usual care.65 For the same outcome, results 
showed that for the self-management interventions, five were in a positive direction (longer 
TTR, one statistically significant) and three were in a negative direction (shorter TTR, all 
not statistically significant) compared with usual care. 
 
In terms of the 11 trials reporting INR values in target range (11 trials with AF or mixed 
populations), two were self-testing interventions and eight were self-management 
interventions. According to the table of results (Heneghan et al. 2016, Additional tables, 
Table 1, pp80-81), with the exception of one self-management intervention (Grunau et al. 
2011; 82.4 control, 80.2 intervention; -2)66 the remaining ten trials assessing INR value in 
target range showed higher percentages in the intervention group compared with usual care 
(five statistically significant, p<0.05).  
 
In summary, results of the Heneghan et al. 2016 review for the TTR outcome were mixed 
for the trials sampling AF or mixed populations, with approximately equal numbers of trials 
reporting successful and unsuccessful interventions, for both type of self-monitoring 
interventions (self-testing and self-management). For the eleven studies assessing mean 
percentage of INR values in target range, the results were more consistently in favour of 
the intervention which was predominately self-management (assessed in eight studies).67 
Pharmacist-managed interventions 
Three reviews assessed the effectiveness of pharmacist-managed interventions: Manzoor et 
al. (2017), Entezari-Maleki et al. (2016) and Zhou et al. (2016). 
 
Manzoor et al. (2017) conducted a systematic review to evaluate the quality of warfarin 
anticoagulation control in outpatient pharmacist-managed anticoagulation services (PMAS) 
compared with routine medical care (RMC). Twenty-five studies met the inclusion criteria. 
Of these, three were RCTs and 22 were non-randomised controlled studies. A total of 12,252 
participants were included across studies with a mean age that ranged from 47.4 to 81.0 
years. The majority of patients were treated for AF or VTE (including DVT and PE) (n=23 of 
25, 92.0%). Gender was not recorded and only seven studies reported race/ethnicity (mainly 
Caucasian, n=4; Malay, n=2; Qatari, n=1). In terms of the country, most of the studies were 
carried out in the United States (n=13), followed by Asia (n=4); Canada (n=3), United 
Kingdom (n=2) and others (one each in Spain, Qatar, and New Zealand). 
                                             
were not labelled. The authors were contacted for clarification, but we did not receive a response 
in time for this publication. 
65  GP management, hospital anticoagulation service,  anticoagulation clinic 
66 This was also reported to be positive in the text (p16), whereas Kaatz et al. (unpublished data; 
see Kaatz et al. 2001) was reported to be negative (unfavourable to the intervention). 
67 The results in the text of Heneghan et al. (2016)’s report differed from those in the table, 
particularly for TTR, for which the results were much more favourable in the text. The results were 
more consistent for the percentage of values in range, but this lack of consistency casts some doubt 
on all the conclusions of the review. Without checking each individual paper’s results, the 
directions of the effects, and the conclusions, cannot be relied upon. 
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Whilst most of the studies (n=19 of 25, 76.0%) used the linear interpolation approach to 
determine TTR, meta-analysis across studies was not conducted due to variation in 
measurements of TTR. Follow-ups ranged from three months to four years, with the highest 
proportion of studies having a follow-up ≥18 months (n=10 of 25, 40.0%). Individual study 
quality was assessed using the Downs and Black checklist (Downs and Black 1998). Results 
showed that the mean ± SD Down’s score was 19.5 ± 5.7, (range 16 to 28). Because the 
authors did not provide any guidance on how the Downs and Black checklist should be 
interpreted, nor any other comments on study quality, there is uncertainty about the quality 
of the primary studies included in the review. 
 
Overall, a higher TTR was reported in the PMAS group, compared with RMC, in the majority 
of the studies (n=23, including two of the three RCTs). Of these 23 studies, 19 (83.0%) 
reported a statistically significant result for TTR (including two of the three RCTs), 
indicating that the quality of anticoagulation control was better in the PMAS group, 
compared with control. This improvement in TTR ranged from 1.7% to 28.0% in the PMAS 
group, relative to control, and 16 studies (69.6%) showed a larger improvement in TTR than 
7%. Manzoor et al. (2017) concluded that pharmacist-managed outpatient-based 
anticoagulation services attained better quality of anticoagulation control, compared with 
routine care. Variation in the levels of improvement may be due to the various settings and 
countries in which the studies took place. Furthermore, due to the uncertainty about the 
quality of the individual studies, these findings should be interpreted cautiously. 
 
Entezari-Maleki et al. (2016) conducted a systematic review to evaluate the quality of 
warfarin anticoagulation control in outpatient pharmacist-managed warfarin therapy 
(PMWT) compared with usual medical care. Twenty-four studies met the inclusion criteria. 
Of these, four were RCTs and 20 were observational studies. In total, 11,607 participants 
were included across studies (summary statistics for age, gender and ethnicity were not 
reported). The majority of patients were treated for AF, deep vein thrombosis, pulmonary 
thromboembolism, or valvular heart diseases (relative proportions not reported). In terms 
of the country, most of the studies were carried out in the USA (n=12), followed by Canada 
(n=6), and the United Kingdom (n=4).68 One study was conducted in Spain and one in 
Australia. Three RCTs and five observational studies reported on TTR by the Rosendaal et 
al. (1993) method. For these studies reporting the TTR outcome, follow-up ranged from 
three to six months among the RCTs and between at least two months and 17 months among 
the observational studies. Individual study quality was assessed using the Downs and Black 
checklist (Downs and Black 1998). RCTs were additionally assessed using the Jadad scale 
(Oxford scale). 
Among the studies that included TTR by the Rosendaal et al. (1993) method, the Downs and 
Black score ranged between 21 and 29 for the RCTs, and between 15 and 22 for the 
                                             
68 Figures extracted from table 2 in Entezari-Maleki et al. (2016) as they differed to the figures 
reported in the text. 
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observational studies. It was also reported that the Jadad scale for RCTs was scored 3 as a 
high-quality RCT, although it is unclear what this meant. Unfortunately, the authors did not 
provide any guidance on how the Downs and Black checklist should be interpreted, nor 
provide any other comments on study quality, thus there is some uncertainty about the 
quality of the observational studies reviewed. 
 
Data, pooled (but not weighted) using the three RCTs, showed that percentage of time in 
the therapeutic range (TTR) was longer in the PMWT group (84.3%, ±3.2%), compared with 
in the UMC groups, (82.2%, ±8.7%), though the findings did not obtain statistical significance 
(95% CI -26.3% to 30.5%, p=0.781). Among the observational studies (n=5), TTR was 
statistically significantly higher for PMWT, when compared with UMC (72.1% ±7.7% v. 56.7% 
±7.6%; 95% CI 4.2% to 26.6%; p=0.013). 
 
Overall, whilst those receiving pharmacist-managed Warfarin therapy attained better 
quality of anticoagulation control, compared with routine care, among the lower quality 
non-randomised studies, the difference among the more robust RCTs, whilst favouring 
PMWT, was small and not statistically significant. Furthermore, due to the uncertainty about 
the quality of the individual studies, these findings should be interpreted cautiously. 
 
Zhou et al. (2016) conducted a systematic review to evaluate the quality of pharmacist-
managed warfarin, compared with other models of care. Eight RCTs were included with a 
total of 1,493 patients. However, only four trials (comprising 646 participants) reported the 
percentage of time within the standard therapeutic range (INR 2.5 ±0.5) and within the 
expanded therapeutic range (INR 2.5 ±0.7) using the Rosendaal et al. (1993) interpolation 
method for TTR. 
 
All four relevant trials reported sampling patients with mixed indications that included two 
or more of the following diagnoses: AF, DVT, PE, mechanical valve replacement (MVR), MI, 
stroke, cardiomyopathy and others (unspecified) (relative proportions of each not reported). 
 
Control groups varied and included usual care (n=1), physician managed (n=2) and one 
labelled as PCP but not defined. Across studies, age ranged from 57.7 to 70 years and gender 
from 51.2% to 68.4% male. Ethnicity data were not reported. Three of the studies were 
conducted in Canada and one was conducted in Canada and one in the UK. Follow-up ranged 
from three to six months. Risk of bias in the individual studies was assessed using the 
Cochrane Risk of Bias tool and GRADE (Grade Working Group 2004). 
 
Meta-analysis of the four RCTs showed that the percentage of time within the standard 
therapeutic range was longer in the pharmacist-managed care, compared with other models 
(mean difference = 3.66, 95% CI 2.20 to 5.11; p<0.00001, high-quality evidence), without 
heterogeneity. For the percentage of time within the expanded therapeutic range, whilst 
the pharmacist-managed group increased time in range, compared with other models, the 
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difference did not obtain statistical significance (MD 2.85, 95% CI -0.56 to 6.26; p=0.10, 
moderate-quality evidence), with heterogeneity. 
 
Overall those receiving pharmacist-managed Warfarin therapy attained better quality of 
anticoagulation control, compared with other models, in trials rated as being of moderate-
(due to heterogeneity) to-high quality. 
 
AMSTAR risk of bias assessment 
As shown in Appendix 24, the AMSTAR quality appraisal of the reviews showed a low risk of 
bias across seven domains (including use of PICO, duplicate screening, duplicate data 
extraction, description of included studies, risk of bias assessment for RCTs/nRCTs and 
appropriate meta-analytic methods for RCTs/nRCTs). Moderate risk of bias was reported 
across six domains (due to the absence of a study protocol or statements about deviations 
from it, information on potential conflict of interests, funding arrangements, links between 
meta-analytic findings with risk of bias assessments, discussion of heterogeneity, and a list 
of excluded studies). A high risk of bias was coded for the remaining three domains 
(including specification of inclusion criteria, search strategy, and examination of publication 
bias). 
 
Summary  
Overall, there appears to be some low-quality evidence to support the beneficial effects of 
education (based on two RCTs) and education plus patient decision aid among participants 
with AF (based on one RCT) on TTR (using the Rosendaal et al. (1993) method), though the 
lack of long-term effects indicates that booster sessions may be helpful. 
 
Only two reviews examined self-testing interventions using an AF population (Sharma et al. 
2015; Heneghan et al. 2016) and one study (Khan et al. 2004), with uncertain quality, was 
identified for inclusion. Results indicated that there was little evidence to support the 
effectiveness of self-testing on improving time in INR, compared with usual care, but it did 
not perform worse. 
 
In terms of self-management, exclusively within AF populations, only three primary studies 
were located (Voller et al. 2005; Christensen et al. 2007; Gadisseur et al. 2003) across three 
reviews (Sharma et al. 2015; Clarkesmith et al. 2017; Heneghan et al. 2016).69 Results 
indicate that there was low-quality evidence suggesting that, self-management may 
improve TTR compared with usual care. However, two reviews identified a high risk of bias 
in the relevant trials (Clarkesmith et al. 2017 and Sharma et al. 2015) therefore, the effect 
of self-management on TTR, compared with usual care, is uncertain, especially given the 
few studies that had examined this research question. 
                                             
69 Voller et al. (2005) was assessed in all three reviews, whereas Christensen et al. (2007) and 
Gadisseur et al. (2003) were synthesised only by Clarkesmith et al. (2017), who obtained 
unpublished data from the primary authors. 
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Overall, in light of the few studies that focus exclusively on AF populations, reliable 
conclusions about the impact of self-monitoring interventions on this patient population 
cannot be drawn. 
 
Among mixed-diagnoses groups, the low-to-moderate quality evidence suggests that self-
testing interventions may improve the INR numbers in therapeutic range, compared with 
usual care. However, for the TTR outcome, findings from moderate-quality evidence were 
more mixed, with both positive (longer) and negative (shorter) time in therapeutic range 
for the self-testing intervention compared with usual care. 
 
For the Self-management interventions, the evidence was mixed for types of outcomes, 
with both higher and lower INR numbers in therapeutic range, and shorter and longer time 
in therapeutic range, compared with usual care. Low-quality meta-analytic evidence 
indicated that self-management may be as effective as usual care but does not offer 
enhancements over and above usual care, in terms of TTR. The variation in findings indicates 
the presence of potential moderators operating. 
 
The evidence for pharmacist-managed anticoagulation (from mixed-quality studies rated as 
high and uncertain) was more consistent across the reviews indicating that pharmacist-
managed anticoagulation may improve TTR, compared with usual care, among mixed-
diagnoses groups. There were no reviews evaluating pharmacist-managed anticoagulation 
services exclusively in populations with AF and none of the interventions were exclusively 
examined in populations with VTE. 
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8  Results: Reviews of stakeholder perspectives 
Summary of evidence 
• Nine reviews met our inclusion criteria and were included in this synthesis. All of the 
reviews included studies that examined atrial fibrillation (AF) patients; five reviews 
focused on AF patients only, and four examined a range of conditions that included 
venous thromboembolism (VTE). 
 
• Most reviews focused on general populations receiving VKA or oral anticoagulants 
(OACs) therapy, with only one review focused specifically on NOACs adherence and 
satisfaction amongst renal patients. The number of studies included across the 
reviews ranged from three to 140; where reported, between 341 and 7,295 people 
participated. 
 
• Four reviews examined factors influencing the optimal use of warfarin in AF; three 
of these additionally looked at the role of NOACs in optimising OAC use. These 
reviews included a wide range of primary study designs, including systematic 
reviews, trials, observational studies, and patient data registries and guidelines. 
 
• Two reviews examined the preferences and values of patients toward VKA use and 
NOAC use, including discrete-choice experiment studies and other economic 
evaluations. 
 
• Three reviews examined patient satisfaction and/or adherence within evaluations of 
either educational/behavioural interventions or pharmacist-managed therapy. 
 
• While all nine reviews examined data from patients, only one included studies which 
examined patients’ experiences directly using qualitative methods. This review also 
sought qualitative studies of physicians’ perspectives. 
 
• The quality of studies was assessed using eleven domains70 of the Joanna Briggs 
Institute (JBI) Quality Assessment Tool, which determines whether the domain was 
‘met’ or ‘not met/unclear’ for each study. Across all reviews, the JBI quality 
                                             
70 1. Clearly stated review question; 2. Appropriate inclusion criteria; 3. Appropriate search 
strategy; 4. Adequate sources searched; 5. Appropriate critical appraisal criteria; 6. Dual 
independent critical appraisal; 7. Methods to minimise data extraction errors; 8. Appropriate 
methods to combine studies; 9. Assessed publication bias; 10. Data supported recommendations; 
11. Appropriate new research recommendations made. 
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assessment showed five domains were low risk,71 four domains were moderate risk72 
and two domains were high risk.73 
 
• The reviews were determined to be of moderate-to-high quality; however, the 
quality of included primary studies varied, where authors conducted quality 
assessment. Most reviews lacked assessment of publication bias or could have errors 
in data extraction. 
 
• A total of 159 primary studies were included across the nine reviews. Of these, 23 
primary studies (39%) contributed findings to more than one review. However, only 
three were included in more than two reviews, suggesting a limited amount of overlap. 
 
Summary of findings 
• Drug efficacy matters most to patients and physicians, followed next by safety (i.e. 
risk of bleeding); but after efficacy and safety, no clear patterns emerge about which 
‘convenience attributes’ or factors involved in daily management are most important 
to facilitate patient adherence. 
 
• Beyond efficacy and safety, a wide range of factors influence patients’ decisions on 
initiating, switching or continuing OACs therapy; little evidence was located to 
suggest which factors are more important for different groups during each of these 
decision points. 
 
• The need for, lack of, or inaccurate knowledge influences patients’ decisions about 
initiating or continuing therapy; and one review of educational and behavioural 
interventions suggested these can have a small but significant positive effect on 
quality of life anxiety and depression sub-scale measures. 
 
• Patients are also influenced by previous experience of stroke, bleeding and/or 
therapy, and by the experiences and support of their families. 
 
• Clinicians draw on rapidly evolving scientific knowledge, their knowledge of the 
patient, and their clinical experiences; however clinical management can be 
complicated by the involvement of, and communications with, other professionals. 
 
                                             
71 All included reviews met: clear review question; appropriate inclusion criteria; appropriate 
search strategy; adequate sources searched; data supported recommendations. 
72 Three reviews failed to report appropriate criteria for appraising studies and dual critical 
appraisal; two reviews failed to report appropriate methods to combine studies; one review failed 
to make appropriate directives for new research. 
73 Six reviews failed to minimise errors in data extraction; eight reviews failed to assess for 
publication bias. 
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• Decisions about initiating or maintaining OACs therapy may depend on the extent to 
which patients and clinicians feel the responsibility for deciding is their own or is 
shared; a review of decision-aid interventions suggested that patients report higher 
decision conflict with their use and did not significantly affect patients’ satisfaction 
with their physician consultation. 
 
• Patients and clinicians indicated that improvements were needed in how information 
about OACs therapy was communicated during the clinical encounter. 
 
• Patients reported a need for ongoing support and information from providers when 
deciding and managing OACs therapy; reviews of pharmacist-led interventions 
suggest patients may be more satisfied with this support than usual care. 
 
General findings 
Nine systematic reviews examined stakeholder issues related to the utilisation and uptake 
of OACs Alamneh et al. 2016, Clarkesmith et al. 2017, Entezari-Maleki et al. 2016, Loewen 
et al. 2017, Mas Dalmau et al. 2017, Pandya and Bajorek 2017, Wilke et al. 2017, Willett 
and Morrill 2017, Zhou et al. 2016. The characteristics and findings of each review are 
presented in Appendix 26. All of the reviews included studies that examined AF patients; 
five reviews examined AF alone Alamneh et al. 2016, Clarkesmith et al. 2017, Loewen et al. 
2017, Mas Dalmau et al. 2017, Pandya and Bajorek 2017. The remainder examined a range 
of conditions that included VTE. Reviews of stakeholder perspectives did not focus on 
specific populations of patients beyond the conditions of AF or VTE, with one exception: 
one review focused specifically on NOACs adherence and satisfaction amongst renal patients 
Willett and Morrill 2017. 
 
Four reviews examined the factors influencing the overuse/underuse/optimal use of 
warfarin in AF, using diverse methods Alamneh et al. 2016, Mas Dalmau et al. 2017, Pandya 
and Bajorek 2017, Willett and Morrill 2017. Two of these included systematic reviews, meta-
analyses, guidelines, trials and non-experimental research Alamneh et al. 2016, Willett and 
Morrill 2017. The other two reviews sought data from studies of patients and physicians 
using qualitative and mixed methods Mas Dalmau et al. 2017, Pandya and Bajorek 2017. 
Another two reviews examined the preferences and values of patients toward the use of 
VKAs and NOACs, including discrete-choice experiment studies and other economic 
evaluation designs Loewen et al. 2017, Wilke et al. 2017. Finally, three reviews examined 
patient satisfaction and/or adherence through evaluations that either examined RCTs of 
educational/behavioural interventions Clarkesmith et al. 2017 or pharmacist-managed 
therapy evaluated in RCTs only Zhou et al. 2016 or via RCTs and non-RCTs Entezari-Maleki 
et al. 2016. 
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The number of studies included across the reviews ranged from three to 140. Only five of 
the nine included reviews provided data concerning the number of participants Clarkesmith 
et al. 2017, Loewen et al. 2017, Mas Dalmau et al. 2017, Pandya and Bajorek 2017, Wilke 
et al. 2017. Here, the review authors reported that between 341 and 7,295 people 
participated in the included studies. 
 
Overall, the quality assessment of included reviews was moderate to high. Using the Joanna 
Briggs Institute review quality rating criteria, most reviews failed to assess publication bias 
and/or did not take steps to minimise errors in data extraction. The ratings for individual 
quality characteristics used in the JBI tool are presented for each review in Appendix 27. 
 
Data from a total of 159 primary studies within the nine reviews were included in this 
overview. These are shown in Appendix 28. Of these, 23 primary studies contributed 
findings to more than one review. This represents a 39% overlap of primary studies across 
the reviews Pollock et al. 2017. Only three of these 23 overlapping primary studies were 
included in more than two reviews, suggesting a limited amount of overlap. 
 
Review summaries 
The aims of the included reviews suggest three distinct areas in which factors examining 
prescribing, utilisation and uptake were described: 
 
• reviews examining factors related to overuse or underuse of OACs, 
• reviews seeking to understand patient preferences and values, and  
• reviews of interventions which included measures of decision-making, adherence, 
quality of life or satisfaction. 
Each of these types of review will be discussed in turn below. 
 
Reviews examining perceptions and attitudes about factors related to OAC over/underuse  
A total of four reviews examined patients’ and physicians’ perceptions and attitudes toward 
OACs therapy. Alamneh et al. (2016) aimed to evaluate current use, overuse and underuse 
of OACs in AF, and the current features of adoption patterns of NOAC use. A total of 140 
primary studies were included. The number of participants was unclear. Study designs were 
both prospective and retrospective and included observational studies, reviews, meta-
analyses, RCTs and published AF treatment guidelines. The review met seven of 11 quality 
criteria upon assessment. Review authors primarily reported current use patterns for OACs, 
but in terms of factors influencing this only noted that TTR rates were higher in North 
America (50.9%) and western Europe (62.4%), while varying between 32% and 40% in India, 
China, Southeast Asia and Africa (Oldgren et al. 2014). Reasons for this variation were not 
provided. Regarding NOAC use, review authors noted concerns with the lack of a reversal 
agent and the risks of not remembering to take NOACs without the reminder of regular blood 
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monitoring tests. Broad availability and practice-related integration of NOACs were 
suggested to be limited, prompting review authors to suggest that these factors may be 
related to poor compliance with guidelines on OAC therapy. 
  
Mas Dalmau et al. (2017) sought to understand patients’ and physicians’ perceptions and 
attitudes about the barriers and facilitators of VKA use, to explore the factors associated 
with its underuse. A total of nine qualitative or mixed-methods studies reported on the 
views of 250 AF patients and 91 physicians. Review authors synthesised three themes related 
to VKA use that were experienced by patients and clinicians: the information needed to 
reinforce coagulation use, the balance of advantages and disadvantages of VKAs, and roles 
in decision-making and therapy management. Review authors identified a further three 
patient-specific themes: the need for information and understanding, the impact of therapy 
on daily life, and factors influencing their satisfaction with therapy. 
 
Pandya et al. (2017) sought to understand the factors underpinning patients’ acceptance 
of and decision to use anticoagulant therapy in order to explain OAC non-adherence in 
patients with AF, and to what extent NOACs might address these factors given that NOACs 
may address some issues but create others. A total of 48 studies were included, comprised 
predominantly of surveys, interviews and one discrete-choice experiment with 4,151 patient 
participants. This review met seven of 11 quality criteria upon assessment. Review authors 
reported a range of factors influencing adherence to warfarin and/or NOACs, organised into 
five main categories. These included therapy-related factors, patient-related factors, 
factors specific to the disease, socioeconomic factors, and health system-related factors. 
  
Willett and Morrill (2017) aimed to describe patient adherence and satisfaction in the use 
of NOACs amongst renal patients, as a specific population for whom this evidence was 
needed. Review authors reported ten included studies but only cited nine, which included 
systematic reviews, meta-analyses, trials and surveys involving an unknown number of 
participants with AF and/or VTE. The review met five of 11 quality criteria on assessment. 
Review authors noted that after establishing the safety and efficacy of NOACs in renal-
impaired patients, patient preferences should also be considered. These included costs, 
dosing frequency, monitoring, and dietary interactions. 
Reviews examining patient preferences and choices 
Two systematic reviews examined patient preferences and values in relation to warfarin 
and/or NOACs. Loewen et al. (2017) aimed to provide insights into the values and 
preferences of AF patients for stroke prevention therapy, as well as the specific factors that 
influences those values and preferences. This was undertaken to try and explain previously 
identified heterogeneity in values and preferences for antithrombotic therapy (MacLean et 
al. 2012), while also focusing on AF. Examining discrete-choice experiments, standard 
gamble, time/probability trade-off, qualitative, conjoint analysis, questionnaires and 
scenario ranking methods amongst patients requiring antithrombotic therapy in AF, a total 
of 25 studies were included with 641 participants. Some of these examined values in relation 
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with warfarin alone, some examined warfarin compared with aspirin, and others evaluated 
warfarin versus NOAC preferences. Quality assessment of this review was high: 10 of 11 
quality criteria were achieved. Review authors noted a wide variation in the attributes of 
antithrombotic therapy most valued by patients, suggesting a need for tailored provision of 
information. 
 
Wilke et al. (2017) aimed to review the preferences of AF patients when deciding on an 
OAC treatment, including both warfarin and NOACs. Comprising 26 included studies of 7,295 
patients and 266 physicians, this review included discrete-choice analysis, trade-off studies, 
gamble techniques, analytical hierarchy methods and traditional conjoint analysis. Some 
included studies also incorporated physician surveys. This review was considered to be of 
high quality, meeting 9 out of 11 quality criteria. Findings suggested that patients across 
studies were more willing to accept a higher risk of bleeding if a drug could achieve a certain 
threshold risk of reducing stroke; however, the threshold varied across studies. Further, no 
other factors were prioritised above each other when considering warfarin or NOACs, also 
patients preferred once daily administration with no dietary or drug interactions, no need 
for bridging therapy and no blood control monitoring. 
Reviews of intervention studies reporting factors related to uptake  
Three systematic reviews reported factors related to uptake. Clarkesmith et al. (2017) 
aimed to evaluate the effects of educational and behavioural interventions for OAT on TTR 
patients with AF. Examining randomised controlled trials, a total of 11 studies were included 
examining 2,246 participants. The trials and their effects were compared with usual care, 
the types of interventions included; educational (booklets, videos, self-management and 
decision aids) and behavioural: CBT, self-monitoring, motivational interviewing, heart rate 
variability and biofeedback. Quality assessment of this review was high: 10 of 11 quality 
criteria were achieved. Review authors concluded that there was inadequate evidence to 
draw conclusions regarding the impact of educational or behavioural interventions on TTR 
in AF patients: based on two trials of low-quality evidence, involving 587 participants in 
total, the findings suggested small but positive effects of education on anxiety measures in 
a HADS quality of life outcome (MD -0.62, 95% CI -1.21 to -0.04) and depression (MD -0.74, 
95% CI -1.34 to -0.14), compared with usual care, over 12 months. Educational interventions 
centred on patient information included: educational booklets; video as media for additional 
information; self-management interventions (such as INR self-monitoring), which also 
educated patients on decision aids and talking interventions. The behavioural interventions 
included techniques that attempted to modify patients’ behaviour towards treatment and 
symptoms, such as: cognitive behaviour therapy (CBT); self-monitoring or management 
interventions that included significant educational components; motivational interviewing 
and heart rate variability biofeedback. Patient satisfaction was reported as a secondary 
outcome with only four trials and one education intervention. The single education 
intervention did not provide any AF-specific data. Finally, the use of the decision aids did 
not significantly affect patients’ satisfaction with their physician consultation. 
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Entezari-Maleki et al. (2016) sought to compare two anticoagulant management services 
(AMS): pharmacist–managed warfarin therapy (PMWT) versus usual care medicine (UCM) in 
order to see which would assist patients in managing serious adverse events, such as 
bleeding and thromboembolic events, but also rates of hospitalisation, visits to emergency 
departments, cost, patient satisfaction and quality of life. RCTs and non-RCTS were 
examined to compare PMWT and UCM. This review focused on the findings on patient 
satisfaction and quality of life. There were 24 studies (of which six reported relevant 
findings) examining 11,607 participants. Quality assessment of this review was relatively 
high: 9 of 11 quality criteria were achieved. Patient satisfaction was high: 96% of 221 
patients 'very satisfied' or 'satisfied' with the PMWT service compared with 84% of patients 
in family physician group (p=0.001). Scores for overall satisfaction from treatment and 
positive emotional affect were significantly higher in PMWT than UMC. The review authors 
supported PMWT regarding cost saving and patient satisfaction. “The results showed that 
the PMWT model is superior to UMC in managing warfarin therapy based on observational 
studies. As well, it is comparable to UMC based on RCT studies.” (p24). 
 
Similarly, Zhou et al. (2016) also aimed to compare the effectiveness of pharmacist–
managed anticoagulant control of warfarin with other models (physicians, nurses, self -
managed care) and to tackle the rates of hospitalisation and emergency visits following an 
adverse event. RCTs were examined both for PMWT and other types of UCM. There were a 
total of eight studies with 1,493 participants. Quality assessment of this review was high: 
10 of 11 quality criteria were achieved. Meta-analysis of the RCTs showed that a statistically 
significant difference existed between pharmacist-managed care and other models for 
satisfaction (MD 0.41, 95% CI 0.01 to 0.81; p=0.04, low-quality evidence), with significant 
heterogeneity. The review authors suggested that pharmacist-managed warfarin 
anticoagulation therapy; “achieved better anticoagulation control measured as percentage 
of time within the standard therapeutic range; however, it has similar percentages in the 
expanded therapeutic range.” (p.606). Similarly to Entezari-Maleki et al. (2016), the review 
authors reported that overall, participants were significantly more satisfied with 
pharmacist-managed interventions compared with usual care (0.41 (95% CI 0.01 to 0.81; 
p=0.04), with heterogeneity (p=0.0001, I2=89%). 
 
Themes across reviews 
Taking the findings of these reviews together, several themes emerged. These are 
illustrated below in Figure 1. 
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Figure 1. Thematic factors influencing OACs utilisation and uptake 
 
 
 
 
 
Reviews of stakeholders’ perspectives of uptake and utilisation broadly focused on two main 
issues: deciding on an OAC therapy (i.e. choosing warfarin over no therapy, deciding on 
warfarin v.  NOAC) and ongoing anticoagulation management. The reviews suggested a range 
of factors that that influence patients and clinicians when considering whether to initiate 
or maintain OAC treatment. Further, both patients and clinicians identified several issues 
within the clinical encounter itself, which could influence the nature and quality of decisions 
about initiating OACs and ongoing management. 
Patient perspectives 
Review authors reported a range of patient factors that could influence their choice of 
and/or adherence to OACs therapy. These reflected aspects of the patient’s knowledge and 
understanding, their own or others’ experiences, their support needs, and characteristics 
related to the disease condition itself. 
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Patients’ need for knowledge and understanding 
Reviews of patients’ preferences and values suggested that when considering or continuing 
OAC therapy, patients appear to highly value stroke prevention. In one review, authors 
suggested that across included studies and all therapy options, patients valued the efficacy 
of stroke prevention over any other attribute, including the risk of bleeding (Loewen et al. 
2017). Both reviews stated that bleeding risks were important to, or highly valued by 
patients (Loewen et al. 2017, Wilke et al. 2017). However, one of these also noted that 
patients’ valuation of the risk of bleeding was highly variable and suggested that this was 
likely to be due to a lack of disclosure of the risk of death from bleeding across included 
studies (Loewen et al. 2017). Review findings suggested that patients would accept several 
serious bleeding episodes in order to avoid one stroke (Lahaye et al. 2014; Devereaux et al. 
2001; Alonso-Coello et al. 2015). However, this high value placed on stroke prevention may 
be more likely if patients or those they know have previous experience of stroke or have 
had prior warfarin use (Loewen et al. 2017). Men and women may prefer different attributes 
of therapy. While most included studies did not find an association, findings from two 
primary studies suggested that women assigned more disutility to major bleeding, had an 
increased treatment threshold, and tolerated fewer major bleeds per stroke (Lahaye et al. 
2014). However, women were also more likely to value warfarin therapy over no therapy 
(Man-Son-Hing et al. 2002). Men were more likely to be decisive about therapy and to make 
all-or-none decisions despite knowing efficacy or bleeding risk (Lahaye et al. 2014). Findings 
from the other review suggested that while patients were willing to accept a higher risk of 
bleeding if a certain threshold in stroke risk reduction could be reached, this value varied 
across included studies (Wilke et al. 2017). Review authors suggested this variation may 
have been due to the differences in study designs, patient selection and data collection 
methods within the review. 
 
Patients’ preferences may differ from what is recommended by current guidance or by 
clinicians. Both reviews of preferences suggested that patient preferences and values 
related to bleeding risk and stroke risk also differed unpredictably from those that underpin 
guidance and the attributes preferred by physicians, although data from physicians was not 
provided in the review by Loewen et al. (2017). Wilke et al. (2017) noted that in one study, 
61% fewer patients would be willing to accept OAC therapy than is recommended in clinical 
guidelines (Protheroe et al. 2001). 
 
Costs to patients also appear to influence patients’ therapy decisions. The relationship 
between stroke risk reduction and risk of bleeding was valued in terms of cost in one review 
Loewen et al. 2017. One study in this review found that patients were willing to pay two 
times more per month in medication cost for every 1% reduction in stroke risk compared 
with bleed risk (Shafrin et al. 2016). 
 
The four reviews of patient perceptions echoed this valuing of efficacy and safety, but 
further highlighted issues in the way patients acquired and used this knowledge. Mas Dalmau 
et al. (2017) noted that patients reported using this information to balance the benefits of 
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warfarin therapy against the risks of bleeding, hematomas or other adverse effects, thereby 
suggesting that complete information is important. However, findings from other reviews 
suggest that their knowledge and understanding of the safety and efficacy of recommended 
therapy options could be limited. In one review, authors noted that not all patients may 
understand the indications for therapy and management: i.e. that the purpose of medication 
is to prevent stroke and that INR monitoring was intended to help prevent stroke or bleeding 
(Mas Dalmau et al. 2017). Two reviews reported that a lack of knowledge could influence 
patients’ choice of therapy and their adherence (Mas Dalmau et al. 2017, Pandya and 
Bajorek 2017). Related to this, patients’ understanding about the risk of bleeding and the 
purpose of warfarin may have influenced their adherence (Pandya and Bajorek 2017). 
Patients’ own or others’ experience 
After drug safety and efficacy, other factors were considered related to patients’ 
management of their condition. Reviews of patient perceptions and attitudes identified a 
range of factors related to patient experience. For example, patients’ (or their family 
members’) previous experiences of stroke or bleed were noted to influence how patients 
balance their risks of stroke versus bleeding when deciding whether to use warfarin or not 
(Mas Dalmau et al. 2017). In one review patients concerns about the lack of a reversal agent 
or antidote influenced their likelihood of switching to NOAC use (Alamneh et al. 2016). The 
need to take some NOAC drugs more frequently (Pandya and Bajorek 2017, Willett and 
Morrill 2017) as well as the need for frequent dosage adjustments in warfarin therapy 
(Pandya and Bajorek 2017) were identified as factors influencing patient satisfaction with 
therapy or willingness to switch. Reviews of patient perceptions and attitudes also identified 
the frequency of INR monitoring as a factor influencing their decision/adherence (Alamneh 
et al. 2016, Mas Dalmau et al. 2017, Pandya and Bajorek 2017). However, it could be seen 
as a both a burden associated with poor adherence in warfarin therapy (Mas Dalmau et al. 
2017, Pandya and Bajorek 2017) or as a way to provide security that patients were within 
range to prevent stroke or bleeds (Alamneh et al. 2016, Mas Dalmau et al. 2017). Costs 
related to INR monitoring and travelling to clinics were also suggested to influence 
adherence (Pandya and Bajorek 2017). Other factors influencing patients’ day-to-day 
management included concerns about diet restrictions (Mas Dalmau et al. 2017, Pandya and 
Bajorek 2017, Willett and Morrill 2017), drug interactions (Mas Dalmau et al. 2017, Pandya 
and Bajorek 2017), the effects of alcohol on drug therapy (Mas Dalmau et al. 2017, Pandya 
and Bajorek 2017, Willett and Morrill 2017), and restrictions on physical activity (Mas Dalmau 
et al. 2017, Pandya and Bajorek 2017). Here, it was suggested that younger patients who 
were physically active were more likely to be non-adherent in warfarin therapy (Arnsten et 
al. 1997). 
 
Within the reviews of patient preferences and values, it appeared that, beyond risk of stroke 
and risk of bleeding, these day-to-day ‘convenience’ attributes matter to patients. 
However, there was wide variation in which is more important and to whom. The reviews 
also examined a range of other ‘convenience’ attributes, which included dosage, food/drug 
interactions, ongoing monitoring, bridging therapy and cost. These were generally valued 
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below risk of bleeding (Loewen et al. 2017, Wilke et al. 2017). With respect to NOACs, one 
review suggested that patients may prefer once daily administration, without any food or 
drug interactions and without the need for bridging or frequent controls (Wilke et al. 2017). 
However, patients in one study included in Loewen et al. (2017) were found to be willing to 
pay for a NOAC antidote; but preferences for NOACs over warfarin were diminished by even 
small costs to the patient (Ghijben et al. 2014). Across included studies in both reviews, 
patients varied widely in the importance they placed on each of these convenience 
attributes. Review authors offered a variety of reasons for this variation, including: 
differences in sociodemographic characteristics, study setting (hospital, clinic, GP or 
specialist), current treatment or previous blood monitoring (Wilke et al. 2017); latent 
effects, such as cultural or familial attitudes and personal experiences, as well as how the 
risks were framed to, and individualised for, the patient based on their preferences (Loewen 
et al. 2017). 
Patients’ support needs 
The reviews noted a range of support needs identified by patients. Within reviews of 
perceptions/attitudes, spousal or family support was suggested to influence patient 
adherence to warfarin (Pandya and Bajorek 2017). Review authors also suggested that busy 
work schedules may also influence adherence to warfarin therapy, as employed patients in 
one study were found to be more adherent than unemployed patients (Arnsten et al. 1997). 
Mas Dalmau et al. (2017) also noted that patients reported an expectation of support from 
their health care providers and wanted opportunities to check back with clinicians to 
“increase their confidence” in managing therapy (p7) (Mas Dalmau et al. 2017). Two reviews 
of interventions to evaluate pharmacist-led OACs management noted that patients were 
more satisfied with this type of support. In these reviews, authors identified four different 
types of models in managing anticoagulant therapy or anticoagulant management services 
(AMS): Usual medical care, pharmacist-managed anticoagulant services (PMAS), nurse-
managed anticoagulant services and finally patient-directed models. UMC is normally 
managed by a healthcare provider such as a physician. The major activities of the 
pharmacist at clinics include visiting patients and assessing their medical conditions, 
adjusting warfarin dose based on INR results usually using point-of-care testing (finger stick 
method), patient consultation and education, monitoring of patients regarding 
anticoagulation-related adverse effects, and checking drug and dietary interactions with 
warfarin (p24) (Entezari-Maleki et al. 2016). 
 
In both reviews the pharmacist-led anticoagulation services resulted in high/superior levels 
of satisfaction from patients. Overall, their effectiveness was higher than other models: 
“patients believed pharmacists were more expert in anticoagulant therapy compared with 
their physicians” (p34) (Entezari-Maleki et al. 2016). However, this may not translate out to 
long-term benefits: one review demonstrated a minimal impact on quality of life in patients 
on oral anticoagulation therapy (Lalonde et al. 2008). 
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Disease characteristics influencing patient choices and adherence 
Some review authors suggested that characteristics of the disease itself may influence 
patient choices and adherence. For example, patients may have difficulty remembering to 
take NOACs due to cognitive decline associated with AF (Alamneh et al. 2016, Pandya and 
Bajorek 2017), although this may be confounded by the older age of patients (Mas Dalmau 
et al. 2017). It was also suggested that AF patients may have more difficulty understanding 
risk and benefits than do patients with VTE (Mas Dalmau et al. 2017). Further, the 
asymptomatic nature of AF may also prevent patients from realising the risks of their 
condition and the importance of therapy (Mas Dalmau et al. 2017). 
Clinician perspectives 
In some reviews, clinicians were reported to be influenced by a different set of factors. 
These were grouped into three broad themes: the weight of scientific evidence, clinicians’ 
knowledge of the patient, and their own experience. 
Clinicians’ views of scientific evidence 
One review examined physicians’ attitudes to the use and underuse of warfarin (Mas Dalmau 
et al. 2017). Review authors noted that physicians needed enough information establishing 
the clear efficacy and safety of warfarin in order to foster decision-making around 
treatment. However, review authors reported that this could be challenging where scientific 
evidence was so rapidly changing. Related to this, physicians were concerned about the lack 
of a reversal agent or antidote when considering switching their patients onto a NOAC 
(Alamneh et al. 2016). 
Clinicians’ knowledge of their patient 
Physicians were also reported to rely on their knowledge of their patients when considering 
OAC therapy. Individual patient risks such as age and cognition were suggested to influence 
physician decisions on OAC therapy (Mas Dalmau et al. 2017), as was the patient’s likely 
response to therapy recommendations (Mas Dalmau et al. 2017). Physicians in some studies 
also reported perceptions that their patients were negative about OAC therapy because they 
were misinformed by friends, family or other non-medical sources (Mas Dalmau et al. 2017). 
Clinicians’ experiences 
Finally, some primary studies in one review suggested that physicians preferred to rely on 
their own experience of managing AF over research evidence and recommendations (Mas 
Dalmau et al. 2017). This may have arisen in part because the research evidence was not 
necessarily applicable to the patients seen in the physician’s practice setting (Mas Dalmau 
et al. 2017). It was also noted in this review that geriatricians tended to focus on patient 
risks more than benefits when discussing therapy options, particularly where these patients 
also had other complicating conditions (Mas Dalmau et al. 2017). Further, three included 
primary studies from one review noted that physicians interpreted bleeding risks as more 
important and stroke risk as less important than did patients (Devereaux et al. 2001; Levitan 
et al. 2013; Sudlow et al. 1998). 
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Decisions around choice of therapy and management 
Both clinicians and patients offered similar insights into factors that took place during the 
clinical encounter. Two factors were suggested as influences on OAC decision-making and 
ongoing management: role expectations of patients and clinicians; and the nature of 
information and quality of communications between patients, clinicians and the wider team 
of health care providers. 
Role expectations 
In deciding whether to initiate warfarin treatment, or to consider NOAC use, one review 
described a range of perspectives from patients and physician participants (Mas Dalmau et 
al. 2017). Here, authors reported that patients varied across studies in the extent to which 
they saw decision-making as a shared activity (Bajorek et al. 2009), in their opinions about 
the patients’ responsibility for decision-making (Bajorek et al. 2009), or in their views about 
the physician’s responsibility. This latter was based on their confidence in the physicians’ 
ability or objectivity, or an expectation that it was the physician’s role (Dantas et al. 2004; 
Alonso-Coello et al. 2008). This review also reported variation in the extent to which 
physicians considered shared decision-making as important. While most of the review’s 
included studies reported physicians supporting shared decision-making (Lipman et al. 2004; 
Anderson et al. 2007; Alonso-Coello et al. 2008), the amount of patient involvement varied 
depending on the clarity of the evidence (Anderson et al. 2007; Alonso-Coello et al. 2008), 
and the physician’s perception that patients should be responsible for their own 
management and even self-monitoring (Bajorek et al. 2007; Carlsen et al. 2007; Alonso-
Coello et al. 2008). 
Nature and quality of information and communication 
Reviews of patient and clinician perceptions and attitudes suggested that information was 
more easily understood and likely to influence adherence if it was tailored to the patient’s 
situation, detailed enough to meet their decision-making needs and was provided in both 
written and oral formats (Mas Dalmau et al. 2017). The review authors suggested that 
patients expressed a desire for more specific information on drug indications and dosages 
when deciding on a treatment therapy (Mas Dalmau et al. 2017). This review also reported 
that patients were less satisfied when they felt that not enough information was provided, 
or when clinicians were not aware of the patient’s medical history (Mas Dalmau et al. 2017). 
Similarly, review authors also noted that physicians in included studies reported that the 
quality of the communication and information provided would influence whether OAC 
therapy was adopted (Mas Dalmau et al. 2017). In this review, the authors also concluded 
that physicians also noted challenges in decision-making related to the involvement of 
different physicians and lack of communication between professionals (Mas Dalmau et al. 
2017). 
  
Reviews of educational or behavioural interventions to facilitate OACs uptake and 
adherence in patients evaluated a range of interventions to communicate risks and help 
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patients balance the challenges and risks of therapy against its benefits. However, this 
review suggested limited effects in fostering patient adherence, facilitating decision-making 
or improving quality of life (Clarkesmith et al. 2017). Here, only a few included studies had 
comparable groups and data on information and communication. One intervention which 
compared individually-received education to usual care demonstrated small and positive 
effects on anxiety and depression in the education group. The review authors concluded: 
“Patients participating in both educational interventions and self-monitoring interventions 
(with education) appear to spend more time within the therapeutic INR range, but pooled 
analyses of the AF data did not significantly favour self-monitoring plus education over usual 
care. Evidence is limited, as there were few trials with small samples of AF patients.” (p27). 
Interestingly within this same review, when the intervention involved the use of decision 
aids, participants reported feeling conflicted in making their own specific choices (Man-Son-
Hing et al. 1999; McAlister et al. 2005; Thomson et al. 2007; O'Connor 1995). The authors 
argued that this decision conflict may be connected to patient adherence by drawing on 
other researchers work: “By increasing patient knowledge and understanding surrounding 
atrial fibrillation and oral anticoagulant therapy we may reduce the prevalence of 
intentional and unintentional non-adherence, and increase patient motivation to adhere, in 
addition to providing patients with the tools to improve their planning and capability to 
incorporate the regimen required with vitamin K antagonist therapy into their lifestyle” 
(Jackson et al. 2014). 
 
Therefore, the patients’ intentional or unintentional attitudes towards therapy can play an 
integral role in uptake behaviour. Review authors suggested that this could be influenced 
by the beliefs, age and level of knowledge of the patient. For example, an older patient 
may be at a cognitive disadvantage and demonstrate unintentional poor adherence due to 
memory loss or poor knowledge and understanding of drug actions and effects in comparison 
to a younger patient (Clifford et al. 2008). The review authors suggested that memory aids, 
such as (reminders or tablet dosettes) could assist with this. 
 
Summary 
In summary, findings from reviews of patient and physician perceptions, preferences and 
values, and interventions measuring adherence, satisfaction and quality of life outcomes 
suggested that patients and most clinicians both value efficacy (i.e. prevention of stroke) 
first, then prioritise safety (i.e. risk of bleed) when deciding to initiate or change OAC 
therapy, although limited evidence suggests that geriatricians may prioritise bleeding over 
efficacy. Due to the variability in which aspects of OAC or NOAC therapy are under 
consideration, review authors suggested that where efficacy and safety are equal, there 
exists a need for individualised discussions with patients, which should include a tailored 
framing of all potential risks from both treatment and side-effects. The review authors 
recommended that these factors should be integrated into decision-making tools, to help 
structure discussions with patients about therapy and allow both patients and physicians to 
clarify their preferences and values. However, interventions to address these issues have 
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shown limited success, which may be influenced by communication styles, a clarification of 
which factors matter most to each patient, and the extent to which patients and clinicians 
feel that the decision to adopt or switch OAC therapy is their responsibility. 
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9  Discussion and Conclusions 
Main findings 
The findings of Sterne et al. (2017)’s review indicate that for prevention of stroke and 
systemic embolism in atrial fibrillation populations, NOACs show advantages over warfarin 
for most efficacy and safety outcomes. Of these, apixaban (5mg bd) offered the best 
balance between efficacy and safety and had the highest probability of being most cost-
effective. These findings support the use of NOACs for the prevention of stroke and systemic 
embolism in atrial fibrillation patients and suggest that apixaban (5mg bd) is the best option. 
There is no strong evidence to support the use NOACs for VTE for: 
 
• primary prevention (compared with low-molecular-weight heparin, (LMWH); 
• acute treatment (compared with warfarin); and 
• secondary prevention (compared with warfarin and aspirin). 
However, in terms of safety, apixaban (5mg bd) and rivaroxaban (15mg bd, then 20mg od) 
may reduce the risk of major and clinically relevant bleeding, compared with warfarin for 
the acute and secondary prevention of VTE. Note that for primary prevention of VTE, 
conclusions should be limited to hip and knee surgery patients, as no trials among patients 
who were undergoing neurosurgery, gastroenterological surgery or gynaecological surgery 
were identified. 
 
For secondary prevention of VTE, aspirin was likely to be the most cost-effective alternative 
to warfarin. These findings provided no evidence that NOACs should replace the use of: 
 
• LMWH for primary prevention of VTE; 
• warfarin for acute treatment of VTE; and 
• aspirin for the secondary prevention of VTE. 
The NICE 2014 guideline on treatment of atrial fibrillation and VTE recommends using NOACs 
or a vitamin K antagonist (warfarin) as anticoagulant treatment (NICE 2014). Among these 
treatments, however, no frontrunner is identified for the management of AF and VTE. 
Rather, guidance states that individual characteristics and preferences should be taken into 
consideration when deciding which drug to prescribe. By contrast, low-molecular-weight 
heparin (LMWH) is the standard treatment for reducing the risk of VTE during hospitalisation 
(primary prevention) (NICE 2016c). 
 
Among AF populations, Sterne et al. (2017)’s findings indicate that NOACs show advantages 
over warfarin for most efficacy and safety outcomes. Of these, apixaban (5mg bd) offers 
the best balance between efficacy and safety and had the highest probability of being most 
cost-effective. However, there were no direct head-to-head comparisons between different 
NOAC drugs (as all were indirect comparisons from the networks). Sterne et al. (2017) note 
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that a new trial that directly compares the most promising NOACs and NOAC doses would be 
prohibitively expensive (if it was to account for a large number of variables including costs, 
the effect of past events on future hazard ratios, and probabilities of treatment switching) 
and, therefore, they called for calculations to assess the cost benefit of any potential new 
trial. 
 
Sterne and colleagues noted that whilst NOACS are easier to take and manage, compared 
with warfarin (which requires regular monitoring), the efficacy and safety profiles of NOACs 
may be improved by monitoring and dose adjustment. Evidence on long-term adherence 
rates of NOACS and the impact of therapeutic monitoring on the safety and efficacy of 
NOACs, in patients receiving NOACs for AF, may further clarify the role of NOACs in AF 
populations. Finally, Sterne and colleagues noted that decision making may also be 
influenced by the current unavailability of an antidote to anticoagulation with NOACs, which 
are still in the developmental phase, and whilst NOACs are currently more expensive, the 
cost of these will probably be greatly reduced once generic NOACs become available. 
 
Whilst Sterne and colleagues were careful to keep analyses of the different doses or 
frequencies of administration (i.e. od or bd) of oral anticoagulants separate and to focus on 
longest period of follow-up the duration of treatment varied widely across trials. A need for 
studies with longer follow-up (e.g., data from registries or health records), which would 
provide evidence on the longer-term safety and cost-effectiveness of NOACs among AF 
populations (currently mainly based on short-term trial evidence) was therefore identified. 
They stated that NHS health record data could provide data on absolute event rates, for 
efficacy and safety outcomes, rather than relative effects (as assessed in their reviews) 
which would facilitate more reliable estimations of the cost-effectiveness of NOACs for 
anticoagulation. Overall, Sterne and colleagues concluded that whilst some evidence 
suggests that NOACs are more effective than warfarin among AF populations, it is unlikely 
that NOACs will be suitable for all patients with this condition. They noted the importance 
of identifying which patient cohorts would be better suited to alternative options.  
 
More generally, Sterne and colleagues highlighted that the characteristics of patients in 
trials may not be generalisable to those in clinical practice, who may be older and have 
more comorbidities. For example, they noted that it is possible that bleeding complications 
are higher among patients treated with warfarin in practice, than those in trials, due to 
more comorbidities and less management of anticoagulation. However, they highlighted 
additionally that the efficacy of NOACs over warfarin could also be exaggerated due to 
suboptimal management of INR among patients in the warfarin trial arms. For example, 
variation in TTR was substantial among the studies on stroke prevention in AF (from 45.1% 
to 83%). However, due to the low event rates and insufficient replication of intervention 
comparisons (especially in the reviews on the primary and secondary prevention of VTE), 
analyses were based on Bayesian fixed-effect models, meaning that investigation of 
potential moderators (such as mean TTR) of effects was not possible. Finally, it was noted 
that nearly all trials on NOACs included in the Sterne et al. (2017) reviews were funded by 
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pharmaceutical companies. In light of these concerns regarding the relevance of the data 
to clinical populations, we concur with Sterne and colleagues’ conclusions that prescribers 
and patients may like to exercise caution when considering the results of these reviews. 
 
Genotyping may provide a way to tailor drug therapy more effectively for specific 
populations; however, the located reviews of genotyping did not provide evidence specific 
to AF and VTE populations. This rendered their findings ungeneralisable to the overview 
research questions. These reviews were determined to be of low quality and contained 
considerable overlap of primary studies. The reviews examined four main genotypes: the 
CYP4F2, the VKORC1, the CYP2C9 and the Apolipoprotein E (ApoE), focused in Asian, 
Caucasian, African American and Hispanic populations. A very recent review of evidence, 
published in March 2018, was located too late for inclusion in this overview (King et al. 
2018). It examines the clinical utility and cost-effectiveness of genotyping to inform OAC 
dosing, similarly noting that conclusions are limited by the low quality of the primary 
studies. 
 
Interventions that focus on improving patient adherence report largely mixed results. 
Amongst AF patients, limited evidence, of low quality, supports the beneficial effects of 
education and education plus patient decision aid on TTR. Self-testing interventions showed 
little evidence of improvements in TTR, and uncertain improvements in self-monitoring 
care, compared with usual care. Among mixed-diagnoses groups, the low-to-moderate 
quality evidence suggested that self-testing interventions may improve the INR values in 
therapeutic range, compared with usual care. However, when examining TTR outcomes, 
moderate-quality evidence suggested both positive (longer) and negative (shorter) time in 
therapeutic range for the self-testing intervention, compared with usual care. The evidence 
for self-management interventions was mixed for both INR and TTR outcomes, with both 
higher and lower INR numbers in therapeutic range, and shorter and longer time in 
therapeutic range, compared with usual care. Low-quality meta-analytic evidence indicated 
that self-management may be as effective as usual care, but does not offer enhancements 
over and above usual care, in terms of TTR. The variation in findings suggests the presence 
of potential moderators. However, the evidence for pharmacist-managed anticoagulation 
(from mixed-quality studies, rated as high and uncertain) was more consistent across the 
reviews. This suggests that pharmacist-managed anticoagulation may improve TTR, 
compared with usual care, among mixed-diagnoses groups. There were no reviews 
evaluating pharmacist-managed anticoagulation services exclusively in populations with AF 
and none of the interventions were exclusively examined in populations with VTE. 
 
Reviews of stakeholder experiences suggest that patients and most clinicians both value 
efficacy (i.e. prevention of stroke) first, then prioritise safety (i.e. risk of bleed) when 
deciding to initiate or change OAC therapy, although limited evidence suggests that some 
geriatricians may prioritise bleeding over efficacy. Where efficacy and safety of specific 
therapies have been established, the next priority should be to consider which factors 
matter to patients and clinicians, and where their preferences lie with respect to decision-
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making. This will help guide the balance of supporting patients to decide on a therapy with 
the clear provision of information and communication of risks, benefits and preferences. 
Beyond efficacy and safety, patients and clinicians are influenced by a variety of other 
factors. These include knowledge, experience, changes in patient cognition and memory 
due to the condition itself, or patient characteristics, such as age, gender, lifestyle, 
employment status, support needs, or patient-clinician factors, such as communication and 
perceptions about who bears the responsibility for decision-making. These findings echo 
those of previous evidence syntheses concerning stakeholder experiences and models of 
adherence in OAC therapy (Borg et al. 2012; Brown et al. 2012). 
 
Careful elicitation should take place to determine which factors matter to, or could 
influence patients, before a decision can occur about initiating, continuing or switching 
OACs (Di Minno et al. 2014). However, our findings from reviews of interventions suggest 
limited impact from interventions that employ education and/or decision-aids that should 
identify these needs in order to improve patient knowledge or decision-making. It may be 
that a lack of recognition of these factors, and the need to assess each patient individually 
may explain that lack of large improvements in self-monitoring, self-management or 
educational or decision-making interventions. It may also be that variations in the factors 
that influence shared decision-making, such as time constraints, provider motivation, 
decreased continuity of care, preparation for and processes of shared decision-making could 
also influence the effectiveness of educational and decision-aid interventions in OAC 
therapy (Legare et al. 2008; Joseph-Williams et al. 2014). 
 
Overview findings also suggest that there is wide variation in patients’ and clinicians’ 
attitudes to shared decision-making. This suggests a need to assess both clinicians and 
patients’ attitudes to shared decision-making. By tailoring the decision-making encounter 
to reflect these values, it may become more likely that patients will both make the decision 
that they are most satisfied with and will improve their therapy adherence. It may also be 
that patients’ and clinicians’ readiness to make a decision changes over time: this should 
also be studied to determine its impact on OACs decision-making at the point of initiation, 
continuation and switching OAC therapy. 
 
Finally, patients’ identified need for ongoing support could be met through pharmacist-led 
management interventions, as these suggest patients are more satisfied with pharmacist-
managed care, compared with usual care. The integration of community pharmacists into 
primary care has been recently recommended (Murray 2016). 
 
Quality of reviews and included primary studies 
The quality of the included reviews may have influenced the results seen in this overview. 
While the reviews of efficacy and safety were of high quality, publication bias was not 
explored; further searches were conducted 2.5 years before publication, no reporting of 
protocol revisions was provided, and it was unclear whether the risk of bias rating of primary 
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studies was integrated into the reviews’ syntheses. These factors may have served to 
overestimate the size of meta-analytic effects. The reviews of self-monitoring, genotyping 
and stakeholder experience were of moderate-to-high quality, but their included primary 
studies were low-to-moderate quality. This introduces the possibility that review findings 
could have been influenced by bias operating in primary studies, which could overestimate 
the size of the reported effects. This should also be taken into consideration when 
interpreting these reviews’ findings. 
 
Overlap of primary studies across reviews 
The overlap of primary studies across reviews varied for each synthesis provided here. No 
primary studies overlapped in the reviews of efficacy and safety, suggesting that findings 
were not ‘double-counted’. Considerable overlap was found in primary studies included 
across reviews of genotyping. Although only 27% of included primary studies overlapped 
across reviews, over half of these were found in three or more reviews. Moderate overlap 
was noted in reviews of self-monitoring (40%) and reviews of stakeholder perspectives (39%); 
although in both of these primary studies occurred in only two reviews. 
 
It is uncertain whether the overlap of primary studies across qualitative evidence syntheses, 
such as the review of stakeholder experiences, should be as concerning as for the other 
syntheses of reviews in this report. The aims of reviews included in the synthesis of 
stakeholder experiences are quite broad, reflecting the complex nature of drug utilisation 
and uptake. It has been recommended that where overlap exists, overview authors may 
select the highest quality most representative review from which to extract findings (Caird 
et al. 2015; Lunny et al. 2016). Thus efforts to select only one systematic review per topic 
would likely miss others with important concepts that could add value to the overview 
(Ballard and Montgomery 2017, McKenzie and Brennan 2017). While it might be suggested 
that the moderately high overlap of included primary studies could influence the broad 
conclusions of this overview, it may also be argued that the overlapping nature of the 
reviews themselves “represent appropriate replications of data analysis by different groups 
with different viewpoints” (pII-40) (Grimshaw et al. 2002). The issue of overlap in overviews 
of reviews remains debatable, and guidance on dealing with it is limited (Ballard and 
Montgomery 2017). Here, we have endeavoured to report the overlap with the review of 
stakeholder experiences and the other reviews as transparently as possible. However, we 
were unable to analyse its impact further due to the rapid nature of this project. 
   
Answering overview research questions 
This overview of reviews sought to address several inter-related policy questions: 
1. What evidence syntheses have been conducted to address the efficacy of UK-
approved oral anticoagulant therapy with respect to: 
a. Warfarin versus NOACs in different patient cohorts? 
b. The impact of warfarin versus NOACs on INR clinic capacity? 
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c. The evidence for an optimised pathway on self-monitoring? 
d. The evidence for an optimised pathway on genotyping? 
2. What evidence syntheses have been conducted to address the safety of UK-approved 
oral anticoagulant therapy with respect to: 
a. Renal function and the long-term use of NOACs? 
b. Complications associated with warfarin and NOACs including bleeding and 
stroke risk? 
 
We identified over 400 systematic reviews published within the past four years to address 
questions of efficacy and safety. To address this question in the available timelines, we 
chose the most recent, comprehensive well-conducted review (Sterne et al. 2017). This 
review suggested that among AF populations, NOACs show advantages over warfarin for most 
efficacy and safety outcomes. Of these, apixaban (5mg bd) offers the best balance between 
efficacy and safety and had the highest probability of being most cost-effective. There was 
no strong evidence to support the use of NOACs for VTE for primary prevention (compared 
with low-molecular-weight heparin (LMWH), acute treatment (compared with warfarin) and 
secondary prevention (compared with warfarin and aspirin). However, in terms of safety, 
apixaban (5mg bd) and rivaroxaban (15mg bd, then 20mg od) may reduce the risk of major 
and clinically relevant bleeding, compared with warfarin, for the acute treatment of VTE. 
For secondary prevention of VTE, aspirin was likely to be the most cost-effective alternative 
to warfarin. This review did not report clearly differences in effect by age, gender or 
ethnicity; nor did it examine INR clinic capacity, different patient cohorts or long-term renal 
function. Further examination of the remaining recent systematic reviews of efficacy and 
safety may elicit further information about differential effectiveness. Reviews of genotyping 
do not yet provide robust evidence specific to AF and/or VTE populations, suggesting an 
optimised pathway is not yet available. Reviews of interventions to promote self-
monitoring, self-management, education and decision-aid use are similarly based on mixed- 
or low-quality evidence and show small effects, suggesting that more rigorous evaluation is 
required. 
 
3. What are patient and clinician experiences of UK-approved oral anticoagulant 
therapy concerning: 
 
a. The impact of NOACs and warfarin on patient lifestyle? 
b. Medicines adherence and compliance of NOACs and warfarin? 
c. Clinician perceptions of NOACs and warfarin? 
d. Monitoring INRs in patients receiving VKAs and effects on patient adherence?  
 
Findings from reviews of stakeholder experiences suggest that the impact of NOACs and/or 
warfarin on patient lifestyle and medicines adherence are likely to be affected by a wide 
range of factors that will be unique to each patient’s circumstances. Efficacy and safety of 
drugs appear to be most highly valued; but a range of other factors could influence decision-
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making and adherence. These include patient and clinician knowledge and experience, 
changes due to the condition itself or to the patient’s age or gender, lifestyle or employment 
status, patient support needs, communication, and perceptions about who bears the 
responsibility for decision-making. However patient satisfaction, quality of life and decision 
conflict outcomes in educational and decision-aid interventions are reported as having 
limited impact; while reviews of pharmacist-led management interventions suggest patients 
are more satisfied with this care, compared with usual care. 
 
Strengths and limitations 
This represents the most current evidence derived from systematic reviews of OAC research 
and it demonstrates the extent of research synthesis in this area. As an overview, it 
conforms to systematic review principles (please see the PRISMA checklist in Appendix 29 
for more detail). 
 
However, some limitations should be considered. The overview relies mainly on review-level 
findings and has a wide focus, which means that some of the detail usually found in a highly 
focused systematic review, addressing a specific question, is missing. The focus on one 
comprehensive review of efficacy and safety of OACs may mean that evidence specific to 
particular patient populations was excluded. Given the large number of systematic reviews 
identified, and the short project timeline, it was not possible to assess all the available 
evidence. The decision to limit our examination of efficacy and safety to just one systematic 
review was pragmatic, for three reasons. First, the policy need for this project meant that 
a short timeline was necessary, which precluded the amount of time available for locating, 
assessing and analysing reviews. Second, each of the reviews would have considerable 
overlap of included primary studies, which would require consideration in analysis and 
require further time to clarify the true weight of evidence each primary study contributed 
to each review. Third, the location of a comprehensive, robust, recent and NHS-focused 
report directly answering our overview research question suggested that there would be 
little gain in identifying and analysing less relevant reviews.   
 
 
Conclusions and recommendations for future research 
Some questions could not be addressed, or only limited or mixed evidence was identified. 
New evidence syntheses could usefully address: 
 
• the impact of OACs on renal functions; 
• the efficacy of self-monitoring or self-management for a range of conditions in which 
VTE is a risk factor; 
• differences between genotypes in examining clinical outcomes, treatment 
maintenance and adverse effects specific to AF and VTE populations; and 
• the influence of gender and age on the OACs’ efficacy, safety, and patient 
experience. 
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Research gaps were also apparent and new primary research could address: 
 
• the relationships between age, cognition and memory in AF and VTE populations; 
• AF and VTE patients’ support needs and preferences with respect to the specific 
drug therapies recommended by Sterne et al. (2017); 
• the most effective strategies to help clinicians assess AF and VTE patients’ 
willingness and ability to decide on OACs therapy; 
• self-monitoring and self-management in AF and VTE; 
• the limited effectiveness seen in interventions using decision aids; and 
• the need for a practical tool to guide clinicians in appraising patients’ and their 
own perception of their role and responsibility when decisions must be made 
regarding the initiation and maintenance of OACs therapy. 
 
Focusing future research efforts in these areas may help clinicians to understand their 
choices in prescribing, as well as to better inform patients about treatment options so they 
can contribute to decisions about OAC therapy. These efforts to improve communication 
quality may further foster the patient experience in care (Doyle et al. 2013). 
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11 Appendices 
Appendix 1: Search Strategy terms 
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to 
Present> 
 
1     Anticoagulants/ (70885) 
2     Administration, Oral/ (140536) 
3     1 and 2 (5342) 
4     (oral$ adj3 anticoagulant$).mp. (11057) 
5     (oral$ adj3 anticoagulation).mp. (4884) 
6     (OAC adj3 (treat$ or therap$)).ti,ab. (506) 
7     DOAC$.mp. (818) 
8     NOAC$.mp. (1588) 
9     (warfarin or coumadin).ti,ab. (23229) 
10     warfarin/ (18867) 
11     (apixaban or eliquis).ti,ab. (2180) 
12     Dabigatran/ (2503) 
13     (dabigatran or pradaxa).ti,ab. (3813) 
14     (edoxaban or lixiana).ti,ab. (894) 
15     Rivaroxaban/ (2172) 
16     (rivaroxaban or xarelto).ti,ab. (3482) 
17     Aspirin/ (45105) 
18     aspirin.ti,ab. (46772) 
19     17 or 18 (65844) 
20     Stroke/ or Ischaemic Attack, Transient/ (87442) 
21     Myocardial Infarction/ or Venous Thrombosis/ (193741) 
22     Thromboembolism/ or Pulmonary Embolism/ or Atrial Fibrillation/ 
(107659) 
23     Anticoagulants/ (70885) 
24     20 or 21 or 22 or 23 (410719) 
25     19 and 24 (12727) 
26     (aspirin adj3 (stroke$ or transient ischaemic attack$ or transient 
ischemic attack$ or TIA or heart attack$)).ti,ab. (822) 
27     (aspirin adj3 (thrombosis or embolism or thromboembolism or atrial 
fibrillation)).ti,ab. (337) 
28     (aspirin adj3 anticoagul$).ti,ab. (689) 
29     "Vitamin K"/ (11631) 
30     vitamin K.ti,ab. (13391) 
31     29 or 30 (19806) 
32     31 and 24 (5825) 
33     (vitamin K adj3 (stroke$ or transient ischaemic attack$ or transient 
ischemic attack$ or TIA or heart attack$)).ti,ab. (67) 
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34     (VKA$ adj3 (stroke$ or transient ischaemic attack$ or transient 
ischemic attack$ or TIA or heart attack$)).ti,ab. (62) 
35     (vitamin K adj3 (thrombosis or embolism or atrial fibrillation)).ti,ab. 
(125) 
36     (VKA$ adj3 (thrombosis or embolism or thromboembolism or atrial 
fibrillation)).ti,ab. (67) 
37     (vitamin K adj3 anticoagul$).ti,ab. (1549) 
38     vitamin K antagonist$.ti,ab. (4736) 
39     3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
or 25 or 26 or 27 or 28 or 32 or 33 or 34 or 35 or 37 or 38 (54568) 
40     Meta-Analysis as Topic/ (17376) 
41     meta analy$.tw. (132487) 
42     metaanaly$.tw. (1966) 
43     Meta-Analysis/ (94843) 
44     (systematic adj (review$1 or overview$1)).tw. (121548) 
45     exp Review Literature as Topic/ (10322) 
46     or/40-45 (237989) 
47     cochrane.ab. (61716) 
48     embase.ab. (65920) 
49     (psychlit or psyclit).ab. (957) 
50     (psychinfo or psycinfo).ab. (22044) 
51     (cinahl or cinhal).ab. (20870) 
52     science citation index.ab. (2933) 
53     cancerlit.ab. (679) 
54     or/47-53 (106215) 
55     reference list$.ab. (15901) 
56     bibliograph$.ab. (16317) 
57     hand-search$.ab. (6091) 
58     relevant journals.ab. (1104) 
59     manual search$.ab. (3840) 
60     55 or 56 or 57 or 58 or 59 (38732) 
61     selection criteria.ab. (28310) 
62     data extraction.ab. (16717) 
63     61 or 62 (42844) 
64     Review/ (2480860) 
65     63 and 64 (28687) 
66     comment/ (735999) 
67     letter/ (1035172) 
68     editorial/ (470242) 
69     animal/ (6598857) 
70     human/ (18058112) 
71     69 not (69 and 70) (4708497) 
72     66 or 67 or 68 or 71 (6336983) 
73     46 or 54 or 60 or 65 (284883) 
74     73 not 72 (270201) 
75     39 and 74 (2082) 
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76     qualitative systematic review$.ti,ab. (511) 
77     (systematic review and qualitative).ti,ab. (5075) 
78     evidence synthesis.ti,ab. (3012) 
79     realist synthesis.ti,ab. (155) 
80     (qualitative and synthesis).ti,ab. (5761) 
81     (meta-synthesis$ or meta synthesis$ or metasynthesis$).ti,ab. (868) 
82     (meta-ethnograph$ or metaethnograph$ or meta ethnograph$).ti,ab. 
(412) 
83     (meta-study or metastudy or meta study).ti,ab. (85) 
84     76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 (12431) 
85     39 and 84 (23) 
86     75 or 85 (2088) 
87     limit 86 to yr="2014 -Current" (895) 
 
*************************** 
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Appendix 2: AMSTAR Quality appraisal 
1. Did the research questions and inclusion criteria for the review include the 
components of PICO? Yes/No 
 
 For Yes: Optional (recommended) 
Population  Timeframe for follow-up  
Intervention    
Comparator group    
Outcome   
 
2. Did the report of the review contain an explicit statement that the review methods 
were established prior to the conduct of the review and did the report justify any 
significant deviations from the protocol?  Yes/Partial Yes/No 
 
For Partial Yes:  For Yes:   
The authors state that they had a 
written protocol or guide that 
included ALL the  following:    
As for partial yes, plus the protocol  
should be registered and should also  
have specified: 
• review question(s)  
• a search strategy 
• inclusion/exclusion criteria 
• a risk of bias assessment  
 
• a meta-analysis/synthesis plan,  
if appropriate, and 
• a plan for investigating causes  
of heterogeneity 
• justification for any deviations from the 
protocol 
 
3. Did the review authors explain their selection of the study designs for inclusion in 
the review?  Yes/No 
 
For Yes, the review should satisfy ONE of the following: 
• Explanation for including only RCTs 
• OR Explanation for including only NRSI 
• OR Explanation for including both RCTs and NRSI 
   
4. Did the review authors use a comprehensive literature search strategy?  
Yes/Partial Yes/No 
 
For Partial Yes (all the following):  For Yes, should also have (all the 
following):    
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• searched at least 2 databases 
(relevant to research question)   
• provided key word and/or search 
strategy   
• justified publication restrictions 
(e.g. language)   
• searched the reference lists / 
bibliographies of included studies   
• searched trial/study registries 
• included/consulted content experts in 
the field 
• where relevant, searched for grey 
literature 
• conducted search within 24 months of 
completion of the review 
  
5. Did the review authors perform study selection in duplicate?  Yes/No 
 
For Yes, either ONE of the following:    
• at least two reviewers independently agreed on selection of eligible studies and 
achieved consensus on which studies to include 
• OR two reviewers selected a sample of eligible studies and achieved good 
agreement (at least 80 percent), with the remainder selected by one reviewer.  
  
6. Did the review authors perform data extraction in duplicate? Yes/No 
 
For Yes, either ONE of the following:    
• at least two reviewers achieved consensus on which data to extract from included 
studies 
• OR two reviewers extracted data from a sample of eligible studies and achieved 
good agreement (at least 80 percent), with the remainder extracted by one 
reviewer.  
  
7. Did the review authors provide a list of excluded studies and justify the exclusions?   
Yes/Partial Yes/No 
 
For Partial Yes:  For Yes must also have:    
provided a list of all potentially relevant 
studies that were read in full-text form 
but excluded from the review 
justified the exclusion from the review 
of each potentially relevant study   
  
8. Did the review authors describe the included studies in adequate detail?  
Yes/Partial Yes/No 
 
For Partial Yes (ALL the 
following): 
For Yes should also have ALL the following: 
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• described populations   
• described interventions   
• described comparators   
• described outcomes   
• described research designs   
• described population in detail   
• described intervention in detail (including 
doses where relevant) 
• described comparator in detail (including 
doses where relevant) 
• described study’s setting 
• timeframe for follow-up 
  
9. Did the review authors use a satisfactory technique for assessing the risk of bias 
(RoB) in individual studies that were included in the review?  
 
RCTs      
For Partial Yes, must have 
assessed RoB from: 
For Yes, must also have 
assessed RoB from: 
Yes  
Partial Yes  
No 
Includes only NRSI 
• unconcealed allocation, 
and   
• lack of blinding of 
patients and assessors 
when assessing 
outcomes (unnecessary 
for objective outcomes 
such as all-cause 
mortality)   
• allocation sequence that 
was not truly random, and   
• selection of the reported 
result from among multiple 
measurements or analyses 
of a specified outcome 
NRSI 
For Partial Yes, must have 
assessed RoB: 
For Yes, must also have 
assessed RoB:    
Yes  
Partial Yes  
No  
Includes only RCTs  
• from confounding, and   
• from selection bias   
• methods used to ascertain 
exposures and outcomes, 
and   
• selection of the reported 
result from among multiple 
measurements or analyses 
of a specified outcome  
 
10. Did the review authors report on the sources of funding for the studies included 
in the review?  Yes/No 
 
For Yes: 
• Must have reported on the sources of funding for individual studies included in the 
review. Note: Reporting that the reviewers looked for this information but it was 
not reported by study authors also qualifies 
  
11. If meta-analysis was performed did the review authors use appropriate methods 
for statistical combination of results?  Yes/No/No meta-analysis conducted  
 
The effective, safe and appropriate use of anticoagulation medicines: A systematic 
overview of reviews 
 
 
98 
 
RCTs for Yes: 
• The authors justified combining the data in a meta-analysis 
• AND they used an appropriate weighted technique to combine study results and 
adjusted for heterogeneity if present.  
• AND investigated the causes of any heterogeneity  
     
NRSI for Yes: 
• The authors justified combining the data in a meta-analysis  
• AND they used an appropriate weighted technique to combine study results, 
adjusting for heterogeneity if present  
• AND they statistically combined effect estimates from NRSI that were adjusted 
for confounding, rather than combining raw data, or justified combining raw data 
when adjusted effect estimates were not available  
• AND they reported separate summary estimates for RCTs and NRSI separately 
when both were included in the review   
  
12. If meta-analysis was performed, did the review authors assess the potential 
impact of RoB in individual studies on the results of the meta-analysis or other 
evidence synthesis?  Yes/No/No meta-analysis conducted 
 
For Yes:    
• included only low risk of bias RCTs 
• OR, if the pooled estimate was based on RCTs and/or NRSI at variable RoB, the 
authors performed analyses to investigate possible impact of RoB on summary 
estimates of effect.  
   
13. Did the review authors account for RoB in individual studies when interpreting/ 
discussing the results of the review?  Yes/No 
 
For Yes:    
• included only low risk of bias RCTs  
• OR, if RCTs with moderate or high RoB, or NRSI were included the review provided 
a discussion of the likely impact of RoB on the results    
  
14. Did the review authors provide a satisfactory explanation for, and discussion of, 
any heterogeneity observed in the results of the review?  Yes/No 
 
For Yes:    
• There was no significant heterogeneity in the results 
• OR if heterogeneity was present the authors performed an investigation of sources 
of any heterogeneity in the results and discussed the impact of this on the results 
of the review    
  
15. If they performed quantitative synthesis did the review authors carry out an 
adequate investigation of publication bias (small study bias) and discuss its likely 
impact on the results of the review?  Yes/No/No meta-analysis conducted 
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For Yes:    
• performed graphical or statistical tests for publication bias and discussed the 
likelihood and magnitude of impact of publication bias 
 
16. Did the review authors report any potential sources of conflict of interest, 
including any funding they received for conducting the review?  Yes/No 
 
For Yes:    
• The authors reported no competing interests OR 
• The authors described their funding sources and how they managed potential 
conflicts of interest.
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Appendix 3: JBI Critical Appraisal Checklist for Systematic Reviews and Research 
Syntheses 
Reviewer     Date      
 
Author      Year    Record Number  
 
Yes No Unclear Not applicable 
 
1. Is the review question clearly and explicitly stated?  
 □  □  □  □  
 
2. Were the inclusion criteria appropriate for the review question?  
 □  □  □  □  
 
3. Was the search strategy appropriate?  
 □  □  □  □  
 
4. Were the sources and resources used to search for studies adequate?  
 □  □  □  □  
 
5. Were the criteria for appraising studies appropriate?  
 □  □  □  □  
 
6. Was critical appraisal conducted by two or more reviewers independently?  
 □  □  □  □  
 
7. Were there methods to minimize errors in data extraction?  
 □  □  □  □  
 
8. Were the methods used to combine studies appropriate?  
 □  □  □  □  
 
9. Was the likelihood of publication bias assessed?  
 □  □  □  □  
 
10. Were recommendations for policy and/or practice supported by the reported data?  
 □  □  □  □  
 
11. Were the specific directives for new research appropriate?  
 □  □  □  □  
 
Overall appraisal:   Include □  Exclude □  Seek further info □  
Comments (Including reason for exclusion) 
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Appendix 4: Flow of literature through the review 
 
Not screened due to 
focus on 
efficacy/safety 
 N = 424 
Duplicate reports removed 
N = 1,279 
Criteria on which reports 
were excluded (abstract 
and full text) 
Exclude 1: date of 
publication (pre 2014) 
Exclude 2: not reported in 
the English language 
Exclude 3: not an OECD 
country 
Exclude 4: not a systematic 
review 
Exclude 5: Children (aged 
17 or younger) 
Exclude 6: not focused on 
anticoagulation 
Exclude 7: focus not on UK 
recommended OACs 
Exclude 8: not on stroke 
prevention in non-valvular 
AF or prevention/treatment 
of VTE 
Exclude 9: intervention is 
polypharmacy in nature 
Exclude 10: topic: does not 
focus on drug 
efficacy/safety, adherence, 
experiences 
Exclude 11: no comparator 
(applies to quantitative 
studies only) 
Exclude 12: on comparator 
type (if drug 
efficacy/safety) 
Exclude 13: does not 
include health or cost 
outcomes  
Exclude 14: duplicate 
Total records screened  
N = 1,840 
Total records 
N = 3,119 
Full reports retrieved and screened 
N = 50 
Full reports included  
N = 23 
Excluded on abstract 
N = 1,366 
Exclusion 1: 0 
Exclusion 2: 63 
Exclusion 3: 22 
Exclusion 4: 415 
Exclusion 5: 14 
Exclusion 6: 299 
Exclusion 7: 229 
Exclusion 8: 29 
Exclusion 9: 36 
Exclusion 10: 26  
Exclusion 11: 63 
Exclusion 12: 169 
Exclusion 13: 0 
Duplicates: 1 
Excluded on full text 
N = 27 
Exclusion 1: 0 
Exclusion 2: 1  
Exclusion 3: 0 
Exclusion 4: 13 
Exclusion 5: 0 
Exclusion 6: 1 
Exclusion 7: 0 
Exclusion 8: 6 
Exclusion 9: 0 
Exclusion 10: 5  
Exclusion 11: 0 
Exclusion 12: 0 
Exclusion 13: 1 
Duplicates: 0 
Not obtained on 
time 
 N = 0 
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Appendix 7: Effectiveness, safety and cost-effectiveness review; UK-licensed doses of 
the NOACs 
NOAC AF VTE treatment VTE primary 
prevention 
VTE secondary 
prevention 
Rivaroxaban 20mg od 15mg/20mg bd 10mg od 15mg/20mg od74 
Edoxaban 60mg od 60mg od75  60mg od76 
Dabigatran 150mg bd 150mg bd 220mg od 150mg bd 
Apixaban 5mg bd 10mg/5mg bd 2.5mg bd 2.5mg bd77 
Betrixaban78     
Source: https://cks.nice.org.uk/anticoagulation-oral#!management 
  
                                             
74 Only 20mg in the analyses 
75 Or 30mg od (17.6%) in the analyses 
76 Not included in analyses 
77 Also 5mg in the analyses 
78 40mg as the licensed dose in the analyses for AF 
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Appendix 8: Effectiveness, safety and cost-effectiveness review; summary of the reviews 
Study 
Author 
(year) 
Topic Focus Search + Year 
range of 
synthesised studies 
Studies included Included primary studies relevant to ths review 
Sterne et 
al. (2017); 
Review 1 
Prevention of AF-
related stroke: 
efficacy, safety & 
cost-effectiveness 
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Databases searched 
in March 2014 and 
updated in 
September 2014. 
 
Year range of 
included studies: 
1989 to 2014 
Number reviewed: 
23 (41 articles) 
 
Related to AF/VTE 
adult population: 
23 (AF) 
 
Type of study: RCTs 
The ACTIVE Writing Group 2006; Petersen et al. 1989; Gulløv et al. 
1998; Liu et al. 2014; Yamaguchi 2010; Chung et al. 2011; Garcia et 
al. 2010; Weitz et al. 2010; Chen et al. 2012; Lopes et al. 2010; 
Granger et al. 2011; Hohnloser et al. 2012; Easton et al. 2012; Flaker 
et al. 2013; Al-Khatib et al. 2013; Bahit et al. 2013; Garcia et al. 
2013; McMurray et al. 2013; Alexander et al. 2014; Hylek et al. 2014; 
Ogawa et al. 2011; Eikelboom et al. 2010; Hohnloser et al. 2011; 
Connolly et al. 2011; Diener et al. 2012; Mant et al. 2007; Hu et al. 
2006; Ruff et al. 2010; Giugliano et al. 2013; Connolly et al. 2013; 
Hori et al. 2012; Hellemons et al. 1999; Ezekowitz et al. 2007; 
Connolly et al. 2009; Connolly et al. 2010; ROCKET AF Study 
Investigators 2010; Patel et al. 2011; Hankey et al. 2012; Mahaffey et 
al. 2013; Stroke Prevention in Atrial Fibrillation Investigators 1994; 
Rash et al. 2007 
Sterne et 
al. (2017); 
Review 2 
VTE primary 
prevention: 
efficacy, safety & 
cost-effectiveness  
Search: 
Databases searched 
in March 2014 and 
updated in 
September 2014. 
 
Year range of 
included studies: 
1996 to 2012 
Number reviewed: 
43 (46 articles) 
 
Related to AF/VTE 
adult population: 
43 (VTE) 
 
Type of study: RCTs 
Goldhaber et al. 2011; Lassen et al. 2009; Lassen et al. 2010b; Lassen 
et al. 2010a; Lassen et al. 2007; Heit et al. 1997; Eriksson et al. 
2005; Turpie et al. 2009a; Kakkar et al. 2011; Cohen et al. 2010; 
Cohen et al. 2013; Eriksson et al. 2007a; Eriksson et al. 2006a; Turpie 
et al. 2005; Eriksson et al. 2006b; Agnelli et al. 2009; Eriksson et al. 
2008; Kakkar et al. 2008; Lassen et al. 2008; Turpie et al. 2009b; 
Ginsberg et al. 2009; Eriksson et al. 2007c; Eriksson et al. 2007b; 
Eriksson et al. 2010; Eriksson et al. 2011; Fuji et al. 2010d; Fuji et al. 
2009a; Fuji et al. 2010b; Fuji et al. 2009b; Fuji et al. 2014, Fujita et 
al. 2010; Fuji et al. 2010c; Haas et al. 2012; Levine et al. 2012; 
Iliopoulos et al. 2011; Fuji et al. 2010a; Raskob et al. 2010; Goel et 
al. 2009; Yokote et al. 2011; Kanan et al. 2008; Zhang et al. 2013; 
Leclerc et al. 1996; Francis et al. 1997; Colwell et al. 1999; Hull et 
al. 2000; Fitzgerald et al. 2001 
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Study 
Author 
(year) 
Topic Focus Search + Year 
range of 
synthesised studies 
Studies included Included primary studies relevant to ths review 
Sterne et 
al. (2017); 
Review 3 
Acute treatment of 
VTE:  efficacy, 
safety & cost-
effectiveness 
Search: March 2014, 
updated September 
2014 
 
Year range of 
included studies: 
2007 to 2014 
Number reviewed: 
9 (10 articles) 
 
Related to AF/VTE 
adult population: 9 
(VTE) 
 
Type of study: RCTs 
Hokusai et al. 2013; Agnelli  et al. 2007; Büller et al.  2008; 
Schulman et al. 2009; Bauersachs  et al. 2010; Büller et al. 2012; 
Raskob et al. 2013; 
Hokusai et al. 2013; Agnelli et al. 2013; Schulman et al 2014 
Sterne et 
al. (2017); 
Review 4 
Secondary 
prevention of VTE:  
efficacy, safety & 
cost-effectiveness 
Search: 
March 2014, 
updated September 
2014 
 
Year range of 
included studies: 
1999 to 2013 
Number reviewed: 
10 (11 articles) 
 
Related to AF/VTE 
adult population: 
10 (VTE) 
 
Type of study: RCTs 
Agnelli et al. 2012; Brighton et al. 2012; Buller 2009; The EINSTEIN 
Investigators 2010; Romualdi et al. 2011; Kearon et al. 1999; Ridker 
et al. 2003; Schulman et al. 2013; Becattini et al. 2012; Agnelli et al. 
2001; Agnelli et al. 2003 
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Appendix 9: Effectiveness, safety and cost-effectiveness review; detailed characteristics of the four reviews 
Review Number 
of studies 
reviewed 
Sample 
size  
 
Population 
character-
istics 
 
Number 
of studies 
reporting 
primary 
outcomes 
 
Anticoagulants 
directly compared 
(k) 
Targeting 
population 
Setting and 
follow-ups (k) 
Primary 
outcomes79 (k) 
Quality 
appraisal 
tool 
Prevent
ion of 
AF- 
related 
stroke 
23 (AF) Total: 
94,656 
 
Range: 
From 75 
to 
21,105 
Mean age: 
Ranged 
from 63.3 
to 81.5 
years 
NR: 9 
 
Gender: 
Male (%) 
ranged 
from 44.9 
to 82.9 
NR: 5 
 
Ethnicity: 
NR  
 
23 NOACs vs warfarin 
(12) 
Apixaban (2) 
Dabigatran (3) 
Edoxaban (4) 
Rivaroxaban (2) 
Betrixaban (1) 
 
Other 
comparisons (11): 
Antiplatelet v 
warfarin (9) 
Antiplatelet v 
apixaban (1) 
Antiplatelet v 
antiplatelet and 
warfarin (1) 
Age: 
Adults ≥ 18 
years 
 
Health 
condition: 
People with 
non 
valvular AF, 
with or 
without 
previous 
stroke, 
hypertensio
n or chronic 
heart 
failure 
Setting: 
Primary care 
and 
anticoagulation 
clinics 
 
Treatment 
duration 
(months): 
Ranged from 3 
to 42; NR: 2. 
 
Mean time in 
therapeutic 
range for 
warfarin (%): 
Ranged from 
45.1 to 83; NR: 
7/21. 
 
 
Efficacy: 
Stroke or systemic 
embolism (15); 
Ischaemic stroke 
(13); myocardial 
infarction (15)  
 
Safety: 
Major bleeding 
(18); CRB (12); 
intracranial 
bleeding (6); all-
cause mortality 
(18) 
Cochrane 
Risk of 
Bias Tool 
                                             
79 Not mutually exclusive, i.e. the numbers do not add up since most trials assessed more than one intervention and outcome. 
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Review Number 
of studies 
reviewed 
Sample 
size  
 
Population 
character-
istics 
 
Number 
of studies 
reporting 
primary 
outcomes 
 
Anticoagulants 
directly compared 
(k) 
Targeting 
population 
Setting and 
follow-ups (k) 
Primary 
outcomes79 (k) 
Quality 
appraisal 
tool 
VTE – 
Primary 
prevent
ion 
43 (VTE) Total: 
77,563 
 
Range: 
From 67 
to 8,323 
Mean age: 
Ranged 
from 41 to 
76 years 
NR: 5 
 
Gender: 
Male (%) 
ranged 
from 13.1 
to 62.7 
NR: 5 
 
Ethnicity: 
NR  
 
4380 NOACs v LMWH 
(27): 
Apixaban (4) 
Dabigatran (6) 
Edoxaban (5) 
Rivaroxaban (11) 
Betrixaban (1) 
 
NOACs v LMWH 
and warfarin (1): 
Apixaban (1) 
 
NOACs v placebo 
(3): 
Apixaban (1) 
Dabigatran (1) 
Edoxaban (1) 
 
Other 
comparisons (12): 
LMWH v warfarin 
(6) 
LMWH v placebo 
(6) 
Age: 
Adults ≥ 18 
years 
 
Health 
conditions: 
Hip surgery 
(18) 
Knee 
surgery (17) 
Hip & knee 
surgery (1) 
Other 
medical 
conditions 
(7) 
Setting: 
Hospital 
 
Treatment 
duration 
(days): 
Ranged from 4 
to 182.681; NR: 
1 
 
Mean time in 
therapeutic 
range for 
warfarin (%): 
NR in any of the 
primary studies 
with warfarin 
(7/7) 
Efficacy: 
Symptomatic VTE 
(29)82; 
symptomatic DVT 
(25); symptomatic 
PE (35) 
 
Safety: 
Myocardial 
infarction (9);  
major bleeding 
(39); CRB (27); all-
cause mortality 
(28) 
Cochrane 
Risk of 
Bias Tool 
                                             
80 38 RCTs were included in the analyses, with the exception of major bleeding (39).  
81 The majority of treatment durations for the primary studies were reported as ranges. The shortest and longest durations for all trials were noted. 
82 28 trials were included in the analyses for VTE, 20 for DVT, 30 for PE, nine for MI, 34 for major bleeding, 25 for CRB, and 24 for mortality. 
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Review Number 
of studies 
reviewed 
Sample 
size  
 
Population 
character-
istics 
 
Number 
of studies 
reporting 
primary 
outcomes 
 
Anticoagulants 
directly compared 
(k) 
Targeting 
population 
Setting and 
follow-ups (k) 
Primary 
outcomes79 (k) 
Quality 
appraisal 
tool 
VTE – 
Acute 
treatme
nt 
9 trials 
(VTE; 
reference
d in 10 
articles) 
Total: 
28,803 
 
Range: 
From 
520 to 
8,292 
Mean age: 
Ranged 
from 54.7 
to 
59.1years  
NR: 0 
Gender: 
Male (%) 
ranged 
from 
51% to 62% 
NR: 0 
Ethnicity: 
NR 
9 NOACs v warfarin 
(9): 
Apixaban (2) 
Rivaroxaban (4) 
Edoxaban (1) 
Dabigatran (2) 
 
 
 
 
 
Age:  
Adults ≥ 18 
years 
 
Health 
conditions: 
New or 
recurrent 
objectively 
confirmed 
diagnosis 
of acute 
symptomati
c VTE 
 
Setting: 
Hospital 
 
Treatment 
duration  
12 to 48 weeks 
 
Mean time in 
therapeutic 
range for 
warfarin (%): 
56.9 to 63.5 
Efficacy: 
Symptomatic VTE 
(8)83; symptomatic 
DVT (9); 
symptomatic PE 
(9); MI (5) 
 
Safety: 
Major bleeding (9); 
CRB (8); all-cause 
mortality (8) 
Cochrane 
Risk of 
Bias Tool 
VTE – 
Seconda
ry 
prevent
ion 
10 (VTE) Total: 
10,390 
 
Range: 
From 
162 to 
2,866 
Mean age: 
Ranged 
from 53 to 
67.3 years 
NR: 1 
 
Gender: 
Male (%) 
ranged 
from 52.8 
to 63.9 
10 NOACs v warfarin 
(1): 
Dabigatran (1) 
 
NOACs v placebo 
(3): 
Apixaban (1) 
Dabigatran (1) 
Rivaroxaban (1) 
 
Age: 
Adults ≥ 18 
years 
 
Health 
conditions: 
On 
anticoagula
nts for 3 
months or 
more after 
Setting: 
Primary care 
and 
anticoagulation 
clinics 
 
Treatment 
duration 
(months): 
Ranged from 3 
to 51.6; NR: 0. 
Efficacy: 
Symptomatic VTE 
(10); symptomatic 
DVT (9); 
symptomatic PE 
(9) 
 
Safety: 
Myocardial 
infarction (5); 
major bleeding 
Cochrane 
Risk of 
Bias Tool 
                                             
83 Table 107 in Sterne’s report shows eight studies with this outcome, while the summary (p171) only mentions seven. 
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Review Number 
of studies 
reviewed 
Sample 
size  
 
Population 
character-
istics 
 
Number 
of studies 
reporting 
primary 
outcomes 
 
Anticoagulants 
directly compared 
(k) 
Targeting 
population 
Setting and 
follow-ups (k) 
Primary 
outcomes79 (k) 
Quality 
appraisal 
tool 
NR: 0 
 
Ethnicity: 
NR 
Other 
comparisons (6): 
Warfarin v placebo 
(2) 
Warfarin v no 
treatment (2) 
Aspirin v placebo 
(2) 
a first VTE, 
without 
recurrence 
NOACs only: 6 
to 36; NR: 0 
 
Mean time in 
therapeutic 
range for 
warfarin (%): 
Values: 64 and 
81; NR: 3/5. 
Median with 
dabigatran: 65.3 
(10); CRB (6); all-
cause mortality (9) 
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Appendix 10: Effectiveness, safety and cost-effectiveness review; risk of bias assessment of included reviews 
 1 2 3 4 5 6 7 8 9a 9b 10 11a 11b 12 13 14 15 16 
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? 
Sterne (2017); 
Review 1 + 
PYa + PYb + + - + + N/A + + N/A + PYc + - + 
Sterne (2017); 
Review 2 + 
PYa + PYb + + - + + N/A + + N/A + PYc + - + 
Sterne (2017); 
Review 3 + 
PYa + PYb + + - + + N/A + + N/A + PYc + - + 
Sterne (2017); 
Review 4 + 
PYa + PYb + + - + + N/A + + N/A + PYc + - + 
PY = partial yes, N/A = not applicable, a = there was no statement to say whether and to what extent deviations from the protocol were made, b = the 
search was last updated 2.5 years before publication, c = it is unclear whether the risk of bias was integrated into the data synthesis. The terminology 
relating to evidence (e.g., little evidence) was not clearly defined.
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1. Include PICO?   100%   
 
2. Protocol?    100%  
 
3. Inclusion criteria   100%   
 
4. Comprehensive search strategy?    100%  
 
5. Duplicate screening?   100%   
 
6. Duplicate DE?   100%   
 
7. Exclusions?     100% 
 
8. Included described in detail?   100%   
 
9a. RCTs - RoB assessment?   100%   
 
9b. NRSI - RoB assessment?   N/A N/A N/A 
 
10. Funding stated?   100%   
 
11a. RCTs: meta-analysis methods?   100%   
 
11b. NRSI: meta-analysis methods?   N/A N/A N/A 
 
12. RoB impact on meta-analysis?   100%   
 
13. RoB in interpretation of results?    100%  
 
14. Heterogeneity explained/discussed?   100%   
 
15. Publication bias?     100% 
 
16. Conflict of interest stated?   100%   
 
 
  Low risk of 
bias:   
  Unclear risk of 
bias:   
  High risk of 
bias:   
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Appendix 11: Effectiveness, safety and cost-effectiveness review; summary of the relevant main conclusions of the four reviews and 
the cost-effectiveness analyses 
Review  Network meta-analytic comparisons involving 
Warfarin (INR 2-3) and/or NOACs84 
 
Rankogram and cost-effectiveness analyses  
Prevention 
of stroke 
related to 
AF 
(Review 1) 
 
NOACs show advantages over warfarin for all efficacy 
and safety outcomes with few exceptions: 
 
• Edoxaban (30 and 60mg bd) may increase risk 
of clinically relevant bleeding (CRB) and 
ischaemic stroke (30mg od) 
 
• Dabigatran (110mg and 150mg bd, and 
edoxaban 30mg od) may increase risk of 
myocardial infarction 
Among the treatments warfarin (INR 2–3); dabigatran (150mg bd); 
edoxaban (60mg od); rivaroxaban (20mg od); apixaban (5mg bd); 
antiplatelet therapy (≥ 150mg od): 
• The non-NOAC interventions (warfarin and antiplatelet 
therapy; aspirin/clopidogrel >= 150mg bd) were ranked worst 
for stroke or systemic embolism, and were not among the 
best three for any outcome 
• Apixaban (5mg bd) was likely to be one of the best 
anticoagulants to prevent stroke or systemic embolism, 
Ischemic stroke, myocardial infarction, major bleeding, 
intracranial bleeding and all-cause mortality. It also had the 
highest probability of being most cost-effective 
VTE 
primary 
prevention 
(Review 2) 
There is no strong evidence to support the use NOACs 
for the primary prevention of VTE  
 
There were no comparisons between warfarin and 
NOACs 
 
 
Among the treatments warfarin (INR 2–3); apixaban (2.5mg bd); 
dabigatran (220mg bd); rivaroxaban (10mg od); LMWH post/pre-op 
(standard dose)85: 
• Warfarin was likely to be the best for reducing the risk of 
major bleeding 
• Low-molecular-weight heparin (LMWH; post-op, standard 
dose)85 was the best or second-best for reducing the risk of 
CRB 
                                             
84 Comparisons with a ratio, between the confidence interval limits, that exceeded nine were considered to be imprecise. 
85 Standard dose for LMWH included tinzaparin (0.45mL od), enoxaparin (40mg od or 30mg bd) and dalteparin (5,000 IU). 
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Review  Network meta-analytic comparisons involving 
Warfarin (INR 2-3) and/or NOACs84 
 
Rankogram and cost-effectiveness analyses  
• Rivaroxaban (10mg od) had higher risk of major and CRB than 
LMWH (post-op, standard dose)85 
• For both hip and knee, Rivaroxaban was likely to be the most 
cost-effective up to willingness-to-pay thresholds of 
approximately £20,000 per QALY (with high uncertainty for 
hip surgery) 
VTE acute 
treatment 
(Review 3) 
NOACs showed no efficacy advantage over warfarin, 
but apixaban (5mg bd) and rivaroxaban (15mg bd, 
then 20mg od) may reduce the risk of major and 
clinically relevant bleeding than with warfarin 
 
Among the treatments warfarin (INR 2-3), apixaban (5mg bd), 
dabigatran (150mg od), edoxaban (60mg or 30mg (17.6%)86 od) and 
rivaroxaban (15mg bd then 20mg od): 
• Apixaban (5mg bd) had a high probability of being ranked 
best for risk of major and clinically relevant bleeding, and of 
being ranked best, or second best, for symptomatic DVT, 
symptomatic VTE and all-cause mortality 
• Warfarin had a high probability of being ranked worst for 
major bleeding and CRB 
• Apixaban (5mg bd) is likely to be the most cost-effective 
alternative to warfarin for a willingness-to-pay threshold of 
£20,000-30,000 per QALY, although rivaroxaban and 
dabigatran could be the most cost-effective, even at high 
thresholds 
                                             
86 In the edoxaban trial, 17.6% of participants received the 30mg dose, while the remaining participants received the 60mg dose (twice daily). 
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Review  Network meta-analytic comparisons involving 
Warfarin (INR 2-3) and/or NOACs84 
 
Rankogram and cost-effectiveness analyses  
VTE 
secondary 
prevention 
(Review 4) 
No clear evidence of differences between NOACs and 
warfarin 
 
For symptomatic PE, the risk was higher with 
apixaban (2.5mg bd) than warfarin 
 
Risks of clinically relevant bleeding and major 
bleeding were lower with apixaban (2.5 or 5mg) and 
dabigatran (150mg) than with warfarin, with lower 
risk for apixaban than dabigatran 
Rankogram analyses could not be performed due to the substantial 
proportion of imprecise estimates 
 
Aspirin was likely to be the most cost-effective alternative to 
warfarin at willingness-to-pay thresholds of £20,000 and £30,000 per 
QALY. But it was uncertain whether it was better than no treatment. 
Furthermore, evidence suggested that NOACs may reduce the risks of 
VTE and DVT, compared with aspirin 
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Appendix 12: Effectiveness, safety and cost-effectiveness review; main findings by outcome for the review on the prevention of AF-
related stroke (Review 1) 
Outcomes Included in the 
network:  primary 
studies,87 
interventions,88 and 
events 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings89 
 
NOACs vs warfarin (INR 2-3)  NOACs vs NOACs   Comparisons among 
other interventions   
Stroke or 
systemic 
embolism 
Primary studies: 23 
Interventions: 26 
Events: 3,217 
 
Low in all six 
domains: 2/23 
High in one or 
more domains: 
14/23 
Unclear in one or 
more domains, 
none high: 7/23 
Evidence that NOACS apixaban 
(5mg bd), dabigatran (150mg 
bd), edoxaban (60mg od) and 
rivaroxaban (20mg od) may 
have a lower risk than 
warfarin. 
 
Evidence that risk may be lower 
with dabigatran (150mg bd) 
compared with edoxaban (60mg 
od) and rivaroxaban (20mg od). 
Antiplatelets 
increased the risk, 
compared with 
warfarin.  
 
 
Ischaemic 
stroke 
Primary studies: 14 
Interventions: 15 
Events: 2,228 
Low in all six 
domains: 2/14 
High in one or 
more domains: 
7/14 
Unclear in one or 
more domains, 
none high: 5/14  
Evidence that dabigatran 
(150mg bd) may have a lower 
risk than warfarin, while 
edoxaban (30mg od)’s risk may 
be higher than warfarin. 
 
Little evidence of differences in 
risk. 
Antiplatelets 
increased the risk, 
compared with 
warfarin.  
 
 
 
Myocardial 
infarction 
Primary studies: 15 
Interventions: 16 
Events: 1,334 
Low in all six 
domains: 2/15 
Weak evidence that risk may 
be lower with rivaroxaban 
(20mg od) and higher with 
Weak evidence that rivaroxaban 
(20mg od) and apixaban (5mg bd) 
There were no 
differences between 
                                             
87 For all outcomes, some primary studies were only included in the sensitivity analyses, and not the MNAs. The results of the sensitivity analysis did not 
change the interpretation of the findings.  
88 Each dose and frequency of administration for a same drug were considered as distinct interventions. Each dose and frequency of administration for a 
drug was considered as a distinct intervention. See the full list in Sterne et al. (2017)’s report (Table 71). 
89 Standard font: evidence indirect; underlined font: evidence direct; italicised font: evidence both direct and indirect. 
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Outcomes Included in the 
network:  primary 
studies,87 
interventions,88 and 
events 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings89 
 
NOACs vs warfarin (INR 2-3)  NOACs vs NOACs   Comparisons among 
other interventions   
High in one or 
more domains: 
9/15 
Unclear in one or 
more domains, 
none high: 4/15  
dabigatran (both 110mg and 
150mg bd) and edoxaban 
(30mg od) when compared 
with warfarin. 
have a lower risk compared with 
dabigatran (150mg bd). 
antiplatelets and 
warfarin. 
Major 
bleeding 
Primary studies: 1890 
Interventions: 24 
Events: 4,314 
Low in all six 
domains: 2/18 
High in one or 
more domains: 
13/18 
Unclear in one or 
more domains, 
none high: 3/18 
Evidence that apixaban (5mg 
bd), dabigatran (110mg bd) 
and edoxaban (both 30 and 
60mg od) may all have a lower 
risk than warfarin. 
Evidence that rivaroxaban (20mg 
od) increases risk compared with 
apixaban (5mg bd) and edoxaban 
(60mg od) and that apixaban 
(5mg bd) may have a lower risk 
than dabigatran (150mg). 
Weak evidence that 
antiplatelets reduced 
the risk, compared 
with warfarin. 
 
 
CRB Primary studies: 12 
Interventions: 23 
Events: 9,556 
Low in all six 
domains: 2/12 
High in one or 
more domains: 
6/12 
Unclear in one or 
more domains, 
none high: 4/12  
Evidence apixaban (5mg bd) 
and edoxaban (30 and 60mg 
od) may all have reduced risk 
compared with warfarin, while 
edoxaban (30 and 60mg bd) 
may increase that risk. 
Evidence that edoxaban (60mg 
od) and rivaroxaban (20mg od) 
may increase risk compared with 
apixaban (5mg bd) and that 
rivaroxaban (20mg od) may 
increase risk compared with 
edoxaban (60mg od). 
Indirect evidence 
that antiplatelets91 
reduced the risk, 
compared with 
warfarin. 
 
 
Intracranial 
bleeding 
Primary studies: 8 
Interventions: 10 
Events: 757 
Low in all six 
domains: 2/8 
High in one or 
more domains: 3/8 
Strong evidence that apixaban 
(5mg bd), dabigatran (both 110 
and 150mg bd), edoxaban 
(both 30 and 60mg od) and 
Weak evidence that rivaroxaban 
(20mg od) may be at higher risk 
than apixaban (5mg bd), 
There were no 
comparisons. 
                                             
90 Seventeen studies were included in the main analysis, with the remaining study included only in sensitivity analyses 
91 At a lower than recommended dose (<150mg od) 
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Outcomes Included in the 
network:  primary 
studies,87 
interventions,88 and 
events 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings89 
 
NOACs vs warfarin (INR 2-3)  NOACs vs NOACs   Comparisons among 
other interventions   
Unclear in one or 
more domains, 
none high: 3/8  
rivaroxaban (20mg od) have a 
lower risk compared with 
warfarin. 
dabigatran (150mg bd) and 
edoxaban (60mg od). 
All-cause 
mortality 
Primary studies: 18 
Interventions: 15 
Events: 6,479 
Low in all six 
domains: 3/18 
High in one or 
more domains: 
11/18 
Unclear in one or 
more domains, 
none high: 4/18 
Evidence that apixaban (5mg 
bd), dabigatran (both 110 and 
150mg bd), edoxaban (both 30 
and 60mg od) and rivaroxaban 
(20mg od) may all have a 
lower risk compared with 
warfarin. 
Little evidence of differences 
between licensed doses of 
NOACs. 
There were no 
comparisons. 
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Appendix 13: Effectiveness, safety and cost-effectiveness review; main findings by outcome for the review on the primary prevention 
of VTE (Review 2) 
Outcomes Included in the 
network:  primary 
studies92, 
interventions93, and 
events  
 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings94 
 
NOACs vs warfarin 
(INR 2-3) 
NOACs vs NOACs Comparisons among other 
interventions 
Symptomatic 
VTE 
Primary studies: Hip 
9, Knee 10, Medical 
conditions 4, Total 23 
 
Interventions: Hip 13, 
Knee 21, Medical 
conditions 8 
 
Events: Hip 231, Knee 
186, Medical 
conditions 45 
Low in all six 
domains: 7/23 
High in one or 
more domains: 
2/23 
Unclear in one or 
more domains, 
none high: 14/23 
There were no 
comparisons. 
 
 
 
 
Hip and knee surgery: all 
comparisons were 
imprecise95. 
 
Medical conditions: weak 
evidence that the risk of 
symptomatic VTE may be 
lower with apixaban 
(2.5mg bd) compared with 
rivaroxaban (10mg od) 
(imprecise estimates). 
Hip surgery: evidence that risk 
may be lower with rivaroxaban 
(10mg od) compared with LMHW 
(pre-op, standard dose), and 
higher with LMWH (post-op, 
standard dose) and warfarin (INR 
2–3) compared with LMWH (pre-
op, standard dose) (mostly 
imprecise estimates). 
 
Knee surgery: little evidence of 
differences in risk between 
apixaban (2.5mg bd), dabigatran 
(220mg od) or rivaroxaban (10mg 
od) compared with LMWH (post-
op, standard dose). 
 
                                             
92 For all outcomes, some primary studies were only included in the sensitivity analyses, and not the MNAs. The results of the sensitivity analysis did not 
change the interpretation of the findings. 
93 Each dose and frequency of administration for a drug was considered as a distinct intervention. See the full list in Sterne et al. (2017)’s report (Table 
71). 
94 Standard font: evidence indirect; underlined font: evidence direct; italicised font: evidence both direct and indirect. 
95 Comparisons with a ratio, between the confidence interval limits, that exceeded nine were considered to be imprecise. 
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Outcomes Included in the 
network:  primary 
studies92, 
interventions93, and 
events  
 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings94 
 
NOACs vs warfarin 
(INR 2-3) 
NOACs vs NOACs Comparisons among other 
interventions 
Medical conditions: weak 
evidence that risk may be lower 
with apixaban (2.5mg bd) 
compared with LMWH (standard 
dose)96 (imprecise estimates). 
Symptomatic 
DVT 
Primary studies: Hip 
8, Knee 9, Medical 
conditions 3, Total: 
20 
 
Interventions: Hip 9, 
Knee 24, Medical 
conditions 5 
 
Events: Hip 157, Knee 
81, Medical 
conditions 65 
Low in all six 
domains: 6/20 
High in one or 
more: 3/20 
Unclear in one or 
more domains, 
none high: 11/20 
There were no 
comparisons. 
All comparisons were 
imprecise. 
All comparisons were imprecise. 
 
Hip surgery: risk higher for LMWH 
(post-op, standard dose) and 
warfarin than LMWH (pre-op, 
standard dose). 
 
Knee surgery: risk higher for 
LMWH pre-op (standard dose) 
than LMWH (post-op, standard 
dose). 
 
Medical conditions: evidence that 
risk may be lower for apixaban 
(2.5mg bd) than LMWH (standard 
dose). 
Symptomatic 
PE97 
Primary studies: Hip 
13, Knee 14, Medical 
conditions 3, Total 30 
 
Low in all six 
domains: 6/30 
There were no 
comparisons. 
 
All comparisons were 
imprecise. 
 
Most comparisons were imprecise. 
 
Knee surgery: some evidence that 
the risk may be lower with 
                                             
96 Standard dose for medical conditions. 
97 Included symptomatic non-fatal and fatal PE events where symptomatic PE was not reported. 
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Outcomes Included in the 
network:  primary 
studies92, 
interventions93, and 
events  
 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings94 
 
NOACs vs warfarin 
(INR 2-3) 
NOACs vs NOACs Comparisons among other 
interventions 
Interventions: Hip 19, 
Knee 26, Medical 
conditions 5 
 
Events: Hip 58, Knee 
74, Medical 
conditions 45 
High in one or 
more domains: 
4/30 
Unclear in one or 
more domains, 
none high: 20/30 
Knee surgery: imprecise 
evidence suggested that 
risk may be lower for 
rivaroxaban (10mg od) 
than apixaban (2.5mg bd). 
dabigatran (150mg od) and higher 
with apixaban (2.5mg bd), 
compared with LMWH (post-op, 
standard dose) (imprecise 
estimates). 
Myocardial 
infarction 
Primary studies: 9 
Interventions: 11 
Events: 63 
Low in all six 
domains: 1/9 
High in one or 
more domains: 
0/9 
Unclear in one or 
more domains, 
none high: 8/9 
There were no 
comparisons. 
All comparisons were 
imprecise. 
Some evidence that risk may be 
lower for rivaroxaban (10mg od) 
than LMWH (post-op, standard 
dose) (imprecise estimates). 
Major 
bleeding 
Primary studies: 34 
Interventions: 32 
Events: 706 
Low in all six 
domains: 9/34 
High in one or 
more domains: 
5/34 
Unclear in one or 
more domains, 
none high: 20/34 
There were no 
comparisons. 
Evidence that risk may be 
higher with rivaroxaban 
(10mg od) than apixaban 
(2.5mg bd) and dabigatran 
(220mg od). 
Little evidence that the risk 
differed between pre-op and 
post-op LMWH (standard dose).  
 
Evidence that risk may be lower 
with warfarin and higher with 
rivaroxaban (10mg od), compared 
with LMWH (post-op, standard 
dose). 
CRB Primary studies: 25 
Interventions: 29 
Events: 1,973 
Low in all six 
domains: 8/25 
There were no 
comparisons. 
Evidence that risk may be 
higher for dabigatran 
(220mg od) and 
rivaroxaban (10mg od), 
Evidence that risk may be higher 
for pre-op LMWH (standard dose) 
than post-op LMWH (standard 
dose), and higher for dabigatran 
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Outcomes Included in the 
network:  primary 
studies92, 
interventions93, and 
events  
 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings94 
 
NOACs vs warfarin 
(INR 2-3) 
NOACs vs NOACs Comparisons among other 
interventions 
High in one or 
more domains: 
3/25 
Unclear in one or 
more domains, 
none high: 14/25 
compared with apixaban 
(2.5mg bd). 
(150mg or 220mg od) and 
rivaroxaban (10mg od) than LMWH 
(post-op, standard dose)98. 
All-cause 
mortality 
Primary studies: 24 
Interventions: 29 
Events: 1,161 
Low in all six 
domains: 6/24 
High in one or 
more domains: 
3/24 
Unclear in one or 
more domains, 
none high: 15/24 
There were no 
comparisons. 
All comparisons were 
imprecise. 
 
Little evidence that risk is 
different for any intervention 
compared with LMWH (post-op, 
standard dose)99. 
                                             
98 Note that there was statistical inconsistency between direct (significant) and indirect (not significant) estimates for rivaroxaban. 
99 Note that the direct evidence for apixaban (2.5mg bd), which indicated a (not statistically significant) reduction compared with post-op LMWH, was 
contrary to the indirect evidence, which suggested a statistically significant increase. 
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Appendix 14: Effectiveness, safety and cost-effectiveness review; main findings by outcome for the review on the acute treatment of 
VTE (Review 3) 
Outcomes Included in the 
network:  primary 
studies, 
interventions100, and 
events 
Risk of bias: number of 
studies/total 
Summary of the network meta-analytic findings101 
 
NOACs vs warfarin (INR 
2-3) 
NOACs vs NOACs Comparisons among 
other interventions 
Symptomatic 
VTE 
Primary studies: 8 
Interventions: 11 
Events: 728  
Low in all six domains: 3/8 
High in one or more 
domains: 3/8 
Unclear in one or more 
domains, none high: 2/8  
Evidence showed no clear 
difference between 
NOACs and warfarin. 
No clear evidence of 
differences between 
NOACs. 
 
 
There were no 
comparisons. 
Symptomatic 
DVT 
Primary studies: 9 
Interventions: 13 
Events: 351 
Low in all domains: 4/9 
High in one or more 
domains: 4/9 
Unclear in one or more 
domains, none high: 1/9  
Evidence showed no clear 
difference between 
NOACs and warfarin. 
No clear evidence of 
differences between 
NOACs. 
 
 
There were no 
comparisons. 
Symptomatic 
PE 
Primary studies: 9102 
Interventions: 13 
Events: 300 
Low in all domains: 3/9 
High in one or more 
domains: 4/9 
Unclear in one or more 
domains, none high: 2/9  
Evidence showed no clear 
difference between 
NOACs and warfarin. 
No clear evidence of 
differences between 
NOACs. 
There were no 
comparisons. 
Myocardial 
infarction 
Primary studies: 5 
Interventions: 5 
Events: 57 
Low in all domains: 3/5 
High in one or more 
domains: 1/5 
All comparisons were 
imprecise103. 
All comparisons were 
imprecise. 
There were no 
comparisons. 
                                             
100 Each dose and frequency of administration for a drug was considered as a distinct intervention. See the full list in Sterne et al. (2017) 
101 Standard font: evidence indirect; underlined font: evidence direct; italicised font: evidence both direct and indirect. 
102 For eight studies, symptomatic PE events were derived by adding fatal PE and symptomatic non-fatal PE events. 
103 Comparisons with a ratio, between the confidence interval limits, that exceeded nine were considered to be imprecise 
The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews 
 
 
129 
 
Outcomes Included in the 
network:  primary 
studies, 
interventions100, and 
events 
Risk of bias: number of 
studies/total 
Summary of the network meta-analytic findings101 
 
NOACs vs warfarin (INR 
2-3) 
NOACs vs NOACs Comparisons among 
other interventions 
Unclear in one or more 
domains, none high: 1/5  
Major 
bleeding 
Primary studies: 9 
Interventions: 13 
Events: 228 
Low in all domains: 3/9 
High in one or more 
domains: 4/9 
Unclear in one or more 
domains, none high: 3/9  
Strong evidence that risk 
lower with apixaban (5mg 
bd) and rivaroxaban 
(15mg bd then 20mg od), 
compared with warfarin. 
Evidence that risk may be 
higher for edoxaban [60mg 
or 30mg (17.6%) od] and 
dabigatran (150mg bd) 
than apixaban (5mg bd). 
There were no 
comparisons. 
CRB Primary studies: 8 
Interventions: 10 
Events: 2,365 
Low in all domains: 3/8 
High in one or more 
domains: 4/8 
Unclear in one or more 
domains, none high: 1/8  
Evidence that risk may be 
lower with apixaban (5mg 
bd), dabigatran (150mg 
bd), edoxaban [60mg or 
30mg (17.6%) od] and 
rivaroxaban (15mg bd 
then 20mg od), compared 
with warfarin. 
 
Evidence that risk may be 
higher with dabigatran 
(150mg bd), edoxaban 
[60mg or 30mg (17.6%) od] 
and rivaroxaban (15mg bd 
then 20mg od) than 
apixaban (5mg bd). 
 
Evidence that risk may be 
higher with edoxaban 
[60mg or 30mg (17.6%) od] 
and rivaroxaban (15mg bd 
then 20mg od) than 
dabigatran (150mg bd). 
There were no 
comparisons. 
All-cause 
mortality 
Primary studies: 8 
Interventions: 10 
Events: 662 
Low in all domains: 3/8 
High in one or more 
domains: 4/8 
Unclear in one or more 
domains, none high: 1/8  
Little evidence showed 
no clear difference 
between NOACs and 
warfarin. 
No clear evidence of 
differences between 
NOACs. 
 
There were no 
comparisons. 
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Appendix 15: Effectiveness, safety and cost-effectiveness review; main findings by outcome for the review on the secondary 
prevention of VTE (Review 4) 
Outcomes Included in the 
network: primary 
studies, 
interventions,104 
and events 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings 105 
 
Warfarin (INR 2-3) v 
NOACs/placebo  
NOACs vs NOACs/ placebo Comparisons among 
other interventions 
Symptomatic 
VTE 
Primary studies: 10 
Interventions: 9 
Events: 578 
Low in all six 
domains: 3/10 
High in one or 
more domains: 
3/10 
Unclear in one or 
more domains, 
none high: 4/10  
Evidence showed no clear 
difference between Dabigatran 
(150mg bd) and warfarin (all 
other comparisons of NOACS v 
warfarin were imprecise)106. 
 
Evidence that warfarin (INR 1.5 
to 2, and 2 to 3) substantially 
reduced the risk, compared 
with placebo. 
No clear evidence of 
differences between NOACs 
(all imprecise). 
 
Evidence that risk may be 
lower with all doses of 
NOACs (apixaban 2.5 and 
5mg bd, dabigatran 150mg 
bd, and rivaroxaban 20mg 
od), compared with placebo. 
Evidence that risk may be 
lower with all doses of 
NOACs, compared with 
aspirin. 
 
Evidence that aspirin 
substantially reduced the 
risk, compared with 
placebo. 
Symptomatic 
DVT 
Primary studies: 9 
Interventions: 8 
Events: 342 
Low in all six 
domains: 2/9 
High in one or 
more domains: 3/9 
Unclear in one or 
more domains, 
none high: 4/9 
No clear evidence of 
differences between NOACs and 
warfarin107 (imprecise 
estimates). 
 
Evidence that warfarin may 
have a significantly lower risk 
than placebo (imprecise 
estimates). 
No clear evidence of 
differences between NOACs 
(all imprecise). 
 
Evidence that all doses of 
NOACs may have a 
significantly lower risk than 
placebo. 
No clear evidence that 
aspirin (100 mg od) 
reduced the risk, 
compared with placebo. 
 
NOACs may greatly 
reduce this risk, 
compared with aspirin. 
                                             
104 Each dose and frequency of administration for a same drug was considered as a distinct intervention. See the full list in Stern’s report (Table 137). 
105 Standard font: evidence indirect; underlined font: evidence direct; italicised font: evidence both direct and indirect. 
106 Comparisons with a ratio, between the interval limits, that exceeded nine were considered to be imprecise. 
107 Direct evidence for Dabigatran (150mg bd) and indirect evidence for Apixaban (2.5mg bd, 5mg bd) Rivaroxaban (20mg od). 
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Outcomes Included in the 
network: primary 
studies, 
interventions,104 
and events 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings 105 
 
Warfarin (INR 2-3) v 
NOACs/placebo  
NOACs vs NOACs/ placebo Comparisons among 
other interventions 
Symptomatic 
PE108 
Primary studies: 9 
Interventions: 8 
Events: 173 
Low in all six 
domains: 2/9 
High in one or 
more domains: 3/9 
Unclear in one or 
more domains, 
none high: 4/9 
Evidence that apixaban (2.5mg 
bd) had a higher risk than 
warfarin (imprecise estimates). 
 
Evidence that warfarin may 
greatly reduce the risk 
compared with placebo. 
Weak evidence that 
apixaban (2.5mg bd) may 
have a higher risk than 
dabigatran (150mg bd) and 
rivaroxaban (20mg od) 
(imprecise estimates). 
 
Evidence that apixaban 
(2.5mg bd), dabigatran 
(150mg bd) and rivaroxaban 
(20mg od) may greatly 
reduce the risk compared 
with placebo. 
Weak evidence that 
dabigatran (150mg bd) 
and rivaroxaban (20mg 
od) may have a lower risk 
than aspirin (imprecise 
estimates). 
Myocardial 
infarction 
Primary studies: 5 
Interventions: 7 
Events: 35 
Low in all six 
domains: 3/5 
High in one or 
more domains: 0/5 
Unclear in one or 
more domains, 
none high: 2/5 
All comparisons were 
imprecise. 
All comparisons were 
imprecise. 
All comparisons were 
imprecise. 
Major bleeding Primary studies: 10 
Interventions: 9 
Events: 87 
Low in all six 
domains: 3/10 
High in one or 
more domains: 
3/10 
Evidence that dabigatran 
(150mg bd) may have a lower 
risk than warfarin. 
 
Evidence that warfarin may 
increase the risk compared with 
placebo (imprecise estimates). 
Evidence that dabigatran 
(150mg bd) and rivaroxaban 
(20mg od) may have a higher 
risk compared with apixaban 
(2.5mg and 5mg bd). 
 
All comparisons were 
imprecise. 
                                             
108 Fatal and non-fatal. 
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Outcomes Included in the 
network: primary 
studies, 
interventions,104 
and events 
Risk of bias: 
number of 
studies/total 
Summary of the network meta-analytic findings 105 
 
Warfarin (INR 2-3) v 
NOACs/placebo  
NOACs vs NOACs/ placebo Comparisons among 
other interventions 
Unclear in one or 
more domains, 
none high: 4/10 
Evidence that rivaroxaban 
(20mg od) may increase the 
risk compared with placebo 
(imprecise estimates). 
CRB Primary studies: 6 
Interventions: 7 
Events: 430 
Low in all six 
domains: 2/6 
High in one or 
more domains: 1/6 
Unclear in one or 
more domains, 
none high: 3/6 
Evidence that apixaban (2.5 and 
5mg bd) and evidence that 
dabigatran (150mg bd) may 
have a lower risk than warfarin. 
 
Evidence that warfarin, may 
have a substantially higher risk 
than placebo. 
Evidence that the risk may 
be lower with apixaban (2.5 
and 5mg bd) than with 
dabigatran (150mg bd) and 
rivaroxaban (20mg od) 
(imprecise). 
 
Evidence that dabigatran 
(150mg od) and rivaroxaban 
(20mg od) may have a 
substantially higher risk than 
placebo. 
Evidence that rivaroxaban 
(20 mg od) may have a 
higher risk than aspirin. 
All-cause 
mortality 
Primary studies: 9 
Interventions: 9 
Events: 158 
Low in all six 
domains: 3/9 
High in one or 
more domains: 3/9 
Unclear in one or 
more domains, 
none high: 3/9 
No evidence of differences 
between NOACs and warfarin 
(most imprecise). 
Evidence that apixaban (5mg 
bd) may have lower risk than 
placebo (imprecise 
estimates). 
Weak evidence that 
apixaban (5mg bd) may 
have a lower risk than 
aspirin (imprecise 
estimates). 
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Appendix 16: Genotyping review; generic characteristics of included reviews 
Study Search databases (year range) Year range 
of 
synthesised 
studies 
Total 
number of 
studies in 
review 
Number of studies 
reviewed related 
to AF/VTE adult 
populations 
Study types 
synthesised 
Any other targeting  
Chen et al. 
2016 
PubMed and Embase (no specific date limits 
reported) 
2009 - 2014 8 7 Case-control 
and cohort  
African descent 
populations 
Dahal et al. 
2015 
MEDLINE, Embase, and Cochrane Central 
Register of Controlled Trials (CENTRAL) 
(inception to March 2014) 
2005 - 2013 10 9 RCTs Adult patients (≥18 
years) 
Franchini et 
al. 2014 
MEDLINE (1980 to March week 1, 2014), 
Embase (1980 to March week 1, 2014) and 
Cochrane Central Register of Controlled Trials 
(CENTRAL) 
2005 - 2013 9 9 RCTs None 
Goulding et 
al. 2014 
MEDLINE, Cochrane Central Register of 
Controlled Trials (CENTRAL) and pharmgkb.org 
(January 1980 to December 2013) 
2002 - 2013 15 8 RCTs Patients from a 
clinical setting 
Jin et al. 2014 MEDLINE and Embase (in June 2013 with 
verification search in July 2013) 
2005 - 2013 32 25 Prospective 
clinical 
trials 
None 
The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews 
 
 
134 
 
Study Search databases (year range) Year range 
of 
synthesised 
studies 
Total 
number of 
studies in 
review 
Number of studies 
reviewed related 
to AF/VTE adult 
populations 
Study types 
synthesised 
Any other targeting  
Shi et al. 2015 PubMed, Embase, The Cochrane library, China 
National Knowledge Infrastructure (CNKI), VIP, 
Wan-fang (from inception to March 2015)  
 
Reference lists of the relevant studies were 
searched for additional literature 
2005 - 2013 11 8 RCTs Patients at least 18 
years old with an 
indication for 
anticoagulation 
Sun et al. 
2016 
PubMed, Embase and CNKI (inception until 
August 5, 2015) 
2009 - 2015 22 11 NR109 Asian population 
Tang et al. 
2015 
PubMed, Embase, Web of Science, and The 
Cochrane Library (January 1, 2000, to March 1, 
2014) 
2007 - 2013 8 7 RCTs None 
Xu et al. 2014 PubMed, OVID, Cochrane Central Register of 
Controlled Trials (CENTRAL) (inception through 
to January 2014) 
2005 - 2013 8 7 RCTs None 
Yu et al. 2016 PubMed, Embase, and CNKI (inception to July 
19, 2015) 
2005 - 2014 9 9 RCTs Caucasian, 
Asian and African 
American patients  
 
                                             
109 Reviews, case reports and editorials were excluded 
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Appendix 17: Genotyping review; specific characteristics of included reviews 
Study 
Author 
and year 
Aim/objective Characteristics of 
included 
populations  
Gene 
polymorphism 
considered 
Intervention/comparator Outcomes assessed  
Chen et 
al. 2016 
To evaluate the impact of 
the CYP4F2 polymorphism on 
bleeding complications and 
over- anticoagulation due to 
coumarin 
Total: 3,101 
Age 
(mean/median: 
4.8110 to 66 
Female (%): 41.0 
to 54.7 
Ethnicity: 
Caucasian, Asian, 
African-American 
CYP4F2*3, 
CYP4F2*1 
VKAs: warfarin and acenocoumarol 
Dose range: 3 to 7mg/day 
Intervention: VKA  
Comparison: CYP4F2*3 v CYP4F2*1 
Follow-up: 3 months to 40 to 45 
months  
Total haemorrhage, 
Major haemorrhage, 
INR<4, Over-
anticoagulation 
Dahal et 
al. 2015 
Comparison of genotype-
guided dosing vs standard 
dosing in adult patients with 
various indications of 
warfarin use 
Total: 2,505 
Age 
(mean/median): 
41.6 to 70.5yrs 
Female (%): 44.6 
to 70% [majority 
were men] 
Ethnicity: 0 to 
100% White, 0 to 
35% Black and 0 to 
100% Asian 
CYP2C9*2 and *3 
& VKORC1; 
CYP2C9, VKORC1 
& CYP4F2 
VKAs: warfarin  
Dose range: 2.5 to 10mg/day (of those 
stated)  
Intervention: genotype-guided dosing 
Comparator: standard dosing 
Follow-up: 2 weeks to 6 months 
Primary: percentage 
time in therapeutic range 
(TTR) 
Secondary: major 
bleeding time to 
maintenance dose (TMD), 
supratherapeutic INR of > 
4, thromboembolism, 
non-major bleeding, and 
all-cause mortality 
                                             
110 Error in text 
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Study 
Author 
and year 
Aim/objective Characteristics of 
included 
populations  
Gene 
polymorphism 
considered 
Intervention/comparator Outcomes assessed  
Franchini 
et al. 
2014 
To assess whether two 
approaches [genotype-
guided or not] resulted in 
different rates of clinically 
relevant events such as 
bleeding, thrombosis and 
death 
Total: 2,812 
Age 
(mean/median): 
64.8 v 64.3yrs 
(int. v control); 
study arms median 
range: 41 to 70yrs 
Female (%): 44.8 v 
48.6% (int v 
control); study 
arms range: 36 to 
58% 
Ethnicity: 65 to 
100% White 
CYP2C9; VKORC1 VKAs: warfarin & other VKAs 
Dose range: NR 
Intervention: genotype-guided dosing 
Comparator: standard dosing 
Follow-up: 22 to 90 days 
Primary: incidence of 
major bleeding, 
thrombosis and death 
Secondary: time to reach 
a therapeutic INR; % of 
TTR; time to reach a 
stable dose; % time spent 
at sub-therapeutic INR, 
number of days in 
hospital 
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Study 
Author 
and year 
Aim/objective Characteristics of 
included 
populations  
Gene 
polymorphism 
considered 
Intervention/comparator Outcomes assessed  
Goulding 
et al. 
2014 
To quantify the clinical 
effectiveness of genotype-
guided prescribing. MAIN 
TEXT: This study examines 
the current randomized 
controlled trial evidence for 
the prospective clinical use 
of pharmacogenetic 
information to improve 
effectiveness of drug 
prescribing as demonstrated 
by reduced harm and 
increased relative 
effectiveness. Prescribing 
has the potential to reduced 
adverse drug events and 
increase drug effectiveness. 
Our aim was to quantify the 
clinical effectiveness of 
genotype-guided prescribing 
Total: 5,688 
Age 
(mean/median): 
41 to 70 years 
Female (%): 17 to 
69% 
Ethnicity: 0 to 
100% Caucasian, 0 
to 100% Chinese, 0 
to 27% Black; 
unspecified % 
Hispanic 
CYP2C29; 
VKORC1; CYP4F2; 
HLA-B*5701; HIV 
anti-retroviral 
resistance 
mutations; TMPT; 
CYP2C19; 
CYP3A5;  
VKAs: Warfarin, 
acenocoumarol/phenprocoumon; 
tacrolimus; 
clopidogrel/prasugrel/azathioprine; 
antiretroviral agents (12); abacavir 
Dose range: NR 
Intervention: genotype-guided dosing 
Comparator: non-genotype guided 
prescribing 
Follow-up: 7 days to 4 months 
Primary: Not stated 
explicitly; abstract 
states: percentage of 
time in therapeutic 
international normalised 
ratio range & adverse 
drug events 
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Study 
Author 
and year 
Aim/objective Characteristics of 
included 
populations  
Gene 
polymorphism 
considered 
Intervention/comparator Outcomes assessed  
Jin et al. 
2014 
To estimate of the impact of 
-1639G 4 A genetic 
polymorphism upon warfarin 
dose requirement 
Total: 5,005 
Age (mean): 36.0 
to 86.7 years 
Female (%): 12.6% 
to 64.9% (2 NR) 
Ethnicity: 
Caucasians, 
Asians, African 
population 
VKORC1-1639G>A VKAs: warfarin 
Dose range: NR 
Intervention: VKA 
Comparator: between genotype 
variation  
Follow-up: NR 
Primary: Weighted mean 
maintenance dosage of 
warfarin 
Shi et al. 
2015 
To determine whether 
genotype-guided warfarin 
dosing can improve clinical 
outcomes in comparison to 
conventional dosing  
Total: 2,678 
Age (median): 
59.7 years 
Female (%): NR 
Ethnicity: NR 
CYP2C9, VKORC1, 
CYP4F2 
VKAs: Warfarin 
Dose range: NR 
Intervention: pharmacogenetics-based 
dosing of warfarin 
Comparator: conventional dosing of 
warfarin 
Follow-up: 28 days to 3 months 
Primary: Time within the 
therapeutic range (TTR). 
Secondary: INR greater 
than 4, time to 
maintenance dose and 
the first target INR, 
adverse events during 
anticoagulation 
treatment, the frequency 
of major bleeding, 
thromboembolic 
events, and death from 
any cause 
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Study 
Author 
and year 
Aim/objective Characteristics of 
included 
populations  
Gene 
polymorphism 
considered 
Intervention/comparator Outcomes assessed  
Sun et al. 
2016 
To investigate the impact of 
the CYP4F2 polymorphism 
rs2108622 (p.V433M) on 
warfarin dose requirement 
Total: 4,549 
Age 
(mean/median): 
NR 
Female (%): 53.5 
Ethnicity: 
Chinese, Indian, 
Turkish, Japanese, 
Korean, Asian 
CYP4F2 VKAs: warfarin 
Dose range: 2.51 to 22.42mg/day 
Intervention: VKA 
Comparison: CT v TT v T carriers 
Follow-up: NR 
Primary: mean 
difference (MD) in daily 
warfarin dose (MDWD) 
(MDs represent the 
relative differences in 
the maintenance dose 
due to the normalisation 
procedure) 
Tang et 
al. 2015 
To determine whether 
genotype-guided dosing of 
coumarin anticoagulants did 
not improve the percentage 
of time in the therapeutic 
INR range 
Total: 1,805 
Age (mean): 
61.42; study arms 
mean range: 41.6 
to 69.2 years 
Female (%): 43.1; 
12 to 70% 
Ethnicity: NR 
VKORC1, CYP2C9 VKAs: NR (coumarin anticoagulants) 
Dose range: NR 
Intervention: genotype-guided dosing 
Comparator: coumarin anticoagulants 
according to a non-genotype-guided 
dosing algorithm 
Follow-up: 58.75 (mean); 28 to 90 
days (range) 
Primary: mean 
difference in percentage 
time within the 
therapeutic INR range 
Secondary: major 
bleeding events, 
thromboembolic events, 
and INR at or greater 
than 4 events 
Xu et al. 
2014 
To assess whether genotype-
guided pharmacogenetic 
dosing of warfarin is superior 
to clinical dosing 
Total: 2,098 
Age 
(mean/median): 
NR 
Female (%): NR 
Ethnicity: NR 
CYP2C9, VKORC1, 
CYP4F2 
VKAs: warfarin 
Dose range: 5 to 10mg 
Intervention: genotype-guided dosing 
Comparator: clinical dosing 
Follow-up: 28 to 90 days  
Primary: Time within the 
therapeutic range (TTR) 
Secondary major 
bleeding, minor bleeding, 
thromboembolic events, 
INR ≥ 4 
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Study 
Author 
and year 
Aim/objective Characteristics of 
included 
populations  
Gene 
polymorphism 
considered 
Intervention/comparator Outcomes assessed  
Yu et al. 
2016 
To show the impact of ApoE 
alleles on mean daily 
warfarin dose (MDWD). We 
also aimed to assess the 
association between ApoE 
alleles and the response to 
warfarin in different ethnic 
groups and to provide a 
reference for future 
warfarin pharmacogenetics 
studies 
Total: 1,766 
Age 
(mean/median): 
42.3 to 71 years 
Female (%): 
46.8%; range 34.6 
to 65.5% 
Ethnicity: 
Caucasian, Asian 
and African 
American 
Apolipoprotein E 
(ApoE) 
VKAs: warfarin 
Dose range: NR 
Intervention: VKA 
Comparator: ApoE alleles E2 v E3 v E4 
Follow-up: NR 
Primary: The warfarin 
dose (mean and SD) 
associated with each 
genotype 
The effective, safe and appropriate use of anticoagulation medicines: A systematic overview of reviews 
 
 
141 
 
 
Appendix 18: Genotyping review; risk of bias assessment of included reviews 
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Chen (2016) + - - - + - - PY N/A + - N/A + + + + - + 
Dahal (2015) + PY - + - - - PY PY N/A - + N/A + + + + + 
Franchini (2014) + PY - + + + - PY + N/A - + N/A - - - - + 
Goulding (2015) + - - PY + + - + + N/A - + N/A - - - - + 
Jin (2014) - - - - - + - PY N/A - - N/A - - - - + + 
Shi (2015) + + + PY + + - + + N/A + + N/A + + + + + 
Sun (2016) + - + PY - + - + PY PY - + + - - + + - 
Tang (2015) + - + PY - + - + + N/A - + N/A + + + - + 
Xu (2014) - - + - - + - + + N/A - + N/A - - + + + 
Yu (2016) + - + PY - + - + PY PY - + + + + + + + 
PY = partial yes, N/A = not applicable
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1. Include PICO?   80%  20% 
 
2. Protocol?   10% 20% 70% 
 
3. Inclusion criteria   50%  50% 
 
4. Comprehensive search strategy?   20% 50% 30% 
 
5. Duplicate screening?   40%  60% 
 
6. Duplicate DE?   80%  20% 
 
7. Exclusions?     100% 
 
8. Included described in detail?   60% 40%  
 
9a. RCTs - RoB assessment?   50% 50%  
 
9b. NRSI - RoB assessment?   10% 80% 10% 
 
10. Funding stated?   10% 90% 
 
11a. RCTs: meta-analysis methods?   80% 20%  
 
11b. NRSI: meta-analysis methods?   30% 60% 10% 
 
12. RoB impact on meta-analysis?   50%  50% 
 
13. RoB in interpretation of results?   50%  50% 
 
14. Heterogeneity explained/discussed?   70%  30% 
 
15. Publication bias?   60%  40% 
 
16. Conflict of interest stated?   90%  10% 
 
 
  Low risk of 
bias:   
  Partial yes/not 
applicable:   
  High risk of 
bias:   
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Appendix 19: Genotyping review; overlap of included primary studies within reviews 
Review Dahal 
(2015) 
Chen 
(2016) 
Franchini 
(2014) 
Jin 
(2014) 
Shi 
(2015) 
Sun 
(2016) 
Tang 
(2015) 
Xu 
(2014) 
Yu 
(2016) Overlap Included study 
Anderson et al. (2007) ✔  ✔  ✔  ✔ ✔  5 
Aquilante et al. (2006)    ✔       
Bazan et al. (2013)    ✔       
Bejarano-Achache et al. (2012)  ✔         
Borgman et al. (2012) ✔  ✔  ✔   ✔  4 
Burmester et al. (2011) ✔  ✔  ✔  ✔ ✔  5 
Caraco et al. (2008) ✔  ✔  ✔     3 
Cavallri (2010)         ✔  
Cerezo-Manchado et al. (2014)  ✔         
Fang et al. (2014)      ✔     
Gan et al. (2011)    ✔       
Hillman et al. (2005) ✔  ✔  ✔  ✔ ✔  5 
Hirai et al. (2015)      ✔     
Jimenez-Varo et al. (2014)  ✔         
John (2010)         ✔  
Jonas et al. (2013) ✔  ✔  ✔  ✔ ✔  5 
Kawai et al. (2014)  ✔         
Kimmel (2007)         ✔  
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Review Dahal 
(2015) 
Chen 
(2016) 
Franchini 
(2014) 
Jin 
(2014) 
Shi 
(2015) 
Sun 
(2016) 
Tang 
(2015) 
Xu 
(2014) 
Yu 
(2016) Overlap Included study 
Kimmel at al. (2013) ✔  ✔  ✔  ✔ ✔  5 
Kohnke (2005)         ✔  
Krishna et al. (2014)      ✔     
Kwon et al. (2011)    ✔       
Lal (2007)         ✔  
Lee et al. (2009)    ✔  ✔    2 
Liang et al. (2012)    ✔  ✔    2 
Lou et al. (2014)      ✔     
Ma et al. (2012)  ✔         
Miao et al. (2007)    ✔       
Michaud et al. (2008)    ✔       
Momary et al. (2007)    ✔       
Namazi et al. (2010)    ✔       
Obayashi et al. (2006)    ✔       
Ohno et al. (2009)    ✔       
Oliveria Almeida (2014)         ✔  
Oner Ozgon et al. (2008)    ✔       
Ozer et al. (2010)    ✔       
Özer et al. (2013)    ✔  ✔    2 
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Review Dahal 
(2015) 
Chen 
(2016) 
Franchini 
(2014) 
Jin 
(2014) 
Shi 
(2015) 
Sun 
(2016) 
Tang 
(2015) 
Xu 
(2014) 
Yu 
(2016) Overlap Included study 
Pautas et al. (2010)    ✔       
Pirmohamed et al, (2013) ✔  ✔  ✔  ✔ ✔  5 
Roth et al (2014)  ✔         
Santos et al. (2013)    ✔       
Sconce (2006)         ✔  
Sconce et al. (2005)    ✔       
Shahin et al.  (2011)    ✔     ✔ 2 
Sheng Wen (2011)         ✔  
Shrif et al. (2011)    ✔       
Singh et al. (2011)      ✔     
Smires et al. (2012)    ✔       
Teh et al. (2012)    ✔       
Verhoef et al, (2013)       ✔    
Wang et al. (2011)      ✔     
Wang et al. (2012) ✔          
Yoshizawa et al. (2009)    ✔       
Yuan et al. (2005)    ✔       
Zhang et al. (2009)  ✔         
Zhang et al. (2013)      ✔     
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Review Dahal 
(2015) 
Chen 
(2016) 
Franchini 
(2014) 
Jin 
(2014) 
Shi 
(2015) 
Sun 
(2016) 
Tang 
(2015) 
Xu 
(2014) 
Yu 
(2016) Overlap Included study 
Zhu et al. (2007)    ✔       
Zhu et al. (2012)      ✔     
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Appendix 20: Genotyping review; included and excluded references 
Initially, 22 reviews were identified for possible inclusion in this overview, on the strength 
of their title and abstract. However, upon full-text screening, 12 studies were excluded. 
The main reasons for exclusion were: conference abstracts (Belley et al., 2014; Smith et 
al., 2015); not focusing predominantly on AF and VTE (Belley et al., 2015; Liu et al., 2015; 
Plumpton et al., 2016; Stergiopoulos et al., 2014; Tang et al., 2014; Tang et al., 2015); did 
not qualify as a systematic review (i.e. less than two databases searched) (Dahal et al., 
2014; Liao et al., 2015); or did not include health or cost outcomes (Martin et al., 2017). 
 
Reference list of included studies 
Chen P, Sun Y Q, Yang G P, Li R, Pan J, and Zhou Y S. (2016). Influence of the CYP4F2 
polymorphism on the risk of hemorrhagic complications in coumarin-treated patients. Saudi 
Medical Journal, 37, pp.361-368. 
Dahal K, Sharma S P, Fung E, Lee J, Moore J H, Unterborn J N, and Williams S M. (2015). 
Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of 
Warfarin. Chest, 148, pp.701-10. 
Franchini M, Mengoli C, Cruciani M, Bonfanti C, and Mannucci P M. (2014). Effects on 
bleeding complications of pharmacogenetic testing for initial dosing of vitamin K 
antagonists: a systematic review and meta-analysis. Journal of Thrombosis & Haemostasis, 
12, pp.1480-7. 
Goulding R, Dawes D, Price M, Wilkie S, and Dawes M. (2015). Genotype-guided drug 
prescribing: a systematic review and meta-analysis of randomized control trials. British 
Journal of Clinical Pharmacology, 80, pp.868-77. 
Jin B, Hong Y, Zhu J, Li Y, and Shi H M. (2014). The impact of VKORC1-1639G>A genetic 
polymorphism upon warfarin dose requirement in different ethnic populations. Current 
Medical Research & Opinion, 30, pp.1505-11. 
Shi C, Yan W, Wang G, Wang F, Li Q, and Lin N. (2015). Pharmacogenetics-Based versus 
Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 
[Electronic Resource], 10, pp. e0144511. 
Sun X, Yu W Y, Ma W L, Huang L H, and Yang G P. (2016). Impact of the CYP4F2 gene 
polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. 
Biomedical Reports, 4, pp.498-506. 
Tang T, Liu J, Zuo K, Cheng J, Chen L, Lu C, Han S, Xu J, Jia Z, Ye M, Pei E, Zhang X, and Li 
M. (2015). Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of 
Randomized Controlled Trials. Journal of Cardiovascular Pharmacology & Therapeutics, 20, 
pp.387-94. 
Xu H, Xie X, Wang B, Chen Y, Meng T, Ma S, and Wang F. (2014). Meta-analysis of efficacy 
and safety of genotype-guided pharmacogenetic dosing of warfarin. International Journal of 
Cardiology, 177, pp.654-657. 
Yu W Y, Sun X, Wadelius M, Huang L, Peng C, Ma W L, and Yang G P. (2016). Influence of 
APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: 
A Systematic Review and Meta-Analysis. Cardiovascular therapeutics, 34, pp.297-307. 
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Reference list of excluded studies 
Belley-Cote E P, Hanif H, D'Aragon F, Eikelboom J, Anderson J L, Borgman M, Jonas D E, 
Kimmel S, Maitland-Van Der Zee, A H, Pirmohamed M, and Whitlock R. (2014). Genotype-
guided vitamin K antagonist dosing algorithms improve time in therapeutic range: A 
systematic review and meta-analysis. Circulation. Conference: American Heart 
Association's, 130, pp. 
Belley-Cote E P, Hanif H, D'Aragon F, Eikelboom J W, Anderson J L, Borgman M, Jonas D E, 
Kimmel S E, Manolopoulos V G, Baranova E, Maitland-van der Zee, A H, Pirmohamed M, and 
Whitlock R P. (2015). Genotype-guided versus standard vitamin K antagonist dosing 
algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. 
Thrombosis & Haemostasis, 114, pp.768-77. 
Dahal K, Sharma S, and Lee J. (2014). A meta-analysis of randomized trials of genotype-
guided versus standard dosing of warfarin. European Heart Journal, 35, pp.381-382. 
Liao Z, Feng S, Ling P, and Zhang G. (2015). Meta-analysis of randomized controlled trials 
reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin 
dosing. Journal of Thrombosis & Thrombolysis, 39, pp.228-34. 
Liu H Q, Zhang C P, Zhang C Z, Liu X C, and Liu Z J. (2015). Influence of two common 
polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis. BioMed 
Research International, 2015, pp.564149. 
Martin A, Downing J, Maden M, Fleeman N, Alfirevic A, Haycox A, and Pirmohamed M. (2017). 
An assessment of the impact of pharmacogenomics on health disparities: a systematic 
literature review. Pharmacogenomics, 18, pp.1541-1550. 
Plumpton C O, Roberts D, Pirmohamed M, and Hughes D A. (2016). A Systematic Review of 
Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. 
PharmacoEconomics, 34, pp.771-793. 
Smith S A. (2015). Systematic review of recent pharmacoeconomic evaluations related to 
genotype-guided therapy in patients at high risk for thrombotic event. Value in Health, 18 
(3), pp.A142. 
Stergiopoulos K, and Brown D L. (2014). Genotype-guided vs clinical dosing of warfarin and 
its analogues: meta-analysis of randomized clinical trials. JAMA Internal Medicine, 174, 
pp.1330-8. 
Sun Y, Wu Z, Li S, Qin X, Li T, Xie L, Deng Y, and Chen J. (2015). Impact of gamma-glutamyl 
carboxylase gene polymorphisms on warfarin dose requirement: a systematic review and 
meta-analysis. Thrombosis Research, 135, pp.739-47. 
Tang H L, Shi W L, Li X G, Zhang T, Zhai S D, and Xie H G. (2015). Limited clinical utility of 
genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-
analysis and trial sequential analysis of 11 randomized controlled trials. Pharmacogenomics 
Journal, 15, pp.496-504. 
Tang W, Shi Q P, Ding F, Yu M L, Hua J, and Wang Y X. (2017). Impact of VKORC1 gene 
polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-
analysis of 53 studies. International Journal of Clinical Pharmacology & Therapeutics, 55, 
pp.304-321.
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Appendix 21: Self-monitoring review; detailed characteristics of the studies included in the reviews 
 
Study Quality 
appraisal111 
 
Study characteristics (k) Intervention characteristics (k) Outcome 
Measure 
Clarkesmith 
et al. 
(2017) 
Cochrane risk 
of bias and 
GRADE (Higgins 
and Green 
2011)  
Type of studies: RCTs   
N studies reviewed AF (11) trials (reported 
in twenty articles) 
Sample size (total): 2,246 
Age: ranged from 59 to 75 years. 
Gender: NR112 
Ethnicity: NR113 
Other targeting: None 
N studies reporting primary outcome AF 
(6) 
Type(s) of anticoagulation: Unspecified 
(6) 
Intervention(s):  Education; decision 
aids; self-management plus education  
Setting(s): Hospital or anticoagulation 
clinic setting (3); general practitioner 
(GP); practices (2); Unspecified (1) 
Follow-up: Ranged from 3-12 months 
Time in 
therapeutic 
range (TTR) 
Rosendaal et al. 
(1993) method; 
TTR in days; INR 
values in range. 
 
Entezari-
Maleki et 
al. (2016) 
Downs and 
Black checklist 
(Downs and 
Black 1998). 
RCTs were 
additionally 
assessed using 
the Jadad scale 
(Oxford scale). 
Type of studies: RCTs/n-RCTs 
N  studies reviewed: Mixed (24)114 
Sample size (total): 11,607 
Age: NR 
Ethnicity: NR 
Other targeting:  None 
N studies reporting primary outcome 
Mixed (8) 
Type(s) of anticoagulation: Warfarin 
(all) 
Intervention(s): pharmacist-managed 
warfarin therapy (PMWT)  
Setting(s): Pharmacist (all) 
Follow-up: 2 to 17 months 
Time in 
therapeutic 
range (TTR) 
Rosendaal et al. 
(1993) methods  
                                             
111 As reported by the primary review’s authors. 
112 Gender reported for each study, but not summarised by the primary review authors. 
113 Ethnicity data were tabularised for individual studies by the primary review authors (see Characteristics of included studies, in Clarkesmith et al. 
(2017), begins p38), but were not referred to or summarised by these authors. 
114 AF, deep vein thrombosis, pulmonary thromboembolism, or valvular heart diseases (relative proportions not reported). 
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Study Quality 
appraisal111 
 
Study characteristics (k) Intervention characteristics (k) Outcome 
Measure 
Heneghan 
et al. 
(2016) 
 
 
GRADE 
 
Type of studies: RCTs  
N studies reviewed: 28 total (reported in 27 
articles); AF (2); Valve replaced (6); Mixed 
(20) 
Sample size (total): 8,950  
Age: NR  
Gender: NR 
Ethnicity: NR 
Other targeting: Long-term treatment 
(2mths+), any indication 
N studies reporting primary outcome 
Mixed/AF (22) 
Type(s) of anticoagulation: Various115 
(mostly Warfarin) 
Intervention(s): Self-testing  or self-
management  compared with usual care 
Setting(s)116: Primary care setting (11), 
specialist anticoagulation clinics (13); 
either of the settings (above) (3), data 
from a medical analysis laboratory (1) 
Follow-up: 2 to 57 months; mean 
duration was 12 months 
Time in 
therapeutic 
range (TTR) 
Rosendaal et al. 
(1993) method 
 
INR values in 
target range  
Manzoor et 
al. (2017) 
 
 
Downs and 
Black checklist 
Downs and 
Black 1998 
Type of studies: RCTs/n-RCTs 
N studies reviewed: Mixed (25)117 
Sample size (total): 12,252 
Age: mean ranged from 47.4 to 81.0 years 
Gender: NR 
Ethnicity: Mainly Caucasian (4); Malay (2); 
Qatari (1); NR (18). 
Other targeting: None 
N studies reporting primary outcome 
Mixed (25) 
Type(s) of anticoagulation: Warfarin 
(25) 
Intervention(s): Outpatient pharmacist-
managed anticoagulation services 
(PMAS) compared with usual care 
Setting(s): Outpatient pharmacist (all) 
Follow-up: ranged from 3 months to 
four years  
TTR (Rosendaal 
et al. (1993) 
interpolation 
method);  
INR values in 
goal INR range 
or given by the 
mean 
prothrombin  
Sharma et 
al. (2015) 
The Cochrane 
Risk of Bias 
Type of studies: RCTs Type(s) of anticoagulation: Warfarin 
(12);  phenprocoumon and/or 
TTR (% of time 
INR in 
                                             
115 Figures not reported 
116 Reported for all included trials only 
117 The majority of patients were treated for atrial fibrillation or venous thromboembolism (including DVT and PE) (N = 23 of 25, 92.0%). 
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Study Quality 
appraisal111 
 
Study characteristics (k) Intervention characteristics (k) Outcome 
Measure 
 
 
N  studies reviewed: 26 trials (published in 
45 articles) AF (2); Mixed (18)118; Artificial 
heart valve (6) 
Sample size (total): 8,763  
Age: ranged from 16 to 91 years (+ 1 trial of 
children)119 
Gender: NR 
Ethnicity: NR 
Other targeting: Patients receiving long-
term vitamin K antagonist 
N studies reporting primary outcome: 
AF(2); Mixed (18) 
acenocoumarol and/or fluindione (6); 
either warfarin or phenprocoumon (1); 
and unspecified (1) 
Intervention(s): Self-testing  or self-
management compared with usual care 
Setting(s): Professionals in 
anticoagulant or hospital outpatient 
clinics (12); physician or a GP in a 
primary 
care setting (3); either of these (3); and 
other120 (2) 
Follow-up: Reported as study duration, 
ranged from 14 weeks to more than 4 
years 
therapeutic 
range) 
 
INR values in 
range 
 
 
Zhou et al. 
(2016) 
The Cochrane 
Risk of Bias 
tool;  
GRADE 
Type of study: RCTs (all) 
N studies reviewed: Mixed (8)121 
Sample size (total): 1,493  
Age range from 57.7 to 70 years 
Gender: range from 51.2% to 68.4% male 
Ethnicity: NR 
Other targeting: None 
Type(s) of anticoagulation: Warfarin 
(all) 
Intervention(s): Outpatient pharmacist-
managed warfarin services (PMWS) 
compared with other models) 
Setting(s): Pharmacists (all) 
Follow-up: Ranged from 3 to 6 months 
Time in 
therapeutic 
range  
                                             
118 Atrial fibrillation, artificial heart valves (AHVs) and venous thromboembolism were the most common clinical indications. 
119 The trial that assessed children reported a median age of 10 years. 
120 Self-testing within anticoagulant clinics 
121 The majority of patients were treated for AF, deep vein thrombosis, pulmonary thromboembolism, or valvular heart diseases (relative proportions not 
reported). 
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Study Quality 
appraisal111 
 
Study characteristics (k) Intervention characteristics (k) Outcome 
Measure 
N studies reporting primary outcome: 
Mixed (4) 
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Appendix 22: Self-monitoring review; results of the included reviews by intervention type 
Intervention Conditions Review Number 
of 
relevant 
primary 
studies 
(k)122  
Relevant primary 
studies 
% of 
overlap 
in 
primary 
studies 
between 
reviews 
Synthesis Outcomes Summary of 
Findings 
Education 
Education Education v. 
usual care  
 
Clarkesmith 
et al. 
(2017) 
2 RCTs 
(exclusive 
AF) 
Clarkesmith et al. 
(2013b); Vormfelde et 
al. (2014)123 
N/A Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
TTR 
(Rosendaal 
et al. (1993) 
interpolation 
method) 
Low-quality 
evidence that 
education may 
improve TTR 
compared with usual 
care, but more 
studies are needed 
Education plus 
patient 
decision aid (to 
inform 
preferences for 
anticoagulation 
therapy) 
Education plus 
patient 
decision v. 
usual care 
Clarkesmith 
et al. 
(2017) 
1 RCT 
(exclusive 
AF) 
McAlister et al. (2005) N/A Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
Percentage 
of INR values 
in range 
Low-quality 
evidence that 
education plus 
patient decision aid 
may increase the 
percentage of INR 
values in therapeutic 
range compared with 
usual care but more 
studies are needed 
Self-monitoring 
                                             
122 k = number of studies. 
123 Gadisseur et al. (2003) also tested education v. usual care but due to a typo in their report, the results could not be established and are, therefore, 
not reproduced here. 
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Intervention Conditions Review Number 
of 
relevant 
primary 
studies 
(k)122  
Relevant primary 
studies 
% of 
overlap 
in 
primary 
studies 
between 
reviews 
Synthesis Outcomes Summary of 
Findings 
Self-testing 
(with guidance 
on dosing from 
a clinician) 
Self-testing v. 
usual care  
Sharma et 
al. (2015) 
Heneghan 
et al. 
(2016) 
1 RCT 
(exclusive 
AF) 
Khan et al. (2004) 100% Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
TTR (% of 
time INR in 
therapeutic 
range) 
Low-quality 
evidence that there 
is no difference 
between self-testing 
on improving time 
INR in therapeutic 
range compared with 
usual care, but more 
studies are needed 
Mixed population (% time in therapeutic range) 
Sharma et 
al. (2015) 
5 RCTs  Azarnoush et al. (2011); 
Christensen (2011); 
Gadisseur et al. (2003); 
Khan et al. (2004); 
Matchar et al. (2010) 
43% Data meta-
analysed 
TTR (% of 
time INR in 
therapeutic 
range) 
Low-quality 
evidence that self-
testing may 
modestly improve 
the percentage of 
time INR is in the 
therapeutic range, 
compared with usual 
care but more 
studies are needed 
Heneghan 
et al. 
(2016) 
7 RCTs  Beyth et al. (2000); 
Christensen et al. 
(2011); Gardiner et al. 
(2005); Kaatz et al. 
(unpublished); Khan et 
al. (2004); Matchar et 
Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance 
TTR 
(Rosendaal 
et al. (1993) 
interpolation 
method) 
Mixed, moderate-
quality evidence for 
self-testing with 
three trials reporting 
longer TTR and four 
trials reporting 
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Intervention Conditions Review Number 
of 
relevant 
primary 
studies 
(k)122  
Relevant primary 
studies 
% of 
overlap 
in 
primary 
studies 
between 
reviews 
Synthesis Outcomes Summary of 
Findings 
al. (2010); Rasmussen et 
al. (2012)  
shorter TTR, 
compared with usual 
care 
  Mixed population (% values in therapeutic range) 
Sharma et 
al. (2015) 
2 RCTs  Christensen (2011); 
Gadisseur et al. (2003) 
0% Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
INR values in 
range 
 
Low-quality 
evidence that self-
testing may improve 
the number of INR 
values in the 
therapeutic range, 
compared with usual 
care though more 
studies are needed 
  Heneghan 
et al. 
(2016) 
2 RCTs  Kaatz et al. 
(unpublished); White et 
al. (1989) 
Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
Moderate-quality 
evidence that self-
testing may enhance 
the mean percentage 
of INR values in 
target range, 
compared with 
control but more 
studies are needed 
Self-
management 
(self-testing 
and treatment 
Education plus 
self-
Clarkesmith 
et al. 
(2017) 
2 RCTs 
(exclusive 
AF) 
Christensen et al. 
(2007); Gadisseur et al. 
(2003)  
N/A Data meta-
analysed 
TTR 
(Rosendaal 
et al. (1993) 
Low-quality 
evidence favoured 
the education plus 
self-management 
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Intervention Conditions Review Number 
of 
relevant 
primary 
studies 
(k)122  
Relevant primary 
studies 
% of 
overlap 
in 
primary 
studies 
between 
reviews 
Synthesis Outcomes Summary of 
Findings 
according to an 
algorithm) 
management124 
v. usual care 
 
interpolation 
method) 
intervention group 
among AF 
populations, in terms 
of TTR compared 
with usual care, but 
was not statistically 
significant. More 
studies are needed 
Self-
management 
v. usual care 
Sharma et 
al. (2015); 
Heneghan 
et al. 
(2016); 
Clarkesmith 
et al. 
(2017) 
1 RCT 
(exclusive 
AF) 
Voller et al. (2005) 100% Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
TTR 
(Cumulative 
days) 
Low-quality 
evidence that among 
AF populations, self-
management 
increases TTR, 
compared with usual 
care, but more 
studies are needed 
Mixed population (% time in therapeutic range) 
Sharma et 
al. (2015) 
 
6 RCTs  Menendez-Jandula et al. 
(2005); Fitzmaurice et 
al. (2005); Verret et al. 
(2012); Fitzmaurice et 
al. (2002); Gadisseur et 
67% Data meta-
analysed 
TTR (% of 
time INR in 
therapeutic 
range) 
Low-quality 
evidence that self-
management has 
little effect on TTR, 
compared with usual 
care. More high-
                                             
124 Clarkesmith et al. (2017) use the term self-testing but the description of the intervention is consistent with our use of the term self-management 
hence this label will be used from herein for this intervention 
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Intervention Conditions Review Number 
of 
relevant 
primary 
studies 
(k)122  
Relevant primary 
studies 
% of 
overlap 
in 
primary 
studies 
between 
reviews 
Synthesis Outcomes Summary of 
Findings 
al. (2003); Sunderji et 
al. (2004) 
quality studies are 
needed 
Heneghan 
et al. 
(2016) 
8 RCTs  Fitzmaurice et al. 
(2002); Fitzmaurice et 
al. (2005);  Sunderji et 
al. (2004); Menendez-
Jandula et al. (2005); 
Siebenhofer et al. 
(2007); Christensen et 
al. (2006); Grunau et al. 
(2011); Verret et al. 
(2012) 
Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
TTR 
(Rosendaal 
et al. (1993) 
interpolation 
method)  
Mixed, moderate-
quality evidence for 
self-management 
with three trials 
reporting longer TTR 
and three trials 
reporting shorter 
TTR compared with 
usual care 
Mixed population (% values in therapeutic range) 
Sharma et 
al. (2015) 
 
7 RCTs  Cromheecke et al. 
(2000); Fitzmaurice et 
al. (2002); Fitzmaurice 
et al. (2005); Menendez-
Jandula et al. (2005); 
Sawicki (1999); Voller et 
al. (2005); Gadisseur et 
al. (2003) 
63% Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
INR values in 
range 
Mixed low-quality 
evidence for self-
management 
intervention with 
five trials reporting 
higher and two trials 
reporting lower 
percentages of INR 
values in therapeutic 
range compared with 
usual care 
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Intervention Conditions Review Number 
of 
relevant 
primary 
studies 
(k)122  
Relevant primary 
studies 
% of 
overlap 
in 
primary 
studies 
between 
reviews 
Synthesis Outcomes Summary of 
Findings 
Heneghan 
et al. 
(2016) 
8125 RCTs  Cromheecke et al. 2000; 
Fitzmaurice et al. 
(2002); Grunau et al. 
(2011); Menendez-
Jandula et al. (2005); 
Sawicki (1999); 
Siebenhofer et al. 
(2007); Sunderji et al. 
(2004); Voller et al. 
(2005) 
Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
Moderate-quality 
evidence that self-
management may 
enhance the mean 
percentage of INR 
values in target 
range, compared 
with control  
Pharmacist-managed anticoagulation services 
Pharmacist-
managed 
anticoagulation 
services (PMAS) 
Pharmacist-
managed 
anticoagulation 
services (PMAS) 
compared with 
usual care 
Manzoor et 
al. (2017) 
3 RCTs + 
22 n-RCTs 
 
RCTs: Chan et al. 
(2006); Wilson et al. 
(2003); Bungard et al. 
(2012)  
n-RCTs: Bungard et al. 
(2009); Chamberlain et 
al. (2001); Chiquette et 
al. (1998); Cohen et al. 
(1985); Duran-Parrondo 
et al. (2011); Elewa et 
al. (2016); Garabedian-
31% Narrative 
synthesis 
(direction of 
effect and 
statistical 
significance) 
TTR 
(Rosendaal 
et al. (1993) 
interpolation 
method; k = 
19);  
INR values in 
goal INR 
range (k = 5) 
or given by 
the mean 
prothrombin 
(PT; k = 1) 
Evidence that the 
quality of 
anticoagulation may 
be better in the 
PMAS, compared 
with usual care. 
However, the quality 
of the evidence is 
uncertain 
                                             
125 Gadisseur et al. (2003) not included as separate data for self-testing and self-management not reported. 
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Intervention Conditions Review Number 
of 
relevant 
primary 
studies 
(k)122  
Relevant primary 
studies 
% of 
overlap 
in 
primary 
studies 
between 
reviews 
Synthesis Outcomes Summary of 
Findings 
Ruffalo et al. (1985)126; 
Garwood et al. (2008); 
Gray et al. (1985); 
Gupta et al. (2015); Hall 
et al. (2011); Harrison 
et al. (2015); Hasan et 
al. (2011); Holden and 
Holden (2000); Motycka 
et al. (2012)126; Patel-
Naik et al. (2010); Poon 
et al. (2007); Rudd and 
Dier (2010); Saokaew et 
al. (2012); Thanimalai 
et al. (2013); Witt et al. 
(2005); Young et al. 
(2011) 
Pharmacist-
managed 
warfarin 
therapy 
(PMWT) 
 
Pharmacist-
managed 
warfarin 
therapy 
(PMWT) 
compared with 
usual care  
Entezari-
Maleki et 
al. (2016) 
3 RCTs  
 
Lalonde et al. (2008); 
Wilson et al. (2003); 
Bungard et al. (2012) 
 Data pooled 
but not 
weighted   
TTR 
(Rosendaal 
et al. (1993) 
interpolation 
method) 
Evidence that PMWT 
may improve TTR, 
compared with usual 
care. However, the 
quality of the 
evidence is 
uncertain 
                                             
126 Not mixed AF/VTE population (population not reported) 
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Intervention Conditions Review Number 
of 
relevant 
primary 
studies 
(k)122  
Relevant primary 
studies 
% of 
overlap 
in 
primary 
studies 
between 
reviews 
Synthesis Outcomes Summary of 
Findings 
 5 n-RCTs  Rudd and Dier (2010); 
Witt et al. (2005); 
Bungard et al. (2009); 
Hall et al. (2011); Young 
et al. (2011) 
Data pooled 
but not 
weighted   
TTR 
(Rosendaal 
et al. (1993) 
interpolation 
method) 
Evidence that PMWT 
may improve TTR 
compared with usual 
care. However, the 
quality of the 
evidence is 
uncertain 
Pharmacist-
managed 
warfarin 
therapy 
(PMWT) v.  
physicians, 
nurses and 
other 
healthcare 
professionals 
providing 
management 
or usual care 
Zhou et al. 
(2016) 
4 RCTs Bungard et al. (2012); 
Lalonde et al. (2008); 
Verret et al. (2012); 
Wilson et al. (2003) 
Data meta-
analysed 
TTR 
(Rosendaal 
et al. (1993) 
interpolation 
method) 
High-quality 
evidence that PMWT 
may improve TTR 
compared with usual 
care 
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Appendix 23: Self-monitoring review; summary of studies included by the reviews  
Study Author and 
year 
Topic Focus Search + Year range of 
synthesised studies 
Total number of 
studies reviewed 
Number of studies 
reviewed related to 
AF/VTE adult 
populations and TTR 
outcome 
Study types synthesised 
Clarkesmith  et al. 
(2017)  
Adherence Search: Update of 
review first published 
in 2013127. Databases 
searched in February 
2016.  
 
Year range of included 
studies: 1999 to 2014. 
11 (reported in twenty 
articles) 
11 (AF) RCTs 
Entezari-Maleki et 
al. (2016) 
Adherence Search: database 
inception to 
January2014 
 
Year range of included 
studies: 1995 to 2013. 
24 (mixed conditions) 8 (mixed conditions) RCTS (3) 
n-RCTs (5) 
Heneghan et al. 
(2016) 
Adherence Search: 
Update of review 
published in 2010. 
Databases searched in 
July, 2015. 
 
Year range of included 
studies: 
1989 to 2012. 
28 20 (mixed conditions; 
2 AF) 
RCTs 
                                             
127 The authors searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects (DARE) in The 
Cochrane Library (2012, Issue 7 of 12), MEDLINE Ovid (1950 to week 4 July 2012), EMBASE Classic + EMBASE Ovid (1947 to Week 31 2012), PsycINFO Ovid 
(1806 to 2012 week 5 July) on 8 August 2012 and CINAHL Plus with Full Text EBSCO (to August 2012) on 9 August 2012. 
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Study Author and 
year 
Topic Focus Search + Year range of 
synthesised studies 
Total number of 
studies reviewed 
Number of studies 
reviewed related to 
AF/VTE adult 
populations and TTR 
outcome 
Study types synthesised 
Manzoor et al. 
(2017) 
Adherence Search: Database 
inception to May 2017. 
 
Year range of included 
studies: 1985 to 2016. 
25 25 (mixed mostly 
AF/VTE) 
RCTs (3), non-randomised 
controlled trials (22) 
Sharma et al. 
(2015) 
Adherence 
 
 
Search: Update of 
existing Cochrane 
review128 published in 
2010.  
Databases searched 
from 2007 to May 
2013129 
 
Year range of included 
studies: 1996 to 2012. 
26 (reported in 45 
articles) 
2 (AF) 
18 (Mixed various)  
RCTs 
Zhou et al. (2016) Adherence Search: From inception 
to July 31, 2015. 
 
Year range of included 
studies: 2003 to 2013. 
8 (mixed conditions)  4 (mixed conditions) RCTS 
                                             
128 Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, et al. Self-monitoring and self-management of oral 
anticoagulation. Cochrane Database Syst Rev 2010;4:CD003839.    
129 Original review searched  major databases searched from inception to 2007 
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Appendix 24: Self-monitoring review; risk of bias assessment of included reviews 
 1 2 3 4 5 6 7 8 9a 9b 10 11a 11b 12 13 14 15 16 
First author (year) 
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Clarkesmith (2017) + + - + + + + + + N/A + + N/A + + + + + 
Entezari-Maleki (2016) + - - PY130 + + + + + + - N/A131 N/A N/A - + - + 
Heneghan (2016) + + - PY132 + + + + + N/A + N/A N/A N/A - - N/A + 
Manzoor (2017) + PY133 - PY + + - + + + - N/A N/A N/A - - N/A + 
Sharma (2015) + PY + PY + + + + + N/A + + N/A -134 + + - + 
Zhou (2016) + - + -135 + + - + + N/A - + N/A + + + - - 
PY = partial yes, N/A = not applicable
                                             
130 There was no search of the grey literature. 
131 The means were pooled, but no meta-analysis weighted by sample size was conducted. 
132 Searches were updated in July 2015, less than 24 months before publication. 
133 The protocol was given, but the authors did not state whether there were any deviations from the protocol. 
134 Risk of bias was considered for other analyses, but not for time in therapeutic range (TTR). 
135 Did not justify the restriction of the searches to English-language journal articles. 
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1. Include PICO?   
 
100%  
 
2. Protocol?   33% 34% 33% 
 
3. Inclusion criteria   33%  67% 
 
4. Comprehensive search strategy?   17% 66% 17% 
 
5. Duplicate screening?   100%   
 
6. Duplicate DE?   100%   
 
7. Exclusions?   67%  33% 
 
8. Included described in detail?   100%   
 
9a. RCTs - RoB assessment?   100%   
 
9b. NRSI - RoB assessment?   100%   
 
10. Funding stated?   50%  50% 
 
11a. RCTs: meta-analysis methods?   100%   
 
11b. NRSI: meta-analysis methods?   N/A N/A N/A 
 
12. RoB impact on meta-analysis?   67%  33% 
 
13. RoB in interpretation of results?   50%  50% 
 
14. Heterogeneity explained/discussed?   67%  33% 
 
15. Publication bias?   40%  60% 
 
16. Conflict of interest stated?   83%  17% 
 
 
  Low risk of 
bias:     
Unclear risk 
of bias:     
High risk of 
bias:   
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Appendix 25: Self-monitoring review; overlap in primary studies 
 
Review Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Heneghan 
(2016) 
Manzoor 
(2017) 
Sharma 
(2015) 
Zhou 
(2016) Overlap Included Studies 
Education 
Clarkesmith et al. (2013b) ✔       
Vormfelde et al. (2014) ✔       
Education plus decision aid 
McAlister et al. (2005) ✔       
Self-testing (% time in therapeutic range) 
Azarnoush et al. (2011)     ✔   
Beyth et al. (2000)   ✔     
Christensen et al. (2011)   ✔  ✔  2 
Gadisseur et al. (2003) ✔    ✔  2 
Gardiner et al. (2005)   ✔     
Kaatz et al. (unpublished)   ✔     
Khan et al. (2004)   ✔  ✔  2 
Matchar et al. (2010)   ✔  ✔  2 
Rasmussen et al. (2012)   ✔     
Self-testing (% values in therapeutic range) 
Christensen et al. (2011)     ✔   
Gadisseur et al. (2003)     ✔   
Kaatz et al. (unpublished)   ✔     
White et al. (1989)   ✔     
Self-management plus education 
Christensen et al. (2007) ✔       
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Review Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Heneghan 
(2016) 
Manzoor 
(2017) 
Sharma 
(2015) 
Zhou 
(2016) Overlap Included Studies 
Gadisseur et al. (2003) ✔       
Self-management (AF only, days in therapeutic range) 
Voller et al. (2005)   ✔  ✔  2 
Self-management (mixed population, % time in therapeutic range) 
Christensen et al. (2006)   ✔     
Fitzmaurice et al. (2002)   ✔  ✔  2 
Fitzmaurice et al. (2005)   ✔  ✔  2 
Gadisseur et al. (2003)     ✔   
Grunau et al. (2011)   ✔     
Menendez-Jandula et al. (2005)   ✔  ✔  2 
Siebenhofer et al. (2007)   ✔     
Sunderji et al. (2004)   ✔  ✔  2 
Verret et al. (2012)   ✔  ✔  2 
Self-management (mixed population, % values in therapeutic range) 
Cromheecke et al. (2000)     ✔   
Fitzmaurice et al. (2002)   ✔  ✔  2 
Fitzmaurice et al. (2005)     ✔   
Gadisseur et al. (2003)     ✔   
Grunau et al. (2011)   ✔     
Menendez-Jandula et al. (2005)   ✔  ✔  2 
Sawicki (1999)   ✔  ✔  2 
Siebenhofer et al. (2007)   ✔     
Sunderji et al. (2004)   ✔     
Voller et al. (2005)   ✔  ✔  2 
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Review Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Heneghan 
(2016) 
Manzoor 
(2017) 
Sharma 
(2015) 
Zhou 
(2016) Overlap Included Studies 
Pharmacist-managed warfarin therapy 
Bungard et al. (2009)  ✔  ✔   2 
Bungard et al. (2012)  ✔  ✔  ✔ 3 
Chamberlain et al. (2001)    ✔    
Chan et al. (2006)    ✔    
Chiquette et al. (1998)    ✔    
Cohen et al. (1985)    ✔    
Duran-Parrondo et al. (2011)    ✔    
Elewa et al. (2016)    ✔    
Garabedian-Ruffalo et al. 
(1985)136 
   ✔    
Garwood et al. (2008)    ✔    
Gray et al. (1985)    ✔    
Gupta et al. (2015)    ✔    
Hall et al. (2011)  ✔  ✔   2 
Harrison et al. (2015)    ✔    
Hasan et al. (2011)    ✔    
Holden and Holden (2000)    ✔    
Lalonde et al. (2008)  ✔    ✔ 2 
Motycka et al. (2012)126    ✔    
Patel-Naik et al. (2010)    ✔    
Poon et al. (2007)    ✔    
                                             
136 Not mixed AF/VTE population (population not reported) 
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Review Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Heneghan 
(2016) 
Manzoor 
(2017) 
Sharma 
(2015) 
Zhou 
(2016) Overlap Included Studies 
Rudd and Dier (2010)  ✔  ✔   2 
Saokaew et al. (2012)    ✔    
Thanimalai et al. (2013)    ✔    
Verret et al. (2012)      ✔  
Wilson et al. (2003)  ✔  ✔  ✔ 3 
Witt et al. (2005)  ✔  ✔   2 
Young et al. (2011)  ✔  ✔   2 
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Appendix 26: Reviews of stakeholder experiences; characteristics of included reviews 
Author, Year 
Quality rating (QR) 
Aims 
Review characteristics Themes 
 
Alamneh et al. (2016)  
 
QR 7/11 
 
Aims to evaluate current 
practices of 
anticoagulation in AF, 
pharmacologic features 
and adoption patterns of 
NOACs, their impacts on 
proportion of eligible 
patients who receive oral 
anti-coagulants, persisting 
challenges and future 
prospects for optimal 
anticoagulation. 
Population: Patients with AF 
 
Drug(s): Warfarin 
NOACs (not further specified) 
 
Number of included primary studies: 
N=140 included studies, unknown number 
of participants 
 
Type of included primary studies:  
- prospective and retrospective  
- observational studies  
- review articles 
- meta-analyses,  
- RCTs,   
- experimental (in vivo and in vitro 
studies)  
- published AF treatment guidelines 
 
Quality assessment of primary studies: 
Not reported 
Perceptions and Attitudes 
Patients  
The lack of a specific reversal agent has been a major concern 
among prescribers and patients, ultimately affecting adoption 
into clinical practice 
Major uncertainties related to NOACs include medication 
adherence and persistence, absence of specific antidote for most 
NOACs, higher cost, and lack of data in some groups of patients 
in which they’ve not been adequately studied  
There are some concerns that patients may have difficulty in 
remembering to take NOACs without the requirement of blood 
monitoring (INR monitoring) 
Practitioner 
NOAC adoption trends are quite variable, with slow integration 
into clinical practice reported in most countries; there has been 
a limited impact to date on prescribing practice. 
Clarkesmith et al. (2017) 
 
QR 10/11 
 
Population: Patients with AF receiving 
oral anticoagulation therapy 
 
Drug(s): Warfarin 
Behaviour and Uptake 
Patients 
We found small but positive effects of education on anxiety [GB: 
HADS score=QOL] (MD-0.62, 95% CI -1.21 to -0.04, Isqu0%, 2 
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Author, Year 
Quality rating (QR) 
Aims 
Review characteristics Themes 
 
Aims to evaluate the 
effects of educational and 
behavioural interventions 
for oral anticoagulation 
therapy. (OAT) on TTR in 
patients with AF. 
 
Number of included primary studies: 
N=11 included studies, 2,246 participants 
 
Type of included primary studies: 
- RCTs 
 
Quality assessment of primary studies: 
Cochrane risk of bias tool 
trials, 587 participants, low quality evidence) and depression (MD 
-0.74, 95% CI -1.34 to -0.14, Isqu 0%, 2 trials, 587 participants, 
low quality evidence) compared with usual care over 12 months.  
Pooled data for the AF patients demonstrated that self-
monitoring plus education did not significantly improve TTR when 
compared to usual care (MD 6.3, 95% CI -5.63 to 18.25. AF 
cohort, self- monitoring is no more successful in increasing INR 
control than usual care.  
Using decision aids didn’t have a significant impact on AF 
patients’ anxiety levels (Thomson 2007) or patient satisfaction 
(Man-Son-Hing 1999). Clarkesmith (2013) found decline in both 
anxiety and depression in groups at the 6 month follow-up. 
Patients may feel more anxious and depressed in the initial 
months following diagnosis and treatment commencement. This 
suggests that patients that took part in the decision aid trial 
were uncertain as to which treatment they were going to choose. 
Entezari-Maleki et al. 
(2016) 
 
QR 9/11 
 
Aims to perform a 
systematic review of 
literature to compare 
pharmacist-managed 
warfarin therapy (PMWT) 
with usual medical care 
(UMC)  
Population: Patients receiving warfarin 
therapy 
 
Condition: AF common to all included 
studies; but some also included patients 
with DVT, PE, myocardial infarction, 
heart valve replacement 
 
Drug(s): Warfarin 
 
Number of included primary studies: 
Behaviour and Uptake 
Patients 
All patients in PMWT and 55% of UMC group preferred the PMWT 
group for future OAC management. 
The study supported PMWT regarding cost saving and patient 
satisfaction, results showed that PMWT model is superior to UMC 
in managing warfarin therapy based on observational studies. As 
well, it is comparable to UMC based on RCT studies.  
Patients believe that the pharmacists were more expert in AC 
control compared with their physicians' -'high satisfaction' of 
patients and 'high insights from pharmacists'  
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Author, Year 
Quality rating (QR) 
Aims 
Review characteristics Themes 
 
N=24 included studies (of which 6 
reported relevant findings); 11,607 
participants 
 
Type of included primary studies:  
- RCTs and non-RCTs 
 
Quality assessment of primary studies: 
Jadad scale 
A literature review showed that impact of PMWT service in 
improving quality of life of patients with oral anticoagulation 
therapy was documented in a very limited number of studies. In 
a Lalonde et al report, health-related quality of life was similar 
between PMWT and UMC. 
Loewen et al. (2017) 
 
QR 10/11 
 
Aims To provide 
clinicians, guideline 
developers and policy-
makers with insights into 
values and preferences of 
AF patients for stroke 
prevention therapy and 
patient specific factors 
which affect those values 
and preferences. 
Population: Patients requiring 
antithrombotic therapy in AF 
 
Drug(s): NOACs 
 
Number of included primary studies: 
N=25 included studies; 641 participants 
 
Type of included primary studies: 
- Discrete choice experiments 
 
Quality assessment of primary studies:  
CONSORT 
STROBE 
COREQ 
ISPOR 
Preferences and Choices 
Patients 
Across all SPAF antithrombotic therapy options, stroke 
prevention efficacy is the most important value. 
After efficacy and safety, one versus two daily doses, antidote 
availability, absence of dietary restrictions and drug-drug 
interactions are of intermediate and variable importance. 
Preferences for INR testing or no INR testing are largely 
unpredictable; 
Prior stroke, bleed or OAC use does not affect patient values 
significantly, although prior experience with warfarin increases 
preference for warfarin over no therapy and for INR testing over 
no INR testing. 
Treatment choices are unpredictable, probably due to latent 
beliefs and framing effects.  
Preferences for NOAC over warfarin are highly variable and 
published studies are susceptible to bias based on sponsorship. 
Preferences for NOAC over warfarin are overwhelmed by even 
small increases in out-of-pocket drug cost. From the available 
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Author, Year 
Quality rating (QR) 
Aims 
Review characteristics Themes 
 
evidence there is no substitute for directly clarifying patients' 
actual values and preferences related to attributes of SPAF 
antithrombotic therapy (e.g. stroke risk, bleeding risk, cost of 
therapy, number of daily doses, need for regular blood testing, 
drug-drug interactions, dietary restrictions, lifestyle 
implications, antidote availability).  
Cultural or familial attitudes and personal experiences are latent 
sources of inter-individual variability in values and preferences 
and may include stigma of taking medication, perceptions of cost 
and risk aversion, among others.  
 
Mas Dalmau et al. (2017) 
 
QR 10/11 
 
Aims to evaluate and 
synthesize patients' and 
physicians' perceptions 
and attitudes towards the 
benefits and downsides of 
vitamin K antagonist, in 
order to explore potential 
factors related with its 
underuse 
Population: Patients with AF and 
physicians who treat these patients 
 
Drug(s): VKAs 
 
Number of included primary studies: 
N=9 included studies; 250 patients and 91 
physicians 
 
Type of included primary studies: 
- qualitative or mixed-methods studies 
 
Quality assessment of primary studies: 
CASP tool 
Perceptions and Attitudes 
Patients 
While patients noted the lack of information and under- standing 
of VKAs therapy as their main concerns it was often inadequately 
provided and insufficient. 
Balance of interests and downsides (patients: assurance of 
treatment success, stroke prevention and longer life; risk of 
stroke perceived or conditions associated with anticoagulation 
understood; basing opinions on friends/family experiences; 
sceptical if perception that treatment was ineffective, never had 
stroke or first time in therapy) 
Three additional themes were of interest to patients: knowledge 
and understanding, impact on daily life, and satisfaction with 
therapy. Patients’ experiences suggested a mix of a paternalistic 
and an interpretative model (the physician take the decision, 
considering the patient’s values and preferences) 
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Author, Year 
Quality rating (QR) 
Aims 
Review characteristics Themes 
 
Patients believed they were ignorant and delegated decision 
management to professional; belief that emergency 
circumstances prevented patient decision management.  
Impact on daily life, factors concerning, dietary, drug alcohol 
restrictions, bruises, activity limitations, monitoring as calming, 
routine, and as a burden. 
Satisfaction with therapy (improved when info given individually 
and focused on care; dissatisfied when lack of information, 
quality and level of info provided by GPs, difficulties and costs 
r/t monitoring, HCPs lack of knowledge of patient's medical 
history). 
 
Practitioner 
Roles in decision-making and therapy management [doctors: 
support SDM, degree of perceived appropriate patient 
involvement varies, negotiating delegation by patient, delegating 
to specialist, belief in patient-centred versus disease-centred 
DM, perceived difficulties communicating with other HCPs, 
psychosocial characteristics of patients] 
Physicians regard uncertainty in specific cases, the need of 
individualized decision-making, and the delegated responsibility 
in decision making as the main difficulties for using VKAs.  
Information to reinforce anticoagulation use, balance of benefits 
and downsides, roles in decision-making and therapy 
management.  
Despite the availability of guidelines and research evidence, 
some physicians considered that this information did not always 
clarify their doubts in a treatment with narrow therapeutic 
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Author, Year 
Quality rating (QR) 
Aims 
Review characteristics Themes 
 
margins. They identified ambiguities in some of the guidelines, 
and stated that the included populations were not necessarily 
representative of the very elderly, the main candidates for 
therapy.  
Moreover, it is crucial to improve the quality of the information 
provided to patients because it is the main factor of 
dissatisfaction with the therapy. 
In one study some family physicians felt that specialized 
physicians delegated the responsibility of decision making to 
them. These two sources of delegation were perceived by family 
physicians as a burden. The feeling of family physicians that 
specialized physicians delegated the responsibility of decision 
making to them could be explained by the lacking certainty 
about the treatment and the inadequate exchange of information 
between them. 
Pandya et al. (2017) 
QR 7/11 
Aims to identify the 
factors underpinning 
patients' non-adherence 
to anticoagulants in atrial 
fibrillation (AF), and 
subsequently 
contemplates to what 
extent the NOACs might 
overcome the known 
Population: Patients taking oral 
anticoagulants for AF 
 
Drug(s): Warfarin and NOACs 
 
Number of included primary studies: 
N=47 included studies; 4,151 participants 
 
Type of included primary studies: 
- Surveys 
- Interviews 
- Discrete choice experiments 
 
Perceptions and Attitudes 
Patients 
This review highlights patients' lack of understanding regarding 
AF and stroke, and the importance of anticoagulant therapy (in 
any form) on stroke prevention. This understanding is integral to 
facilitating adherence, as well as for engaging patients in 
decision-making. 
Factors negatively affecting patients’ day-to-day lives (especially 
regular therapeutic drug monitoring, dose adjustments, and 
dietary considerations) predominantly underpin a patient’s 
reluctance to take warfarin therapy, leading to non-adherence. 
Absence of regular monitoring, limited access to antidotes, high 
costs of the medications, twice-daily dosing (dabigatran and 
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Author, Year 
Quality rating (QR) 
Aims 
Review characteristics Themes 
 
challenges with 
traditional warfarin 
therapy 
Quality assessment of primary studies: 
Not reported 
apixaban) and timing of doses with respect to meals (dabigatran 
and rivaroxaban) are all additional factors that might make it 
difficult for some patients to accept, manage and adhere to the 
NOACs. 
Forgetfulness, attitudes toward stroke and bleeding risk, 
condition-related factors, social and economic factors, and 
healthcare system-related factors, will likely influence patients’ 
adherence to NOACs in a manner similar to warfarin. 
Wilke et al. (2017) 
 
QR 9/11 
 
Aims to conduct a 
systematic literature 
review summarising the 
results of studies dealing 
with the preferences of 
AF patients towards OAC 
treatment. 
Population: Patients with AF 
 
Drug(s): Warfarin and NOACs 
 
Number of included primary studies: 
N=27 included studies; 16 OACs in 
general, 11 NOACs vs. warfarin; 7,295 
patient and 266 physicians 
 
Type of included primary studies: 
- quantitative studies of patients 
preferences 
 
Quality assessment of primary studies: 
reported but no previously developed tool 
described 
Preferences and Choices 
Patients 
All the publications analysed reported a high variability of AF 
patient preferences towards anticoagulation treatment; some of 
the analyses even identified specific AF patient segments, 
defined by different degrees of bleeding risk aversion.  
Data show that AF patients, in accordance with clinical 
guidelines, weigh clinical attributes such as stroke or bleeding 
risk more heavily than convenience attributes. Therefore, it is in 
line with the preferences of AF patients that a treating physician 
first investigates the clinical effectiveness and safety of the 
recommended anticoagulant before suggesting alternative 
treatment choices to the patient.  
Most studies showed that patients were willing to accept higher 
bleeding risks if a certain threshold in stroke risk reduction could 
be reached. Preferences of AF patients towards OACs may differ 
from the perspective of clinical guidelines or the perspective of 
physicians.  
This review also showed that if alternative OAC treatments are 
similar in terms of efficacy and safety, as is the case with may 
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Author, Year 
Quality rating (QR) 
Aims 
Review characteristics Themes 
 
AC options in AF, convenience attributes such as mode of 
application, interactions with food or drugs, availability of an 
antidote, need for bridging, or frequency of application may 
matter to patients.  
It has been shown that a less frequent dosing schedule, such as 
once daily on chronic cardiovascular disease medication, is 
associated with higher treatment adherence.  
 
Willett and Morrill (2017) 
 
QR 5/11 
 
Aims to describe current 
recommended dosing for 
each NOAC and published 
post-marketing data, 
including case reports, on 
the use of these agents in 
the renally impaired; and 
discuss patient adherence 
and satisfaction and the 
cost of these agents  
Population: Patients with reduced renal 
function 
 
Condition: AF and VTE 
 
Drug(s): NOACs: 
Dabigatran 
Rivaroxaban 
Apixaban 
 
Number of included primary studies: 
N=unclear; findings from 9 studies cited 
but authors report pulling findings from 
ten studies 
 
Type of included primary studies: 
- Systematic review 
- Meta-analyses 
- Trial 
- Surveys 
Perceptions and Attitudes 
Patients 
Most of the studies have focused on patients' willingness to 
switch from warfarin to dabigatran or their satisfaction with 
dabigatran. 
Frequency of blood tests, along with dosing frequency and drug–
food interactions, were considered less important than efficacy 
and safety. Likewise, cost was of high importance, and the 
affinity for newer agents increased as cost decreased.  
Further, data from patient-adherence studies have suggested 
that NOACs that are dosed daily (rather than twice daily) are 
optimal and preferred.  
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Author, Year 
Quality rating (QR) 
Aims 
Review characteristics Themes 
 
 
Quality assessment of primary studies: 
Not reported 
Zhou et al. (2016) 
 
QR 10/11 
 
Aims to compare the 
effectiveness of 
pharmacist-managed 
anticoagulation control of 
warfarin with other 
models 
Population: Patients on warfarin therapy 
 
Condition: Majority AF and VTE; some 
focused on additional conditions 
 
Drug(s): Warfarin 
 
Number of included primary studies: 
N=8 included studies; 1,493 participants 
 
Type of included primary studies: 
- RCTs 
 
Quality assessment of primary studies: 
Cochrane risk of bias tool 
Behaviour and Uptake 
Patients 
The pharmacist-led AM group showed a significantly higher 
patients' satisfaction score compared with that of the other 
managed groups, which has been attributed to an improved 
satisfaction in the quality of patient life (i.e. self-efficacy, 
strained social network, daily hassles, and distress), pharmacist 
service, interpersonal manner, communication, time spent and 
accessibility.  
The outcome of percentage of time within the therapeutic range 
in this study indicated that pharmacists provided significantly 
better AC control of warfarin in the standard therapeutic range, 
but not in the expanded therapeutic range. In the pharmacist-led 
INR group, the INR was controlled more strictly and adjusted 
more cautiously.  
In the RCTs, pharmacists played a key role in warfarin 
anticoagulation treatment to achieve better anticoagulation 
control and patients’ satisfaction. The pharmacists focused more 
effort on clinical counselling, patient education, home visit 
monitoring, anticoagulation clinical, standardised follow-up and 
comprehensive pharmaceutical care. 
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Appendix 27: Reviews of stakeholder experiences; risk of bias assessment of included reviews 
First author (year) 
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Alamneh (2016) + + + + - - - - - + + 
Clarkesmith (2017) + + + + + + + + - + + 
Entezari-Maleki (2016) + + + + + + - + - + + 
Loewen (2017) + + + + + + + + - + + 
Mas Dalmau (2017) + + + + + + + + - + + 
Pandya (2017) + + + + - - - + - + + 
Wilke (2017) + + + + + + - + - + + 
Willett (2017) + + + + - - - - - + - 
Zhou (2016) + + + + + + - + + + + 
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1. Is the review question clearly and 
explicitly stated? 
100%   
 
2. Were the inclusion criteria appropriate for 
the review question? 
100%  
 
3. Was the search strategy appropriate? 
 
100%  
 
4. Were the sources and resources used to 
search for studies adequate? 
100%  
 
5. Were the criteria for appraising studies 
appropriate? 
67%  33% 
 
6. Was critical appraisal conducted by two or 
more reviewers independently? 
67%  33% 
 
7. Were there methods to minimise errors in 
data extraction? 
33%  67% 
 
8. Were the methods used to combine studies 
appropriate? 
78%  22% 
 
9. Was the likelihood of publication bias 
assessed? 
11% 89% 
 
10. Were recommendations for policy and/or 
practice supported by the reported data? 
100%  
 
11. Were the specific directives for new 
research appropriate? 
89%  11% 
 
 Low risk 
of bias: 
 Unclear risk 
of bias: 
High risk 
of bias: 
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Appendix 28: Reviews of stakeholder experiences; overlap of included primary studies 
Review Alamneh 
(2016) 
Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Loewen 
(2017) 
Mas 
Dalmau 
(2017) 
Pandya & 
Bajorek 
(2017) 
Wilke 
(2017) 
Willett & 
Morrill 
(2017) 
Zhou 
(2016) 
Overlap 
Included Studies 
Akao (2014) ✔          
Alonso-Coello (2014)    ✔   ✔   2 
Anderson (2006)     ✔      
Andrade (2016)    ✔   ✔   2 
Ansell (2010)      ✔     
Arnsten (1997)      ✔     
Attaya (2012)    ✔  ✔ ✔ ✔  4 
Bajorek (2007)     ✔ ✔    2 
Bajorek (2009)      ✔     
Baker (2009) ✔          
Bannerjee (2012) ✔          
Barcellona (2000)      ✔     
Barcellona (2015)       ✔    
Barnes (2014) ✔          
Beyth (2000)  ✔         
Biskupiak (2014) ✔          
Boom (2015)       ✔    
Bottger (2015)    ✔   ✔   2 
Brandes (2013) ✔          
Bungard (2009)   ✔        
Bungard (2012)   ✔        
Camm (2010) ✔          
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Review Alamneh 
(2016) 
Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Loewen 
(2017) 
Mas 
Dalmau 
(2017) 
Pandya & 
Bajorek 
(2017) 
Wilke 
(2017) 
Willett & 
Morrill 
(2017) 
Zhou 
(2016) 
Overlap 
Included Studies 
Camm (2016)        ✔   
Casais (2005)      ✔ ✔   2 
Chamberlain (2001)   ✔        
Chan (2006)         ✔  
Chan (2011) ✔          
Choi (2014)    ✔  ✔    2 
Christensen (2007)  ✔         
Clarkesmith (2013)  ✔         
Coelho-Dantas (2004)     ✔      
Coleman (2004)   ✔        
Coleman (2013)        ✔   
Cottrell (2009)       ✔    
Cutler & Everett 
(2010) 
✔          
Dantas (2004)      ✔     
Davis (2005)      ✔     
De Caterina (2013) ✔          
De Schryver (2005) ✔          
Decker (2012)     ✔      
Deitelzweig (2012) ✔          
Deitelzweig (2013) ✔          
Deitelzweig (2014) ✔          
Desai (2013) ✔          
Desai (2014) ✔          
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Review Alamneh 
(2016) 
Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Loewen 
(2017) 
Mas 
Dalmau 
(2017) 
Pandya & 
Bajorek 
(2017) 
Wilke 
(2017) 
Willett & 
Morrill 
(2017) 
Zhou 
(2016) 
Overlap 
Included Studies 
Devereaux (2001)    ✔   ✔   2 
DeWilde (2006) ✔          
Duran (2012) ✔          
Duran-Parrondo 
(2011) 
  ✔        
Eikelboom (2013) ✔          
Elewa (2014    ✔  ✔  ✔  3 
Ernst (2003)   ✔        
Fang (2010) ✔          
Fatima (2016)    ✔       
Freeman (2011) ✔          
Fuller (2004)     ✔ ✔    2 
Gadisseur (2003)  ✔         
Gage (1996)    ✔       
Garton (2011)   ✔        
Garwood (2008)   ✔        
Gebler-Hughes (2012)      ✔     
Gebler-Hughes (2014)       ✔    
Ghijben (2014)    ✔   ✔ ✔  3 
Gibbs (2013) ✔          
Gonzales-Rojas 
(2012) 
      ✔    
Greinacher (2015) ✔          
Gupta (2013)   ✔        
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Review Alamneh 
(2016) 
Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Loewen 
(2017) 
Mas 
Dalmau 
(2017) 
Pandya & 
Bajorek 
(2017) 
Wilke 
(2017) 
Willett & 
Morrill 
(2017) 
Zhou 
(2016) 
Overlap 
Included Studies 
Haim (2015) ✔          
Hall (2011)   ✔        
Hamilton (2012) ✔          
Hendriks (2013)  ✔         
Hodden (2000)   ✔        
Holbrook (2007)    ✔       
Holbrook (2013)    ✔       
Hong (2013)    ✔       
Howitt & Armstrong 
(1999) 
   ✔ ✔     2 
Howitt (2000)      ✔     
Huisman (2015) ✔          
Jackson (2004)   ✔        
Kaariainen (2013)      ✔     
Kakkar (2011) ✔          
Kim (2011)      ✔     
Kimmel (2007) ✔     ✔    2 
Kirley (2012) ✔          
LaHay (2014)    ✔   ✔   2 
Lalonde (2008)   ✔      ✔ 2 
Lancaster (1991)     ✔      
Levitan (2013)       ✔    
Lip (2002)      ✔     
Lip (2006)      ✔     
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Review Alamneh 
(2016) 
Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Loewen 
(2017) 
Mas 
Dalmau 
(2017) 
Pandya & 
Bajorek 
(2017) 
Wilke 
(2017) 
Willett & 
Morrill 
(2017) 
Zhou 
(2016) 
Overlap 
Included Studies 
Lip (2014) ✔          
Lip (2015) ✔          
Lipman (2004)     ✔      
Man-Son-Hing (1996)    ✔   ✔   2 
Man-Son-Hing (1999)  ✔  ✔      2 
Man-Son-Hing (2002)    ✔       
McAlister (2005)  ✔         
McCormick (2001) ✔          
Mega (2012) ✔          
Michel (2013)      ✔     
Mohammed (2013) ✔          
Moia (2013)      ✔     
Monz (2013)        ✔   
Motycka (2012)   ✔        
Najafzadeh (2014)       ✔    
Najafzadeh (2015)       ✔    
Nelson (2014)      ✔     
Nieuwlaat (2006) ✔          
Ogilvie (2010) ✔          
Okumura (2012)       ✔    
Okumura (2015)    ✔   ✔   2 
Oldgren (2014) ✔          
Orensky & Holdford 
(2005) 
     ✔     
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Review Alamneh 
(2016) 
Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Loewen 
(2017) 
Mas 
Dalmau 
(2017) 
Pandya & 
Bajorek 
(2017) 
Wilke 
(2017) 
Willett & 
Morrill 
(2017) 
Zhou 
(2016) 
Overlap 
Included Studies 
Palacio (2015)    ✔   ✔   2 
Parker (2007)      ✔     
Patel-Naik (2008)   ✔        
Piyaskulkaew (2014) ✔          
Platt (2008)      ✔     
Poon (2007)   ✔        
Protherhoe (2000)    ✔   ✔   2 
Prothero (2001)       ✔    
Radley (1995)   ✔        
Reynolds (2006) ✔          
Robinson (2001)    ✔   ✔   2 
Rudd (2010)   ✔        
Shafrin (2016)    ✔       
Shah & Gage (2011) ✔          
Shah (2014) ✔          
Sola (2009)     ✔      
Sorea (2014) ✔          
Steinberg (2013) ✔          
Suarez (2012) ✔          
Sudlow (1998)    ✔       
Sudlow (1999)       ✔    
Suryanarayan & 
Shulman (2014) 
✔          
Tan (2012)      ✔     
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Review Alamneh 
(2016) 
Clarkesmith 
(2017) 
Entezari-
Maleki 
(2016) 
Loewen 
(2017) 
Mas 
Dalmau 
(2017) 
Pandya & 
Bajorek 
(2017) 
Wilke 
(2017) 
Willett & 
Morrill 
(2017) 
Zhou 
(2016) 
Overlap 
Included Studies 
Thomson (2007)  ✔         
Thorne (2014)      ✔ ✔   2 
Vaughan Sarrazin 
(2014) 
     ✔     
Verdino (2015) ✔          
Verret (2012)         ✔  
Vormfelde (2014)  ✔         
Waldo (2005) ✔          
Wang (2013)       ✔ ✔  2 
Wang (2014) ✔          
Wang (2015)       ✔    
Waterman (2004)      ✔     
Wild (2004)     ✔      
Wild (2009)    ✔  ✔    2 
Wilson (2003)   ✔        
Wilson (2004)   ✔        
Wilt (1995)   ✔        
Witt (2003)   ✔        
Witt (2005)   ✔        
Witt (2013)      ✔     
Xu (2013) ✔          
Young (2011)   ✔        
Zamorano (2012)      ✔ ✔   2 
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Appendix 29: PRISMA checklist 
Section/topic  # Checklist item  
Reported 
on page 
number  
TITLE   
Title  1 Identify the report as a systematic review, meta-
analysis, or both. 
Cover 
page 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal 
and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review 
registration number. 
Abstract 
11, 
Executive 
summary 
12 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of 
what is already known. 
19 
Objectives  4 Provide an explicit statement of questions being 
addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS). 
21 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can 
be accessed (e.g., Web address), and, if available, 
provide registration information including registration 
number. 
11, 18 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of 
follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as 
criteria for eligibility, giving rationale. 
22 
Information 
sources  
7 Describe all information sources (e.g., databases with 
dates of coverage, contact with study authors to 
identify additional studies) in the search and date last 
searched. 
22 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could 
be repeated. 
92 
Study 
selection  
9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis). 
22, 26, 
101 
Data 
collection 
process  
10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators. 
23, 24 
Data items  11 List and define all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions and 
simplifications made. 
23 
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Risk of bias in 
individual 
systematic 
reviews 
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether 
this was done at the study or outcome level), and how 
this information is to be used in any data synthesis. 
24 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means). 
24 
Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis. 
24 
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